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ABSTRACT 
 
 Vaccination is one of the major achievements of modern medicine. As a result of 
vaccination, diseases such as polio and measles have been controlled and small pox has 
been eliminated. However, despite these successes there are still many diseases of 
microbial origin that cause tremendous suffering because there are no vaccines or the 
vaccines available are inadequate for many diseases. The development of DNA based 
vaccines and immunostimulatory CpG oligonucleotides (ODNs) as adjuvants offers 
possibilities for developing new vaccines.  However, even if vaccines were available for 
all infectious diseases there would be no guarantee that people would use them 
routinely. One of the major impediments to ensuring vaccine efficacy and compliance is 
that of delivery. Presently most vaccines are given by intramuscular administration. 
Unfortunately this is often traumatic, especially in infants. Thus if it were possible to 
replace intramuscular injection by mucosal (oral/intranasal) or transdermal delivery it 
might be possible to both enhance mucosal immunity and improve overall compliance 
rates. 
 
The development of non- invasive methods for the delivery of vaccines through 
the skin will greatly improve the safety and the administration of human and veterinary 
vaccines for different species. This study examined the efficiency of topical delivery of 
plasmids by assessing the localization of gene expression using luciferase as a reporter 
gene and induction of immune responses using a plasmid encoding for the bovine 
herpesvirus type-1 glycoprotein D (pgD). Topical administration of plasmids in a lipid-
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based delivery system (biphasic lipid vesicles [Biphasix™]) resulted in gene expression 
in the draining lymph nodes, whereas with intradermal injection, antigen expression was 
found in the skin. Following administration of plasmid by gene gun, antigen expression 
was observed in both the skin and the draining lymph nodes. Transcutaneous 
immunization with pgD formulated in biphasic lipid vesicles elicited gD-specific 
antibody responses and a Th2 type cellular response. In contrast, immunization by the 
intradermal route resulted in the stimulation of a Th1 type response. These findings have 
implications for both vaccine design and tailoring of specific immune responses. 
 
Electroporation has been shown to increase the potency of DNA vaccines that 
have demonstrated significant potential in mice.  However, there is a need to develop 
non- invasive or minimally invasive vaccination methods.  In pigs, in vivo gene 
expression was assessed to compare intradermal needle injection to a needle-free dermal 
BioJectTM as a means of delivery of plasmids.  Each administration method was further 
tested with and without surface electroporation.  Experiments with plasmid DNA 
encoding luciferase demonstrated that needle-free administration results in higher 
expression levels than needle injection.  Electroporation strongly enhanced gene 
expression for both intradermal delivery methods and immune responses to a DNA 
vaccine encoding hepatitis B surface antigen. Needle-free plasmid injection in 
combination with electroporation led to a more rapid induction of immune responses 
compared to other methods of plasmid administration. Priming and boosting with the 
DNA vaccine heightened the effectiveness of a subsequent protein boost, and 
electroporation after DNA injection augmented those benefits. It was concluded that 
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needle-free topical electroporation significantly enhances gene expression and immune 
response, possibly by improving cellular uptake of plasmid DNA. 
 
It is generally recognized that DNA vaccines are often less effective in large 
animals than in mice. One possible reason for this reduced effectiveness may be 
transfection efficiency and the low level of expression elicited by plasmid vectors in 
large animals. A possible way to improve plasmid gene expression in vivo is 
electroporation. To determine whether immune responses in pigs could be enhanced by 
electroporation, plasmids encoding two different genes [bovine herpes virus 
glycoprotein D (gD) and hepatitis B surface antigen (HBsAg)] and two different 
electrodes, a single-needle electrode and a six-needle electrode, were used. 
Electroporation significantly enhanced immune responses to both antigens. Co-
administration of two different plasmids (pgD and pHBsAg) did not result in significant 
interference between the plasmids. In addition, a DNA prime / protein boost strategy 
was used to show inhanced DNA priming with electroporation on the immune response 
to HBsAg following a protein boost. 
 
One potential mechanism by which electroporation enhances immune responses 
to DNA vaccines is by increasing gene expression. However, the inflammation and 
accompanying cellular infiltration caused by electroporation may also be essential for 
enhancing immune responses to DNA vaccines.  These parameters were investigated in 
pigs using different electroporation conditions that result in different levels of gene 
expression and cellular infiltration.  Results indicated that the least effective strategy 
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was conventional intramuscular injection where there was low gene expression and low 
cellular infiltration. The most efficacious strategy was plasmid administration 
immediately followed by electroporation.  This latter set of conditions elicited a 
combination of high gene expression and high cellular infiltration. This indicates that 
electroporation enhances immune responses to DNA vaccines by increasing gene 
expression and inflammatory cell infiltration.  
 
CpG oligonucleotides (ODNs) are potent mucosal and systemic adjuvants.  For 
practical applications, improvements in delivery need to be developed. It is possible to 
enhance the adjuvant properties of CpG ODNs by (1) physically coupling CpG ODNs to 
an antigen or alternatively (2) formulating the CpG ODNs in an appropriate delivery 
system. In this thesis, the ability of a novel type of biphasic lipid vesicles (BiphasixTM), 
called Vaccine-Targeting Adjuvants (VTA), to enhance the immunoadjuvant activity of 
CpG ODNs following systemic or mucosal administration was assessed. Compared to 
gD alone VTA formulations in combination with CpG and gD were able to increase gD-
specific IgG in serum and gave protection from a lethal HSV-1 challenge following 
subcutaneous immunization in mice. In addition, formulation of CpG ODNs in VTA 
enhanced IL-12 cytokine secretion following systemic administration. These results 
indicate that a suitable delivery system can increase the biological activity of CpG 
ODNs. 
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1.0 LITERATURE REVIEW 
1.1 Overview of traditional vaccination; identification of current and future 
trends including safety and delivery 
Following the first reports by Jenner over 200 years ago, numerous attempts 
have been made to develop safer and more efficacious vaccines.  Thus, approximately 
100 years after Jenner described immunization with a live vaccine, Pasteur introduced 
the concept of using killed vaccines to control infectious diseases.  For the next 100 
years the great debate continued as to the advantages or disadvantages of the two 
different types of conventional vaccination strategies.  For example, killed vaccines are 
better at inducing antibody responses as opposed to cell-mediated immune responses.  In 
contrast, live vaccines generally induce a more balanced response; however, they may 
not be as safe due to the potential risk of reversion to virulence (Hooke, et al., 1985).   
The developments in molecular biology in the 1970’s heralded the era of 
recombinant DNA technology to produce a new generation of vaccines.  Recombinant 
subunit vaccines are considered to be safer than conventional vaccines (Dertzbaugh, 
1998).  However, some challenge the use of the reductionist approach to vaccine 
development because they believe that a combination of proteins has the potential to 
induce a broader level of protection.  Regardless of whether subunit or conventional 
killed vaccines are used, they need to be administered with adjuvants to elicit effective 
immune responses.  Adjuvants can be categorized into two different types: non-specific 
immune stimulants such as lipid A, saponins (Gupta et al., 1993) or bacterial DNA 
(Klinman et al., 1996), and delivery vehicles such as mineral oil and liposomes 
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(Gregoriadis, 1990). Unfortunately many adjuvants cause tissue reactions and currently 
only alum and MF59 emulsion are is licensed for human use.  
To increase the safety of conventional live vaccines, gene deleted vaccines are 
being developed by removing genes involved in pathogenicity of the microbe. Gene 
deleted vaccines are considered to be safer then conventional attenuated vaccines 
because they should not revert to virulence.  This has been supported scientifically with 
a number of viruses (Mackett et al., 1996; Reddy et al., 1999) and bacteria (Kaper et al., 
1984) that have been attenuated by removing virulence genes to create modified live 
vaccines.  In parallel, gene deleted vaccines can also be used as “marker” vaccines to 
differentiate vaccinated individuals from non-vaccinated or potential carriers of the 
disease (Lubroth et al., 1996).  This is especially important in the livestock industry in 
countries embarking on vaccination and eradication programs. Obviously, this has less 
relevance in human medic ine. A further advantage of these gene deleted vaccines is that 
they can be used as vectors for carrying genes encoding foreign antigens, which under 
the proper conditions can elicit a protective immune response to the encoded antigen 
(Johnson, 1991).   The best example of this is the use of vaccinia virus with bait to 
immunize wildlife against rabies virus (Rupprecht et al., 1986).  This technology has 
greatly aided in reducing rabies virus spread from wildlife to domestic livestock and 
humans (Brochier et al., 1996). 
Immunization of animals using plasmids encoding protective antigens is one of 
the most recent vaccination methods described.  The basis behind DNA immunization is 
that an antigen encoded in a plasmid, with the proper regulatory sequences, transfects 
cells in vivo resulting in expression of the antigen and induction of immune response to 
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the expressed protein.  Since the protein antigen is produced in vivo in a manner similar 
to what occurs in natural viral infections, the post-translational and intracellular 
processing of the protein are considered to be authentic and therefore both protective 
cellular and humoral immune responses are induced.  The universality of this approach 
has been shown in various species and with numerous genes from different pathogens 
(Davis, 1998; Kuklin et al., 1997; Ulmer et al., 1998). Furthermore, DNA immunization 
has been shown to be effective in eliciting an immune response following intramuscular 
(Ulmer et al., 1993), intradermal (Tang, et al., 1992), intraperitoneal, intravenous 
(Yokoyama, et al., 1996), oral (Roy et al., 1999), intranasal (Okada et al., 1997a), and 
ocular (Degano, et al., 1998) administration.  These results have encouraged many 
researchers and commercial companies to seriously investigate this vaccination 
approach in humans and animals.  Indeed, DNA immunization has been referred to as 
the “third generation” of vaccines (Alarcon, et al., 1999). 
 
1.1.1 The ideal vaccine of the future and challenges 
Considering the wide variety of vaccine types available, it is critical to determine 
factors contributing to an ideal vaccine.  The ideal vaccine would have the following 
characteristics. It would be safe, effective, inexpensive and would rapidly elicit lifelong 
immunity and delivered non- invasively in a single administration and protect against all 
relevant infectious diseases. In this section I will describe the ideal vaccine of the future 
and potential factors limiting each aspect of the ideal vaccine. 
Safety of vaccines is the most important consideration and greatest concern 
because vaccines are administered in healthy people to prevent disease. Today’s 
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vaccines are highly scrutinized for their safety and undesirable side effects such as tissue 
reactions.  Since protection against microbial diseases requires that specific immune 
responses be mounted, it is essential that vaccines mediate the proper protective immune 
response, in order to be effective. This has become especially important when one 
considers that some inappropriate responses may actually enhance the disease, for 
example as seen with respiratory syncytial virus (Srikiatkhachorn and Braciale, 1997).  
A successful vaccine should not cause any vaccine related complications. But even the 
most successful vaccine, namely the small pox vaccine that eradicated the disease, 
caused significant medical complications in 1 out of 300,000 people. These vaccine 
complications were acceptable under the circumstances, since many more people were 
dying from the disease, and the risk of disease far outweighed the risk associated with 
vaccination. Today, since the risk of the disease caused by smallpox has virtually 
disappeared, the risks associated with smallpox vaccination are too high. Therefore, the 
general public is no longer vaccinated against smallpox. The risk to benefit ratio must be 
assessed for each vaccine to determine if it should be used. It is unlikely that a vaccine 
will ever be 100% risk free; however, the risk associated with a vaccine must be 
substantially lower than the risk of the disease. Injection site reactions are also an 
important safety issue with vaccines; however, the tissue damage caused at the injection 
site may be an important factor in the induction of immune responses. It may be possible 
to mimic the signals caused by tissue damage without causing an injection site reaction.  
 Although very few vaccines are 90-100% effective after a single immunization, 
most successful vaccines have efficacy rates of greater than 90% following secondary 
administration. It is critical that a vaccine be delivered appropriately to induce a 
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protective immune response.  There are many factors to consider for optimal 
vaccination, such as route of delivery, targeting of immune cell compartments and 
stimulation of humoral and cellular immunity.  Although there are several sites in which 
a vaccine can be administered, including muscle, mucosal surfaces and skin, the skin 
may be one of the best sites for vaccination for numerous reasons such as accessibility 
and immuno-competence. 
 Economics is also an important consideration for people who are given the 
vaccines as well as the companies that produce them. Vaccination is still the most cost 
effective way to prevent disease. Given this fact, the cost of vaccines is extremely low 
compared to the economic value to society. Unfortunately, the vast majority of 
individuals in the world cannot afford even the cheapest vaccines. This has impeded the 
development of vaccines against tropical diseases such as malaria. Vaccines are not 
simple drugs. They are complex biological products that require extensive 
manufacturing processes, especially for subunit vaccines. This along with the lower 
profitability of vaccines compared to pharmaceutical products has left only a few 
commercial companies remaining in the business of vaccine development, leading to a 
lower level of research and development in vaccines compared to that of 
pharmaceuticals. 
 Vaccination should also rapidly induce immunity; however, as long as immunity 
is elicited before a possible infection, the vaccine will be successful as illustrated by the 
current HBsAg vaccine. An ideal vaccine should rapidly elicit a lifelong immunity. 
Unfortunately very few vaccines, if any, can elicit lifelong immunity. Whether or not it 
is possible to induce lifelong immunity is not known. It would be possible to induce 
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lifelong immunity if memory lymphocytes were long lived. However, the survival 
requirements for memory lymphocytes, (whether or not they require antigen for 
survival) (Gray, 2002; Murali-Krishna et al., 1999; Swain, et al., 1999) as well as the 
lifespan of memory lymphocytes (Fearon, et al., 2001; Sprent and Tough, 2001) are 
currently unknown.  Regardless of the answers to these questions, it is likely that re-
vaccination will be required to maintain immunity. However, it may be possible to use 
controlled release delivery systems to slowly release antigen to boost immune responses 
(Cleland, 1999). The development of controlled release delivery systems may allow 
continued antigen stimulation allowing generation of effector cells from memory cells. 
This may be important in reducing the amount of time necessary for memory cells to 
become effector cells which are essential for protection against fast replicating 
pathogens. 
 The ideal vaccine would protect against all relevant infectious diseases. One of 
the potentially greatest leaps in vaccination technology would be the ability to vaccinate 
against all antigens simultaneously. Since vaccination is simply used to select specific B 
and T lymphocytes that can provide protection against specific pathogens, it is 
theoretically possible to select a specific network of cells to protect against many 
pathogens. For example, vaccination against one pathogen can protect against a different 
pathogen, potentially through cross-reactive epitopes (Chen et al., 2001b). Most 
vaccines currently used, protect against a single pathogen. However, there are also 
several combination vaccines, such as the measles, mumps and rubella, the diphtheria-
tetanus-pertussis trivalent vaccine, and the Hepatitis A and B combination vaccine. 
Although it seems a simple concept to add all existing antigens into a single vaccine, 
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there are numerous regulatory, scientific and manufacturing issues that need to be 
addressed before more combination vaccines are available. The issue of combining 
different vaccine antigens was evaluated in this project by immunizing pigs with 
plasmids encoding two different antigens. 
Finally, in order to increase compliance, and make the vaccine more economical, 
the ideal vaccine should work after a single immunization and be delivered by a needle-
free method, either, for example, by the oral route or topical application onto the skin.  
Non-invasive administration would eliminate accidental needle sticks and spread of 
disease in poor countries, where reusing needles is tempting. Several different needle-
free approaches are in various stages of development. Although some of these delivery 
systems such as BioJect (b.j.) are already used in clinical applications. Several others 
show promise in experimental systems; however, much more work is required before 
these delivery systems become clinically useful. 
 The following sections will describe DNA immunization, some of the potential 
benefits that make the skin attractive as a site of immunization. A subsequent section 
will describe delivery, adjuvants and will discuss some of the challenges regarding 
delivery of vaccines through the skin. 
 
1.2 Plasmid DNA as a vaccine  
 The observation that administration of plasmid DNA into muscle results 
in expression of its encoded protein (Wolff et al., 1990) led to the idea of using a 
plasmid encoding an antigen to elicit an immune response to the antigen (Ulmer et al., 
1993). For DNA immunization to be effective, the plasmid must enter the cell and the 
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nucleus and express the encoded gene. The mechanism of plasmid uptake remains 
unknown, but the efficiency is low due to the fact that most of the plasmid is degraded 
before gene expression occurs (see Figure 1.1).  
Once the gene is expressed, in order to stimulate an immune response, the 
antigen must be presented to cells of the immune system (Figure 1.2). DNA vaccines 
generally induce efficient antigen presentation through class I MHC, compared to killed 
or subunit protein vaccines, and therefore can induce antigen specific CTLs.  In 
addition, transfection by DNA vaccines may alter cellular function in the same manner 
as certain viral infections, enhancing antigen presentation. 
The location of antigen expression can be altered through modification of the 
plasmid antigen constructs. These include, addition of signal sequences for secreting the 
antigen, addition or removal of membrane anchors (Lewis, et al., 1999) or targeting of 
the antigen to the proteasome through ubiquitination (Delogu et al., 2000; Rodriguez et 
al., 1998; Vidalin et al., 1999). These molecular targeting approaches have been able, in 
certain experimental systems, to enhance and/or modulate immune responses to DNA 
vaccines. However, these molecular targeting approaches are dependent on the antigen 
and there is no clear knowledge why in certain circumstances they are effective.  
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Figure 1.1 Production and presentation of antigen by plasmid DNA.  
Plasmid DNA encoding an antigen enters a cell and the nucleus (1). The antigen is 
expressed by the host cell (2, 3 and 4). Once antigen is expressed it can be presented on 
class I MHC of the host cell (5, 6 and 7) or leave the cell (5).
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Figure 1.2 Antigen presentation to CD4+ and CD8+ T cells.   
With classical antigen presentation intracellular antigens are processed and 
predominantly presented on Class I MHC, whereas extracellular antigens are processed 
and presented predominantly on Class II MHC. Figure from (Tuting, et al., 1998) with 
permission. 
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The inclusion of gene-encoded cytokines administered in separate plasmids, are 
an additional way to enhance or modulate immune responses to DNA vaccines. IL-12 
and GM-CSF have been used to modulate and enhance immune responses elicited by 
DNA vaccines in mice (Iwasaki et al., 1997; Moore et al., 2002; Okada et al., 1997b). 
The cellular location of the cytokine and antigen production may play an important role: 
it was shown that a bicistronic construct (both antigen and cytokine gene on the same 
plasmid) encoding CM-CSF was more effective than co- immunizing with a separate 
GM-CSF plasmid (Barouch et al., 2002). However, if there was increased cytokine gene 
expression, it is likely that the effect of antigen cytokine localization would not be seen. 
The effectiveness of IL-12 as an encoding cytokine to enhance DNA vaccines in cats 
has recently been shown (Dunham et al., 2002). 
 One of the more innovative approaches of DNA vaccination is oral 
immunization of fetal lambs (Gerdts et al., 2000; Gerdts et al., 2002). This work 
demonstrated that fetuses are immunocompetent and protective immune responses can 
be induced by a single DNA immunization. This work was interesting for several 
reasons. Firstly, it contradicted the finding that some conventional vaccines are not as 
effective in newborns as in older subjects.  Secondly, the dogma that fetuses are not 
immuno-competent was disproved.  Thirdly, DNA vaccines administered orally in adult 
lambs do not induce immune responses, but it did in fetuses indicating that it is likely 
that fetal cells are much more permissive to transfection than fully developed cells 
(personal communication Dr. Philip Griebel, VIDO).  In utero DNA vaccination may be 
clinically useful in the future for preventing mother-to- infant transmission of pathogens 
such as herpes, hepatitis C and HIV, once such vaccines have been developed. 
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 DNA vaccines have several advantages over conventional immunization. These 
advantages include the ability to stimulate both humoral and cell-mediated immunity 
including cytotoxic T cells, without the use of conventional adjuvants (mineral oils, 
alum, etc.). The simplicity of this strategy is that it allows easier testing of antigens, by 
using the host cells as a bioreactor producing the antigen. Another advantage is that 
DNA vaccines are more stable and do not require cold storage if they are formulated in 
PBS, whereas conventional vaccines require refrigeration.  Purification procedures for 
plasmid vaccines are also simpler and cheaper compared to protein-based vaccines.  
Due to poor efficacy of DNA vaccines in humans and domestic animals 
improvements in delivery and vector design are very important. Another major hurdle 
for DNA immunization are some regulatory concerns with regards to safety. A primary 
safety concern with DNA immunization is the potential for antibodies being produced to 
the DNA. However, no significant amounts of DNA-specific antibodies are produced by 
DNA immunization (Mor et al., 1997), allowing for repeated administration of the 
vector. Another safety concern is the potential for integration of the plasmid into 
chromosomal DNA.  Several studies have addressed this issue and have concluded there 
is a lack of evidence for integration, suggesting that integration is a very rare event if it 
does occur at all (Martin et al., 1999). The antibiotic resistance gene present in the 
plasmid is also another potential safety issue, however, other selectable markers can be 
used to replace the antibiotic resistance gene in the plasmid or can be removed from the 
plasmid after production using restriction enzymes and ligating the end strands together. 
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1.3 The skin as an immune compartment and a site for vaccine administration 
It is essential to understand the structure and function of the skin in order to 
develop effective transdermal vaccination techniques.  The skin is the outermost layer of 
the body.  The function of the skin is to protect against water loss, ultraviolet light and 
as the first line of defense to prevent the entry of pathogens into the body. It is precisely 
because of these functions, that the skin presents a challenge to the topical delivery of 
both protein and DNA vaccines. This section will describe the structure as well as 
immune competence of the skin, to lay the foundation for the later section describing 
approaches for vaccine delivery through the skin. 
The skin is composed of the epidermis, the dermis and the hypodermis (Figure 
1.3).  The hypodermis forms the deepest layer of the skin. It contains mostly adipocytes 
and fibroblasts.  Above the hypodermis, is the dermis, which is a 2-3 mm thick (in 
human skin) consisting of connective tissue matrix and containing fibroblasts, 
macrophages and mast cells.  Between the dermis and epidermis is the basal lamina, 
which is the basement membrane for the epithelial cells of the epidermis, the outermost 
layer of the skin.  The viable (living) epidermis is composed of approximately 90% 
keratinocytes.  Throughout the viable epidermis, immune competent dendritic cells, 
called Langerhans, present antigen.  These Langerhans cells, despite only composing 
1% of the cell population represent nearly 20% of the surface area of cells in the skin 
through their horizontal orientation and long protrusions which form a meshwork that 
allows them to take up antigens that cross the epidermal barrier (Bodey, et al., 1997).  
This network of Langerhans cells represents the second line of defense after the stratum 
corneum and initiate specific immune responses by presenting the processed antigens to  
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Figure 1.3 Histology of normal mouse skin 
Normal mouse skin (HE stain).  The stratum corneum is the outermost layer of skin in 
the epidermis. Under the epidermis is the dermis, is a layer of smooth muscle and the 
hypodermis. Bar is 100 µm. 
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other cells of the immune system.  Keratinocytes in the epidermis undergo process of 
differentiation to form five different cell layers, namely the basal, spinous, granular, 
clear and horny layers (Eckert, 1989).  The basal cell layer consists of undifferentiated 
keratinocytes and stem cells sitting on the basal lamina (Stanley et al., 1982).   
Above the basal cell layer is the spinous layer (stratum spinosum) of cells, so-
named because of the spine- like appearance created by the desmosomes.  Next is the 
stratum granulosum.  The transition zone or clear layer above the granular zone consists 
of both viable and dead cells.  The cells in the transition zone undergo major continuous 
cellular changes, including remodeling of keratin filaments into more structurally stable 
bundles (Fuchs, 1995) and release of their lipid containing granules into the extracellular 
matrix.  Above the transition zone lies the stratum corneum.  The stratum corneum is 
10-20 mm thick and consists of terminally differentiated keratinocytes called 
corneocytes.  Corneocytes are flattened cells that contain intracellular cross-linked 
fibrillar bundles of keratin, giving the corneocyte a rigid structure.  Desmosomes 
maintain corneocytes into the ordered structure of the stratum corneum (Chapman and 
Walsh, 1990).  The stratum corneum also contains multilamellar arrays of lipids found 
extracellularly between the corneocytes.  These multilamellar arrays are composed 
primarily of cholesterol, free fatty acids, and ceramides (Elias, 1983).  The stratum 
corneum is constantly being sloughed and replaced. When this barrier layer is breached 
physically, chemically or biologically, many metabolic responses such as the synthesis 
of fatty acids, cholesterol, and ceramides occur, as well as secretion of preformed 
lamellar bodies to return the barrier to normal (Tsai et al., 1996). For these reasons the 
stratum corneum is not a static structure, but is continuously being altered in response to 
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the interaction with the environment, thus preventing prolonged disruption of the 
barrier.  The remaining specialized cells include the pigment containing melanocytes, 
the function of which is to protect all of the lower cells from ultraviolet light, the 
epidermotropic lymphocytes and sensory Merkel cells. 
There are differences in skin thickness and lipid composition among different 
animal species. Mouse skin has a much thinner stratum corneum and dermis compared 
to porcine skin (Hammond et al., 2000). 
The skin acts as a barrier to environmental insults and maintains the viable cell 
layer in a state of homeostasis.  When the skin is damaged, keratinocytes and 
Langerhans cells become activated. When activated, keratinocytes can synthesize a large 
number of cytokines involved in modulating the immune response (Luger and Schwarz, 
1991).  In addition, keratinocytes can express intercellular adhesion molecules (ICAMs) 
and other adhesion molecules for various immune cells (Lawley and Kubota, 1991). 
Keratinocytes are therefore immunologically active cells, in addition to providing 
structure to the skin.  On activation, Langerhans cells increase phagocytic activity and 
move from the skin where they encounter antigens into draining lymph nodes where 
they present foreign antigens and initiate immune responses (Cumberbatch et al., 1996). 
Numerous experiments using proteins (Romani et al., 1989) and peptides 
(Celluzzi and Falo, 1997) have established Langerhans cells as antigen presenting cells.  
Additional experiments using DNA have re-enforced the importance of Langerhans cells 
as APCs.  The so called "van Gogh experiments" (Barry and Johnston, 1997) showed 
that removal of the vaccination site after DNA vaccination still resulted in specific 
immune responses to a DNA vaccine.  It was demonstrated that Langerhans cells from 
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the skin, following administration of plasmid encoding green fluorescent protein (GFP) 
via gene gun, migrated to the local lymph nodes and expressed GFP (Condon et al., 
1996). In addition, adoptive transfer of dendritic cells, transfected with antigen encoding 
plasmid in vivo, elicited antigen specific immune responses in vivo (Tuting et al., 1997).  
These studies all support the contention that dendritic cells are involved in inducing 
immunity to the foreign antigens they encounter in the skin.   
Although dendritic cells are critical for the induction of immunity, they do not 
act alone.  To investigate the role of other cells in immune induction and modulation, 
mice were immunized using a gene gun.  After immunization, the skin at the site was 
removed sequentia lly at several time points, and grafted onto non- immunized mice.  
Antibody and cellular immune responses were measured and the results from these 
experiments showed that both dendritic and non-dendritic cells were important for (1) 
the initiation and (2) the magnitude of the response (Klinman et al., 1998).  The specific 
role of CD4+ helper T cells was examined using DNA immunization encoding either a 
MHC class I restricted peptide or the class I restricted peptide plus a class II restricted 
peptide.  These experiments demonstrated that a very weak immune response could be 
elicited from the single class I restricted peptide; however, strong immune responses 
were obtained when both class I and class II restricted peptides were used, clearly 
showing that help is essential for eliciting immune responses (Maecker et al., 1998).  B 
cells are essential for the production of specific antibody and can act as APCs. B cell 
deficient mice were used to examine the role of the B cell in DNA immunization.  B cell 
deficient mice produced cellular immune responses to the encoded antigen in the 
absence of an antibody response (Chen, et al., 1998).  Taken together, these studies 
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support the concept that numerous cell types may be involved in DNA uptake, antigen 
expression and presentation and that the cells in the epidermal/dermal layers are 
excellent sites for vaccine administration. 
 
1.4 Overview of delivery systems and devices currently used for vaccine 
delivery 
 
In order to deliver vaccines and target immune cell compartments there is a wide 
variety of systems ranging from delivery devices to delivery vehicles.  The ideal 
delivery vehicle should have several attributes, namely safe, non-toxic, non-
immunogenic and economical, allowing widespread use.  It would also be effective and 
induce reproducible immune responses to the delivered antigen.  In addition, the 
delivery vehicle would be pharmaceutically acceptable, stable and biocompatible.  As 
well, the ideal delivery vehicle would be non- invasive with the possibility of controlled 
release, thus increasing compliance. 
 
1.4.1 Delivery devices 
 
The skin is one of the most frequently used tissues for vaccination using delivery 
devices, due to the fact that it is easily accessible and monitored. Delivery devices can 
be classified as instruments that use physical brute force to deliver vaccine antigens 
through the stratum corneum into the skin.  There are a wide range of delivery devices 
consisting of injection systems such as needle injection, jet stream injection and 
biolistics devices as well as membrane de-stabilizers such as electroporation, 
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ionophoration and sonophoration. Figure 1.4 compares efficiency and invasiveness of 
the different delivery systems. 
Although injection is one of the most widely used delivery techniques, in 
vaccination it does have a number of drawbacks. These include pain associated with 
injection, risk of accidental needle sticks, spread of disease especially in developing 
countries due to reuse of needles, as well as expenses in biohazard disposal.  
Considering the trauma associated with needles, vaccination compliance may be 
improved if vaccines were to be administered less invasively.  This has led to the 
development of new delivery systems. 
Gene guns use DNA covered gold beads propelled through the skin by helium 
(Figure 1.5) (Fynan et al., 1993).  Although the gene gun was first developed to transfer 
genes into plant cells, later refinements allowed its use in animals.  The gene gun is 
essentially a miniature shotgun with gold beads acting as small projectiles to carry DNA 
through the skin into and around cells.  The DNA is introduced into the cytoplasm and 
nuclei of cells facilitating expression of the plasmid-encoded gene.  Since a gene gun 
delivers plasmids directly into cells, this increases the efficiency of gene transfer. One of 
the first reports of successful DNA immunization used a gene gun to administer plasmid 
(Tang, et al., 1992). Because of direct introduction of plasmid DNA into cells, immune 
responses are generated using nanograms of plasmid DNA (Pertmer et al., 1995).  The 
disadvantage of the gene gun is that it is most suitable for DNA, although it can be used 
to deliver proteins with extensive formulation modifications (Chen et al., 2001a).  It also 
requires extensive equipment and preparation of the vaccine, and only small amounts of 
DNA can be coated onto the gold particles without causing aggregation, requiring  
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Figure 1.4 Current delivery systems for DNA vaccines: Comparison of efficiency and 
level of invasiveness.  
Topical
Microneedles
Needle
injection
ElectroporationGene gun
Jet
injection
Low Invasiveness High
Lo
w
 
E
ffi
ci
en
cy
 
H
ig
h
 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Delivery of plasmid using a gene gun to the epidermis.  
Plasmid coated onto gold beads is propelled into the epidermis by helium using the gene 
gun. 
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numerous shots for animals other than mice.  These inconveniences will probably 
preclude its extensive use unless they can be overcome.   
Jet injection uses air pressure to force liquid through the skin and around cells 
(Figure 1.6).  The liquid follows the path of least resistance; therefore tissue damage is 
reduced compared to conventional injection.  Jet injectors can be used for intradermal, 
subcutaneous and intramuscular injections.  This method was first used for the 
intramuscular delivery of BCG vaccines (Bleasdale, 1965) followed by HBsAg protein 
vaccines (Whittle, et al., 1987).  Following successful use for conventional 
immunization, the jet injector was used for gene transfer experiments as well as DNA 
immunization (Degano, et al., 1998). The results showed the jet injector to be more 
efficient than conventional injection for delivery of plasmid, with the efficiency of DNA 
expression dependent on the force of the injection (Furth, et al., 1995). Varying the 
force varies the depth to which the protein or DNA is delivered.  By using special 
spacers, it is possible to deliver most of the vaccine to the epidermis, a dendritic cell rich 
area of the skin.  The delivery of both protein and DNA vaccines were tested in pigs 
using intradermal administration with the BioJect. 
Recently, it was demonstrated that microfabricated microneedles approximately 
150 mm long could be used to increase permeability of human skin (Henry et al., 1998).  
Arrays of these microneedles create conduits across the stratum corneum, potentially 
allowing transport of DNA and proteins into the epidermis.  Since these microneedles 
only penetrate through the stratum corneum and into the viable epidermis, they do not 
reach nerve endings and applications are essentially painless.  In addition, there are no 
visible skin reactions detected by light microscopy (Henry et al., 1998).  These initial 
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Figure 1.6 Comparison of intramuscular injection by conventional needle and using a 
BioJect jet injector.  
Delivery by jet injection uses a high-pressure stream of liquid to penetrate the stratum 
corneum and delivery the liquid into the tissues. Figure from BioJect website, 
(www.bioject.com/tech/all3.html).  Reprinted with permission. 
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studies are very encouraging and hopefully future experiments will determine the 
efficacy of microfabricated microneedles in delivering DNA and protein to the skin in 
vivo. 
Electroporation is a technique that has been used for several years to deliver 
DNA into cells in vitro.  Based on this success, it has recently been used in vivo (Zhang 
et al., 1996).  The basis behind electroporation is that the plasma membrane of the cell, 
when pulsed with an electric field, becomes stretched and permeabilized so the DNA 
can enter the cell.  Electroporation in vivo is accomplished by placing naked DNA on 
the skin, followed by pulsing the skin with electrical charges through calipers placed on 
the skin (Banga and Prausnitz, 1998).  Recently electroporation was shown to improve 
DNA immunization, by increasing gene expression in mouse muscle and immune 
responses to the vaccine (Widera et al., 2000). There are several different variables in 
electroporation such as the strength of the electric field, pulse length and number of 
pulses. Increasing the electric field (voltage) and pulse length and electric field can all 
increase the effects of electroporation on cells.  However, the relationship between how 
these variables interact with each other is currently unknown.  To find the optimal 
balance between electroporation conditions that allow pore formation in cell membranes 
without causing cell death, as measured by gene expression; it was necessary to test 
these parameters in vivo.  In addition, there are several different types of electrodes. For 
electroporation of deeper tissue, such as muscle, needle electrodes are used. There are 
also several different needle electrodes, for example, the single pair of needle electrode, 
which allows an electric field to be generated between the needles. Improvements to this 
method include arrangement of field array using more needles and switching schemes. 
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However, these arrays are extremely invasive and likely would only be used for severe 
circumstances like cancer (Hofmann et al., 1999b). A less invasive single-needle 
electrode was tested in this project for efficacy in DNA immunization. Other non-
invasive electrodes such as the meander electrode (alternating cathodes and anodes 
placed on a flexible background material) and the MP 35 electrode (a flat disc electrode) 
that allows better skin contact and improved electroporation (personal communication, 
Georg Widera, Genetronics Inc.) were also tested for enhancing gene expression and 
immune responses to DNA vaccines.  
Ionophoration (iontophoresis) is similar to electroporation; the main difference 
being that it uses weaker electric fields, for a longer period of time, than the strong 
electric fields used in electroporation (Oldenburg et al., 1995). 
Sonophoration uses ultrasound waves to disorganize lipids of the stratum 
corneum, increasing the permeability of the skin to be increased (Mitragotri et al., 
1995).  Several proteins such as insulin, IFN-g and erythropoietin have been delivered 
through the skin using this approach in animal models (Mitragotri et al., 1995).  
Sonophoration is a relatively new technique that may be used for delivering both DNA 
and protein based vaccines transdermally.  Membrane destabilizing devices are 
relatively new but they offer great potential for DNA immunization in the future. 
 Photomechanical delivery uses a laser pulse to transiently increase the 
permeability of skin (Lee et al., 1998).  High molecular weight dextrans were delivered 
through the skin using this technique, suggesting that the delivery of proteins and DNA 
possible with this method. 
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Combining delivery systems may be advantageous for enhancing immune 
responses to DNA vaccines, if the delivery systems are compatible.  Since 
electroporation can increase plasmid uptake into cells, and delivery by BioJect increases 
the distribution of plasmid in tissue, the combination of the two would be a needle-free 
surface electroporation that could enhance gene expression and immune responses to a 
DNA vaccine. 
 
1.4.2 Microencapsulation and polymeric complexes 
Polycations have been used to complex DNA, allowing properties of size, charge 
and amphipathic nature to be controlled and have been used for plasmid delivery in 
vitro.  It is believed or hoped that non-viral delivery systems can overcome problems 
such as safety and tissue tropism seen using viral delivery (Kabanov et al., 2002). In 
addition, certain polymers are not immunogenic permitting repeated use of the polymer, 
unlike viral vectors, which may only be used once due to elicitation of immune 
responses. 
Microencapsulation is the physical entrapment of molecules within polymeric 
structures.  In order for a polymer to be useful for microencapsulation it must be 
biodegradable, biocompatible (non-toxic) and non- immunogenic.  Despite the large 
number of possible polymers only a few are biodegradable and therefore, a limited 
number have approval for clinical use in humans.  Once a biological polymer is 
characterized for stability, biocompatibility, safety and the manufacturing conditions are 
optimized, it should be easy to manufacture.  In addition, polymers can be designed to 
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include specific external ligands, which may enhance cell targeting.  These properties 
make microspheres very attractive vaccine delivery systems. 
Polymers can be categorized as either natural or synthetic.  Natural polymers are 
various carbohydrates such as starch (Heritage et al., 1996; Heritage et al., 1998), 
alginate (Bowersock et al., 1999) and chitosan, as well as proteins such as albumin and 
gelatin (Truong-Le et al., 1998).  Synthetic polymers with a proven track record in 
human trials are microspheres composed of D-poly L- lactate (PLA), poly (DL-lactic-co-
glycolic acid) (PLGA) (Jain et al., 1998) or polycaprolactones (Jameela et al., 1997).  
Other synthetic polymers that may have potential use for vaccination are 
polyorthoesters, polyanhydrides (Chiba et al., 1997) and polyphosphazenes (Andrianov 
et al., 1998). 
The advantage of natural polymers is that they do not require the harsh 
conditions of heat and/or organic solvents for encapsulation of antigen, as do some 
synthetic polymers.  Gelatin and chitosan nanospheres allow DNA to be physically 
trapped in a solid matrix through the process of complex coacervation (Truong-Le et al., 
1998; Truong-Le et al., 1999).  In vivo injection of plasmid formulated in gelatin 
nanospheres to muscle showed a higher rate of gene expression as compared to naked 
DNA and DNA/lipofectamine complexes.  Although nanospheres may be useful for 
intradermal delivery if injected, they are not effective for topical delivery.  Other 
delivery vehicles such as alginate microspheres have been used extensively for delivery 
of protein antigens through mucosal surfaces (Bowersock et al., 1998; Moser et al., 
1997).  Based on this early success, alginate microspheres could potentially be used to 
encapsulate DNA for enhanced delivery especially to mucosal surfaces (Aggarwal et al., 
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1999).  Whether they can be designed in such a way as to deliver vaccines topically 
remains to be determined. 
PLA and PLGA polymers can be adapted to improve the delivery of many types 
of vaccines such as proteins (Coombes et al., 1998), carbohydrates (Gupta et al., 1998) 
and DNA (Jones et al., 1998). These polymers are especially useful for delivery through 
mucosal surfaces of the gastrointestinal tract (Jones et al., 1997).  These polymers 
protect the contents of the microsphere from degradation as well as allow controlled 
release of the contents. However, PLGA microspheres may not be suitable as 
transdermal delivery agents because they cannot penetrate the stratum corneum, and 
therefore would require injection. 
Based on these findings, polymers may be useful for non-invasive vaccination at 
mucosal surfaces or possibly injection into the skin using novel delivery devices 
previously described. Even though microspheres would require injection for dermal 
vaccination, a major advantage of microspheres is the potential for controlled release of 
the antigen.  Through the use of controlled release, it might be possible to imitate 
multiple boosts with a single immunization (Cleland, 1999). Even if microspheres have 
to be delivered by injection, they will require fewer administrations. 
Polymers used to form polyelectrolyte complexes with DNA are synthetic 
peptides, dendrimers, polyethyleneimine and polyvinyl pyrrolidone.  These polymers are 
relatively new, but have been shown to be effective in mediating transfection in vitro 
(Bielinska et al., 1996; Haensler and Szoka, 1993).  Dendrimers are spherical structures 
of synthetic polymers that can form complexes with DNA.  They are branched and 
contain a high surface charge due to the many amino groups they carry. Dendrimers 
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have been shown to deliver DNA to a variety of cell lines in vitro (Bielinska et al., 
1996).  Another polymer, polyethyleneimine, which contains net positive charges and 
can condense DNA, has been shown to enhance DNA delivery in vitro to a variety of 
cell lines (Boussif et al., 1995).  2-(dimethylamino) ethyl methacrylate (DMAEMA) 
homopolymers as well as the heteropolymers, DMAEMA methyl methacrylate co-
polymers have been used to effectively introduce plasmid DNA into cells in vitro (van 
de Wetering et al., 1998).  Synthetic peptides such as poly-ornithine, poly- lysine, and 
poly-arginine as well as amphipathic peptides can increase transfection efficiency in 
vitro (Gottschalk et al., 1996; Pouton et al., 1998; Wadhwa et al., 1997).  A major 
concern with using synthetic peptides as delivery vehicles for vaccines is the possibility 
of inducing immune responses to the peptides. If an immune response to the peptide is 
generated, the delivery system may only be useful once due to blocking antibodies or in 
the worst-case scenario, to autoimmunity (Gaur et al., 1992).  Despite these risks, with 
the proper testing and design, peptides may be useful transdermal delivery systems 
because amphipathic peptides can mimic liposomes through their polar and non-polar 
regions.  To improve these peptides, various components such as polyethylene glycol 
(Choi et al., 1998), lipid derivatives such as stearyl-poly- lysine and low-density 
lipoprotein, can be added to form a terplex system (Kim et al., 1998).   
Protective, interactive, non-condensing (PINC) polymers made from polyvinyl 
pyrrolidone, polyvinyl alcohol or derivatives can form complexes with DNA, while able 
to diffuse throughout muscle, increasing the distribution of plasmid through out the 
tissue.  Injection of PINC/plasmid complexes to muscle showed a ten-fold increase in 
reporter gene expression over naked plasmid.  In addition, DNA immunization using 
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PINC/plasmid complexes administered by needle-free injection showed an increase in 
antibody titer compared to naked DNA (Anwer et al., 1999).  The amphipathic nature of 
PINC polymers as well as the ability to diffuse through tissue gives these polymers 
potential to be useful for topical delivery of plasmids.  
However, there has been little testing of these polymers in vivo for efficacy, 
safety, and biological effects such as adjuvant activity.  Future in vivo experiments with 
these polymers will reveal their effectiveness.  When designing vaccine formulations, it 
is critical that any adjuvant properties in the delivery system are compatible with the 
vaccine, since it is essential that the adjuvant induce the proper type of immunity 
necessary for protection. 
 
1.4.3 Liposomes 
The first practical use of liposomes was to enhance the efficacy of amphotericin 
B in vivo (Taylor et al., 1982).  Several cationic lipids demonstrated no significant 
toxicity results in initial clinical trials (Nabel et al., 1994; Nabel et al., 1993).  Following 
these successes, liposomes have been used to deliver various protein antigens for 
immunization studies (Baca-Estrada et al., 1997, Baca-Estrada et al., 1999, Griffiths et 
al., 1998, Kwak et al., 1998).  These studies have shown the ability of liposomes to 
increase immune responses following either systemic or mucosal administration.  In 
addition to enhancing the immune responses to antigens, liposomes can elicit cell-
mediated responses (Walker et al., 1992).  It is for these reasons, that researchers are 
excited about the potential of liposomes as immunization vehicles. 
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Liposomes are vesicles spontaneously formed when phospholipids and water 
mix (Bangham, 1995); however, to produce liposomes with different structures, energy 
from various manufacturing treatments such as sonication, homogenization, extrusion, 
dialysis and filtering are necessary. Liposomes/lipids can be made with a wide variety of 
characteristics. The net charge of liposomes can be cationic, anionic or neutral. Recent 
advances in manufacturing conditions have improved the homogeneity of the liposomes 
produced. Depending on manufacturing conditions, liposomes can be made to vary in 
size, number of lamellae, structure, and respective “payloads”. Manufacturing 
conditions can also influence the different structures formed by the interactions between 
DNA and cationic lipids. These structures can be predominantly lamellar, the most 
stable, spaghetti- like and hexagonal, the least stable (May and Ben-Shaul, 1997).  A 
recent report showed that the hexagonal phase structure was better at transfection 
compared to other structures due to its ability to rapidly fuse to membranes and release 
DNA (Koltover et al., 1998); however, this has only been shown to occur in vitro and 
may not be true in vivo. 
The role of liposome charge in transdermal delivery is not well understood.  The 
interaction of liposomes with skin in vivo showed that a negative charge as well as 
cholesterol inclusion, and the acyl chain length of the phospholipids did not appear to 
affect the penetration efficacy of the liposome into the stratum corneum (Kirjavainen et 
al., 1999).  Although the charge of the liposome may not influence the penetration 
efficacy through the stratum corneum, it may influence the interaction with the 
protein/DNA thus influencing the penetration of proteins. 
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Liposomes can be created from a wide variety of lipids and cholesterol.  When 
formulating vaccine antigens with liposomes, it is critical to determine the compatibility 
of the antigen with the liposomes. Different antigens can have markedly different 
chemical properties that influence their formulation; thus each vaccine must be 
formulated specifically for each antigen. The composition of lipids and cholesterol in 
the liposome give the liposome its properties.  Penetration enhancers, or helper lipids 
such as dioleoylphosphatidylethanolamine (DOPE), allow greater uptake of the 
liposome and its contents through the skin (Kirjavainen et al., 1996), demonstrated, for 
example through experiments showing that liposomes containing DOPE penetrate 
deeper into the stratum corneum than liposomes without DOPE (Kirjavainen et al., 
1999). Other helper lipids such as dilauroylphosphatidylethanolamine (DLPE), 
dimyristoylphosphatidylethanolamine (DMPE) and dipalmitoylphosphatidyl-
ethanolamine (DPPE) are similar to DOPE, varying only in their lipid chain length and 
saturation. 
A major concern with the use of liposomal delivery systems for vaccine antigens 
is toxicity to cells of the immune system.  Cationic lipids are highly toxic to phagocytic 
cells such as macrophages (Filion and Phillips, 1997), perhaps due to destabilization of 
the lysosomal membranes by the cationic lipids (Wattiaux et al., 1997). 
In addition to protein delivery for immunization, liposomes have been used to 
deliver plasmid DNA. The most commonly used lipids for delivery of plasmid DNA are 
the cationic lipids such as N-(1-(2,3-dioleoxyloxy)propyl)-N,N,N,-trimethylammonium- 
methyl-sulfate (DOTAP) (McLachlan et al., 1995), dioleyloxy-propyl- 
trimethylammonium chloride (DOTMA) (van der Woude et al., 1995), 
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dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE) (San et al., 1993), 
dimethyldioctadecyl ammonium bromide (DDAB) (Zhao et al., 1997) and (N(N',N-
dimethylaminoethane) carbamoyl) cholesterol (DC-Chol).  Liposomes for DNA 
immunization have been used for intranasal administration (Klavinskis et al., 1997; 
Okada et al., 1997a).  These experiments demonstrated the induction of strong mucosal 
responses by this approach.  There are also a few reports on the use of liposomes to 
deliver plasmids to other tissue sites.  Enhancement of immune responses over those 
seen with direct injection into muscle was observed, when plasmid was incorporated 
into liposomes (Gregoriadis et al., 1997; Ishii et al., 1997).   
 
1.4.4 Virus like particles 
Virus like particles (VLPs) are the outer capsid viral proteins that spontaneously 
self assemble into particles.  VLPs have been manufactured from numerous viruses such 
as papilloma virus (Kirnbauer et al., 1996), rotavirus (Conner et al., 1996), parvovirus 
(Sedlik et al., 1997), hepatitis B virus (Schirmbeck et al., 1996) and others.  Their major 
advantage is that VLPs are more immunogenic than the individual protein subunits of 
which they are composed.  This may be due to the repetitive nature of the proteins 
making up the VLPs (Bachmann and Zinkernagel, 1997) or to enhanced antigen 
presentation by APCs due to the particulate nature of VLPs (Kingsman and Kingsman, 
1988). VLPs can be used without adjuvants to generate specific immune responses.  
Furthermore, peptide epitopes of a limited size can be directly incorporated into the viral 
protein without affecting assembly (Allsopp et al., 1996). VLPs can be used to 
encapsulate proteins (Adams et al., 1994) or DNA (Touze and Coursaget, 1998) to 
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facilitate vaccine delivery.  Finally, at least some VLPs may be used repeatedly since 
they are not affected by prior exposure to the vector (Frenchick et al., 1992).  VLPs 
made from viruses that generally enter through the skin, such as papilloma virus, may be 
especially attractive for transdermal delivery, although there is no reported evidence for 
their efficacy. 
 
1.4.5 Viral vectors  
The skin was first used as a site for vaccination by Jenner by rubbing infectious 
Variola minor on to scratched skin. Viruses such as papilloma and herpesvirus with a 
tropism for the skin may be good candidates as vectors for carrying antigens and 
eliciting immune responses.  However, the stratum corneum must be breached to allow 
viruses to infect cells.  For example, after mouse skin was treated using a depilatory 
reagent, an adenovirus vector encoding human carcinoembryonic antigen (CEA) placed 
on the skin during recovery from anaesthesia resulted in induction of CEA specific 
antibodies in 23 of 24 immunized mice (Tang et al., 1997).  
Non-replicating viral vectors created through gene deletions resemble artificial 
non-viral vectors.  Sophisticated non-viral vaccines can share more similarities with 
viruses by addition of viral replicons that allow the DNA vector to replicate in RNA 
form once inside a cell (Berglund et al., 1998).  Non-viral based DNA vaccines 
delivered using lipids mimic very closely gene-deleted non-replicating viral vaccines 
with respect to intracellular expression of antigen and induction of immune response.  
However, viral based vaccines are still much more effective at transfecting cells in vivo 
and generally elicit stronger immune responses without adjuvants, compared to non-
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viral vaccines.  The advantages of using non-viral plasmid vaccines over viral vaccines 
are quality control issues as well as manufacturing issues.  The manufacturing of 
plasmid vaccines is considerably easier than the production of viral vaccines due to the 
fact that plasmid vaccines are produced in a prokaryotic system as opposed to the 
complex cell culture system needed for production of viral vectors.  In addition, non-
viral based methods may be able to fulfill many product requirements such as a high 
safety profile, low cost, high reproducibility, and ability to elicit an effective immune 
response (Mumper et al., 1996). 
 
1.5 Adjuvants 
Adjuvants are components added to vaccines to increase their immunogenicity.  
Some killed vaccines such as HSV-1 (ultraviolet inactivated) (Schneweis et al., 1981) 
do not require addition of adjuvants to induce potent immune responses since many of 
their components have adjuvant activity. However, most vaccines (killed or subunit) 
require adjuvants to elicit protective immune responses.  As vaccination technology 
advanced from rather crude killed vaccines that had many undefined components to 
highly purified protein subunit and peptide-based approaches, the immunogenicity of 
vaccines decreased dramatically. 
To enhance immune responses, adjuvants are incorporated into vaccines. 
Adjuvants act either as a depot for the vaccine or by stimulating cells of the innate 
immune system to subsequently increase specific immune responses. The first adjuvant 
used was Freund's adjuvant. Freund's incomplete adjuvant is mineral oil that acts a depot 
and Freund's complete adjuvant is mineral oil containing killed mycobacterium. 
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Although both Freund's adjuvants are effective, they cause extensive tissue damage and 
are not licensed for commercial vaccines. Following Freund's adjuvant, the search for 
safer adjuvants led to the development of aluminum hydroxide (Alum) and MF59, 
currently the only licensed vaccine adjuvants for humans. 
Today it is known that many microbial components such as lipopolysaccharide 
(LPS), flagella, cell wall components and bacterial DNA simulate the innate immune 
system through various receptors of the Toll- like receptor family (Schnare et al., 2001). 
Microbial components that stimulate Toll- like receptors are potential adjuvants. 
 
1.5.1 CpG motifs of bacterial DNA 
1.5.1.1 Introduction 
 
 The immunogenic properties of bacterial DNA were first discovered in tumor 
regression in some mouse models (Tokunaga et al., 1984). The functional sequences of 
bacterial DNA were identified as CpG sequence motifs flanked by two 5’ purines and 
two 3’ pyrimidines. These CpG motifs are found at a much higher frequency in bacterial 
DNA compared to mammalian DNA.  In addition, these motifs are methylated 
differently in bacterial DNA with the cytosine residue being unmethylated, where it is 
methylated in mammalian DNA. These differences in methylation patterns are critical 
for CpG activity since methylation of CpG using mammalian methylases abolishes their 
immunostimulatory activity (Oumouna et al., 2002). Thus, the immune system 
recognizes mammalian DNA as self and immunogenic bacterial DNA as foreign.  These 
CpG motifs can be encoded in synthetic oligonucleotides allowing for a chemically 
defined molecule that displays multiple biological effects. 
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1.5.1.2 Cells which are stimulated by CpG 
CpG motifs have a wide variety of activities, such as triggering B cell 
proliferation (Krieg et al., 1995), activation of macrophages (Stacey et al.1996) and 
activation of NK cells through stimulation of IL-12 (Zhan and Cheers, 1995). With the 
activation of these cells, a variety of cytokines such as IL-6, IL-12, and IFN-? are 
produced (Klinman et al., 1996). In addition, bacterial DNA is a potent stimulator of 
dendritic cells, promoting Th1 responses to antigens (Jakob et al., 1998). Although the 
exact mechanism by which CpG activates cells is currently unknown, CpG ODNs must 
enter cells to be biologically active. This was demonstrated by a lack of immune 
stimulation by immobilized CpG on a Sepharose beads that could not enter the cell 
(Manzel and Macfarlane, 1999). Recently, a Toll- like receptor (TLR9) was found which 
recognizes bacterial DNA.  The possibility that binding to this receptor is essential for 
CpG immunostimulatory activity was suggested by the fact that TLR9 knockout mice 
fail to respond to CpG ODNs (Hemmi et al., 2000).  TLR9 is expressed on B cells, 
macrophages and plasmacytoid dendritic cells in mice.  In addition, transfection of the 
TLR9 gene into CpG non-responsive cells allows the cells to respond to CpG (Bauer et 
al., 2001; Chuang et al., 2002). 
 
1.5.1.3 CpG ODNs as adjuvants and immunoprotective agents 
CpG ODNs have been used as adjuvants with subunit (Davis et al., 1998) and 
killed viral vaccines (Moldoveanu et al., 1998). When CpG ODNs are used as adjuvants 
they promote Th1 type immune responses. This is extremely valuable since some 
pathogens such as Leishmania require induction of Th1 responses for protection (Soares 
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et al., 1994), whereas most conventional adjuvants such as alum promote Th2 type 
responses.  CpG, in addition to being a systemic adjuvant, has also been shown to be a 
potent mucosal adjuvant (McCluskie and Davis, 1999; McCluskie and Davis, 2000; 
McCluskie et al., 2001). 
Since CpG ODNs have potent immunostimulatory activity, they have been tested 
to assess their ability to protect mice against lethal challenge of Listeria monocytogenes 
(Krieg et al., 1998a), Francisella tularensis (Elkins et al., 1999), as well as Leishmania 
major (Zimmermann et al., 1998).  CpG ODNs were able to immunoprotect mice 
against these diseases as well as other pathogens (personal communication, Arthur 
Krieg). 
 
1.5.1.4 CpG motifs and DNA vaccines 
It has been hypothesized that CpG motifs normally present in plasmid vectors 
are essential for DNA vaccines to be effective (Krieg et al., 1998c). There is some 
evidence that the presence of CpG motifs within the DNA backbone contributes 
significantly to the immune response (Klinman et al., 1997; Sato et al., 1996).   Indeed, 
the propensity of DNA vaccines to induce Th1-type or mixed Th1/Th2 responses (Raz 
et al., 1996), appears to be at least partially due to the presence of CpG motifs in the 
plasmid backbone. If CpG motifs are methylated, immune responses are significantly 
reduced (Leclerc et al., 1997). Conversely, the removal of inhibitory CpG motifs 
(additional motifs which suppress the activity of CpG motifs) or the insertion of an 
optimal number of immunostimulatory CpG motifs can enhance immune responses 
(Krieg et al., 1998b). 
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It has been shown in mice that mixing CpG ODN with antigen-encoding plasmid 
DNA either only marginally increased the immune responses (Klinman et al., 1997), or 
resulted in a dose-dependent reduction of the immune response (Weeratna et al., 1998). 
A possible mechanism for reduction in immune responses is inhibition/blocking of entry 
of plasmid DNA into the cells resulting in decreased gene expression.  However, there 
are several reports that show that addition of CpG motifs into plasmid vectors does not 
enhance antigen specific immune responses (Deml et al., 2001; Sun et al., 2002).  From 
these studies it is clear that simply cloning additional CpG motif does not necessarily 
result in the enhancement of immune responses from DNA vaccines. 
 
1.5.1.5 Enhancing biological effects of CpG 
Depending on backbone chemistry, ODN can be degraded within minutes 
following in vivo administration (Semple et al., 2000, Semple et al., 2001). This rapid 
clearance may limit the uptake and subsequently the effectiveness of CpG ODN as an 
immunomodulating agent. Formulation of CpG ODN in appropriate delivery systems 
may potentiate its immunostimulatory effects, by either protecting CpG ODN from 
degradation, increasing uptake by immune cells (Gursel et al., 2001), or by prolonged 
stimulation of infiltrating cells such as macrophages at the site of injection. Liposomes 
provide a vehicle or a carrier system into which antigens and co-adjuvants can be 
incorporated (Gregoriadis, 1990) to induce protective immune responses against 
bacterial, viral and parasitic infections (Baca-Estrada et al., 2000; Childers et al., 1997). 
Cationic liposomes can protect antisense ODNs from nuclease digestion and have been 
used to successfully deliver them to the cytoplasm of target cells (Duzgunes et al., 2001; 
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Zhang et al., 2001). Encapsulation of CpG ODN in liposomes can prolong their stability 
in vivo, increase uptake by immune cells, prolong interaction with APCs and increase 
induction of cytokine responses (IL-12, IFN-g and IL-6). Consequently, liposome 
formulated CpG increases the magnitude and duration of immune responses (Agrewala 
et al., 1996; Gursel et al., 2001; Mui et al., 2001). Liposome formulation of CpG ODN 
may also increase the dose of CpG ODN delivered to the draining lymph nodes, where 
many of the cells activated by CpG ODN are located. More efficient delivery of CpG 
ODN can effectively reduce the amount of CpG ODN required for a biological response.  
In addition to liposomes, other vehicles have been used to enhance the activity of 
CpG ODN. Mice inoculated with CpG ODN mixed with stabilized antisense lipid 
particles (SALP) produced greatly increased levels of IL-12, IFN-g, IL-6, monocyte 
chemoattractant protein-1 and TNF-a compared with mice given the same dose of free 
CpG ODN (Mui et al., 2001). The innate protection afforded by CpG DNA against 
pathogens in mice can be maintained for over five weeks if the CpG ODN is given in a 
formulation providing some sustained release, such as alum (Stacey and Blackwell, 
1999). 
 
1.5.2 Cholera toxin as an adjuvant for transcutaneous immunization 
Several bacterial toxins such as cholera and tetanus toxins are some of the most 
immunogenic proteins known. Cholera toxin (CT) is a well-established mucosal 
adjuvant that has been shown to be a good adjuvant for transcutaneous immunization 
(Glenn et al., 1999, Scharton-Kersten et al., 1999; Scharton-Kersten et al., 2000). 
Furthermore, transcutaneous immunization with cholera toxin and whole inactivated 
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HSV- 1 or cholera toxin and HSV-1 antigens elicited protective immune responses 
against HSV-1 (El-Ghorr et al., 2000). Recently, transcutaneous immunization has been 
shown to be feasible on humans using heat- labile enterotoxin, from E. coli, a toxin 
similar to CT (Glenn et al., 2000).  CT was also able to induce immune responses to a 
peptide from influenza virus haemagglutinin when topically administered on the skin of 
mice (Beignon et al., 2002).  In addition, co-delivery of plasmid encoding CT enhanced 
immune responses to several DNA vaccines administered to the skin by the gene gun 
(Arrington et al., 2002).  CT enhances immune responses by increasing cellular 
infiltration (Jones et al., 2001), as well as by activating dendritic cells (Bagley et al., 
2002).  Adjuvants that stimulate dendritic cells are an ideal approach, since (1) dendritic 
cells are potent initiators of specific immune responses and (2) other adjuvants such as 
CpG ODNs can activate dendritic cells. 
 
1.6 Advantages of dermal delivery of antigens  
The pharmaceutical industry has developed successful transdermal delivery 
systems for a variety of small drugs such as nicotine, nitroglycerine, fentanyl and 
estrogen.  Transdermal delivery (systemic delivery through the skin) is an alternative to 
more invasive administration routes and has the advantage of lower frequency of dosing, 
uniform blood levels and increased compliance.  There has been extensive research on 
transdermal delivery of numerous low molecular weight drugs without the aid of 
physical disruption to the skin.  However, there have been only a few reports on dermal 
and transdermal delivery of proteins or DNA either as therapeutic agents or vaccine 
antigens (Foldvari et al., 1998; M. Foldvari, 1999).  Using a novel type of lipid-based 
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delivery system for leukotoxin (Pasteurella haemolytica) and hen egg lysozyme as 
model antigens, strong Th2 responses could be induced after topical application (Baca-
Estrada et al., 2000). The use of transfersomes allowed induction of immune responses 
to a gap junction protein (Paul et al., 1998). When utilizing the skin as a route of entry 
for protein and DNA vaccine antigens, the main target sites are within the skin.  
Therefore ‘dermal delivery’ terminology will be used to describe the theory as well as 
the literature on the subject. 
In order for vaccine antigens to be effective, it is critical that the vaccine is 
delivered to the epidermis where the APCs are localized. The stratum corneum is 
considered the greatest barrier to effective transdermal delivery (Scheuplein, 1976).  The 
characteristics that make the stratum corneum ideal for protecting the body also provide 
an obstacle to delivery of proteins and polynucleotides.  Comparison of the permeability 
of normal skin with tape stripped skin, where the stratum corneum is removed, revealed 
that tape stripping increases the permeability (Scheuplein, 1976), demonstrating that the 
stratum corneum is the rate- limiting barrier for delivery of many compounds to the 
body.   
There are three possible pathways for the penetration of compounds through the 
skin, the transcorneocyte route, the intercellular pathway, and the transappendageal 
pathway. The specific pathway a vaccine antigen will take depends on the 
physiochemical characteristics of the antigen as well as the method of delivery used.  
In the intercellular pathway, molecules travel through extracellular lipids that 
form continuous pathways surrounding the corneocytes (Muranishi, 1990).  
Experimental evidence, from penetration studies of certain molecules, reveal that 
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penetration is not correlated with the number of cell layers or the thickness but the lipid 
weight of the stratum corneum (Elias et al., 1981).  Therefore lipid synthesis inhibitors 
can increase delivery of certain compounds due to the fact that the extracellular lipid 
barrier is reduced (Tsai et al., 1996).  Compounds delivered via liposomes generally use 
the intercellular pathway for entry (Foldvari et al., 1990).  Liposome/skin interaction 
studies using a fluorescent lipid bilayer marker and confocal laser scanning microscopy 
confirmed that liposomes penetrate through the extracellular lipids (Kirjavainen et al., 
1996). 
 The transcorneocyte pathway of delivery occurs by passage through corneocytes 
(Zhang et al., 1996).  Physical methods of delivery such as the gene gun and 
electroporation use the transcorneocyte pathway.  Since corneocytes are dead cells, 
plasmids must pass through the corneocyte to enter the viable epidermis for gene 
expression to occur. 
 The transappendageal pathway is the route through the hair follicles and sweat 
glands (Lieb et al., 1997).  The hair follicle openings are natural holes in the skin that 
are lined with epithelial cells.  The transappendageal pathway avoids the stratum 
corneum by allowing the biomolecules to travel around it to the cells surrounding the 
hair follicle.  The stratified barrier of epithelial cells lining the hair follicles is thinner 
than the stratum corneum, allowing increased penetration of molecules.  The diameter of 
the hair follicles range from 50 to 100 mm and hair follicles range in density from 10% 
on areas such as the human scalp to 0.1% in areas with low follicle density (Lieb et al., 
1997).  The low percentage of surface area is an underestimation of the actual surface 
area available for dermal delivery of molecules since the hair follicles penetrate through 
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the skin surface.  The transappendageal route may be more important for delivery in 
animals such as mice that have a much greater hair follicle density compared to humans. 
The transappendageal route is thought to be the major route by which large molecules 
such as oligonucleotides (Lieb et al., 1997) or liposome complexed DNA enters the skin 
(Li and Hoffman, 1995; Li et al., 1992).  Topical application of a DNA vaccine 
administered in liposome complexes, elicited antigen specific immune responses in mice 
dependent on the presence of normal hair follicles (Fan et al., 1999). 
Since the hydrophobic barrier of the stratum corneum is one of the major barriers 
to effective transdermal delivery of protein and DNA, transdermal delivery systems 
must be designed to penetrate this barrier. In addition, one must also consider the plasma 
and nuclear membranes as barriers for effective delivery of DNA. Lipid based delivery 
systems (liposomes and others) are suitable vehicles to overcome the plasma membrane 
barrier and are used extensively for transfection of cells in vitro (Felgner et al., 1994). 
Building on the in vitro observations, liposomes were also shown to be effective in 
transferring genes in vivo (Alexander and Akhurst, 1995; Niemiec et al., 1997).  The 
efficacy of both in vitro and in vivo transfection can be modulated by the liposome 
composition (Yu et al., 1999).  Unfortunately there is no correlation between the 
efficacy of liposome delivery in vitro and in vivo making development of liposome 
formulations more difficult. 
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1.7 Influence of formulation and delivery on immune responses elicited from 
vaccines 
 There is a need to increase the potency of DNA vaccines as well as CpG ODNs.  
The magnitude and type of immune responses elicited by polynucleotide vaccines can 
be influenced through formulation and method of delivery.  One possible way to 
improve immune responses elicited by DNA vaccines is through delivery, by improving 
antigen presentation either by (1) targeting APCs or (2) increasing the amount of antigen 
available for presentation.  In addition, the biological activity of CpG ODNs can also be 
enhanced through delivery to APCs. 
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2.0 HYPOTHESES, OVERALL OBJECTIVE AND SPECIFIC AIMS  
2.1 Hypotheses 
 I hypothesized (1) that using delivery approaches such as i) a novel type of 
topical formulation biphasic lipid vehicles (BiphasixTM), ii) gas-powered needle-free 
injection system (BioJect) and iii) electroporation, it might be possible to enhance 
immune responses elicited by DNA vaccines compared to conventional injection.  In 
addition, (2) a novel type of injectable depot formulation [BiphasixTM-VTA (Vaccine 
Targeting Adjuvant)] may be capable of enhancing the immunoadjuvant activity of CpG 
ODNs. 
2.2 Rationale and overall objective 
The rationale for this project is that current methods for the delivery of 
polynucleotides are inadequate for eliciting potent immune responses. The overall 
objective of this project was to investigate novel delivery approaches for 
polynucleotides and oligonucleotides to improve immune responses elicited by gene-
based vaccines.  
2.3 Specific aims  
The specific aims in this thesis were: (1) Evaluation of topical delivery of a 
model plasmid formulated in biphasic lipid vehicles by analysis of gene expression and 
induction of immune responses in mice; (2) Assessment of the suitability of the 
electroporation method to improve gene expression in pig skin and increase immune 
responses after topical electroporation; (3) Assessment of the suitability of the 
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electroporation method to improve gene expression in pig muscle and increase immune 
responses following intramuscular administration; (4) Determination of the role of gene 
expression and cellular infiltration in enhancing immune responses elicited by a DNA 
vaccine delivery using electroporation; (5) Evaluation of CpG ODNs for enhancing 
immune responses elicited by DNA vaccines: (6) Evaluation of a novel injectable depot 
formulation a lipid-based delivery system [BiphasixTM -Vaccine Targeting Adjuvant 
(VTA)] to enhance the immuno-adjuvant activity of CpG ODNs by systemic and 
mucosal routes. 
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3.0 TOPICAL DELIVERY OF PLASMID DNA USING BIPHASIC LIPID 
VESICLES (BiphasixTM) IN MICE 
(Manuscript in press) 
 
3.1 Introduction 
Delivery issues in vaccine development have been recognized as one of the 
important factors to achieve the desired efficacy. Most of the current vaccines are 
administered by injection, however, there is now evidence that transmucosal or 
transdermal delivery of antigens (Tang et al., 1997), including DNA (Cui and Mumper, 
2001; Cui and Mumper, 2002), can elicit an immune response. 
Similarly to the more traditional vaccines (single-shot subunit, therapeutic 
vaccines), genetic immunization also requires the presentation of the antigen in the most 
advantageous form at the required location. The success of DNA vaccines is dependent 
on the delivery of the DNA molecule through several membraneous barriers (i.e. the 
stratum corneum, cell and nuclear membranes) and expression of the antigen. Topical 
plasmid transfection to date could only be achieved by initially compromising the skin 
barrier properties such as by intense brushing with a toothbrush (Yu et al., 1999) or 
chemical depilation (Alexander and Akhurst, 1995; Shi et al., 1999a). 
The epidermis is an ideal site for DNA immunization since the skin is equipped 
with a network of antigen presenting cells (APCs) that mediate the induction of immune 
responses. Immunization by gold particle bombardment of the skin using the gene gun 
has demonstrated that a small number of APCs are transfected (Condon et al., 1996). 
APCs directly transfected may be more effective in inducing immune responses as 
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compared to a large amount of antigen expressed by cells of non- lymphoid lineage 
(Fynan et al., 1993; Heiser et al., 2001; O'Hagan et al., 2001). Improving delivery of 
plasmid through the skin will likely enhance the efficacy of transcutaneous 
immunization with plasmid DNA. 
The feasibility of a novel lipid-based delivery system (BiphasixTM) was 
evaluated as a pharmaceutical delivery approach for the delivery of two model plasmids. 
Previously we have demonstrated that these formulations are effective in mediating the 
induction of immune responses to protein antigens following transcutaneous delivery 
(Baca-Estrada et al., 2000). Unlike conventional liposomes, the BiphasixTM vesicles are 
multi-compartmental lipid vesicles consisting of multiple, concentric mixed- lipid 
bilayers entrapping lipophilic, micellar and aqueous sub-unit compartments.  Our results 
demonstrated that topical delivery of plasmids formulated in biphasic vesicles resulted 
in gene expression in the draining lymph node and in the induction of cellular and 
humoral immune responses.  
 
3.2 Materials and methods  
3.2.1 Animals 
Six-week-old female BALB/c mice purchased from the Animal Resource Centre 
at the University of Saskatchewan were used for all experiments. Animals were treated 
in compliance under the regulations of the Canadian Council for Animal Care.  
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3.2.2 Plasmids  
Plasmid encoding the luciferase enzyme under the CMV promoter (pluc), was a 
gift from Dr. Heather Davis (University of Ottawa, ON) (Weeratna et al., 1998). A 
plasmid expressing bovine herpesvirus glycoprotein D (pgD) was constructed by 
inserting the gD gene into vector pCAN1 under the CMV promoter (Uwiera et al., 
2001). Plasmids were purified using Qiagen (Mississauga, ON) endotoxin free plasmid 
kits.  
 
3.2.3 Preparation of DNA delivery system 
Plasmids were formulated in lipid-based delivery systems (biphasic vesicles) 
(BiphasixTM) at a dose of 100 mg plasmid in 125 mg formulation. The three different 
formulation compositions were prepared based on soya phosphatidylcholine (Natterman 
GmBH, Germany): cholesterol (Sigma Chemical Co., St. Louis, MO) (10:4 weight ratio) 
and the following lipids: formula 1: cholesteryl 3ß-N-(dimethyl-aminoethyl) carbamate) 
(DC-chol, Sigma) at a 1:1 weight ratio; formula 2: dimyristoylphosphatidylcholine 
(DMPC, Sigma) at a 1:4 weight ratio and formula 3: dioleoylphosphatidylethanolamine 
(DOPE, Sigma) at a 1:4 weight ratio. Each lipid phase (vesicle forming lipids) was 
hydrated with a sub-micron emulsion aqueous phase, containing linoleamidopropyl-PG-
dimonium chloride phosphate (Mona, Paterson, NJ), 4% and olive oil, 4% w/w, by 
mixing until a homogeneous cream was achieved (Foldvari, US Patent No. 5, 853, 755).  
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3.2.4 Immunization with gD encoding plasmid 
For topical delivery, mice were carefully shaved with an electric razor 1 day 
prior to administration of plasmids to ascertain an intact skin surface (normal skin). The 
Biphasix formulation was placed on the back of the mouse for 48 hours using a patch 
construction as previously described (Baca-Estrada et al., 2000). Each patch contained 
125 mg formulation with 100 mg DNA covering a surface area of approximately 1 cm2. 
For topical immunization with DNA in solution (‘naked’ DNA), 100 mg of pgD in 30 ml 
of water was placed on the back of anesthetized mice until the solution appeared to 
absorb into the skin or evaporated. For intradermal administration, mice were injected in 
the back with 1.5 mg pgD in 10 ml PBS. For gene gun immunizations, gold beads (1.6 
mm) were prepared according to the manufactures instructions for the Helios Gene Gun 
System (Bio-Rad, Hurcules, CA) as previously described using 0.05 mg of pgD +1.45 
mg of non-coding vector (Loehr et al., 2000). For topical immunization all groups were 
boosted twice at two-week intervals. For intradermal and gene gun immunizations mice 
were boosted once two weeks after primary immunization. Cells were harvested from 
spleens and draining lymph nodes two weeks after the final immunization.  
 
3.2.5 Determination of luciferase expression 
The levels of gene expression were determined using a plasmid encoding the 
luciferase gene in the same manner as for pgD delivery. The doses of pluc were the 
same as those used for immunization with the different delivery methods. Testing of 
pluc delivery was carried out on both intact skin and tape stripped skin. An area of 
approximately 4 cm2 was shaved. For removal of the stratum corneum, but not 
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Langerhans cells, was achieved using 20 times tape stripping with Scotch tape (3M) was 
used (Proksch et al., 1996). Treated skin samples (about 1 cm2 area) as well as the 
axillary and inguinal draining lymph nodes were removed from mice and homogenized 
in 500 mL of lysis buffer (Promega, Madison, WI) with a Polytron homogenizer 
(Brinkmann Instruments, Rexdale, ON) to produce protein extracts. Luciferase activity 
of the protein extracts was determined using Promega’s luciferase assay system. 
Samples were counted for 30 seconds on a Packard Picolite Luminometer (Packard 
Instruments Canada LTD, Mississauga, ON). Tissues from untreated animals were used 
to calculate the background levels of light units (LU). 
 
3.2.6 Characterization of humoral and cellular immune responses 
BHV-1 gD-specific antibody responses were determined using ELISA as 
previously described (Baca-Estrada et al., 1996). Briefly, Immunlon 2 (DYNEX, 
Chantilly, VA) ELISA plates were coated with gD (1 mg/ml) or IgG standards (Serotec, 
Hornby, ON) overnight at 4°C. Glycoprotein D-specific IgG and IgG subclasses were 
determined by biotinylated antibodies specific to IgG and IgG subclasses (Caltag, 
Toronto, Ont.) followed by streptavidin-alkaline phosphatase staining (Jackson 
Immuno-research Labs, West Grove, PA). The alkaline phosphatase activity was 
determined by p-nitrophenol phosphate (PNPP) (Sigma). The absorbance was read after 
15-20 minutes at 405 nm (Bio-Rad).  
ELISPOT assays for IFN-g and IL-4 were performed using cells isolated from 
spleens or draining lymph nodes (axillary and inguinal) as previously described (Baca-
Estrada et al., 1997). Briefly, 1x106 cells/well were placed in 96 well culture plates with 
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and without antigen (gD 0.4 mg/ml) in AIM-V media (Gibco, Life Technologies, 
Burlington, ON) and incubated at 37°C and 5% CO2 for 24 hours. Cells were 
resuspended in fresh media and seeded on nitrocellulose plates (Millipore, Nepean, ON) 
coated with either IFN-g or IL-4 specific mouse cytokine capture antibody 2 mg/ml 
(PharMingen, San Diego, CA). Biotinylated anti mouse IFN-g or IL-4 specific 
antibodies a 2 mg/ml (PharMingen) followed by streptavidin-alkaline phosphatase 
(Jackson Immuno-Research Labs) and developed using 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate tablets (Sigma). Spots 
representing gD specific cytokine secreting cells were counted and expressed as number 
of cytokine secreting cells per 1x106 cells. Con A stimulated cells were used as a 
positive control, with greater then 400 cytokine secreting cells per well. 
 
3.2.7 Statistics  
Differences in immune responses among vaccine groups were analyzed with 
Prism graphpad statistical software (GraphPad Software, Inc.) using a one-way ANOVA 
for the immunization experiments or an unpaired t-test for the gene expression 
experiments. 
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3.3 Results and Discussion 
3.3.1 Evaluation of the delivery of antigen by measuring antigen-specific immune 
response 
Plasmid delivery into the skin was evaluated by measuring the induced anti-gD 
specific antibodies following topical treatment with three different compositions of 
Biphasix™-pgD patches. All three formulations induced anti-gD IgG levels five times 
higher compared to either the ‘naked’ DNA or untreated animals (formulations#1 and #3 
p<0.05) (Figure 3.1A).  Topical delivery of plasmid in Biphasix™ sys tem also induced 
cellular immune responses. Induction of gD-specific cellular response was only 
observed in spleen cells from mice immunized with formulation #3 (Figure 3.1B). This 
response was characterized by the predominant secretion of IL-4 by cells isolated from 
spleen and draining lymph nodes (Figure 3.1B and C). No IFN-g secreting cells were 
observed in the spleen or draining lymph nodes (data not shown). Administration of 
Biphasic formulations without antigen (protein or plasmid), do not elicit any specific 
immune responses that are significantly different from naive. However, lipids in the 
formulation may be able to exert an adjuvant effect (in addition to the delivery effect) in 
combination with antigens. 
In order to compare the magnitude of immune response elicited by topical 
immunization with other methods of delivery, mice were immunized with the gene gun 
or by intradermal injection with varying doses of gD encoding plasmid. Our results 
demonstrated that both of these methods of delivery resulted in the induction of similar 
gD-specific IgG1 antibody titers (Figure 3.2A), which were significantly different from 
the untreated animals (p<0.01 and p<0.05, respectively). The immune responses  
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Figure 3.1 Immune responses following topical application of pgD in 3 different lipid-
based delivery systems.  
All groups (n = 3) were immunized three times at two weeks intervals with pgD (100 
mg) in three different lipid-based formulations (#1-3) or naked pgD. At six weeks, two 
weeks following the final immunization gD-specific IgG was determined using ELISA 
(A) and gD-specific cellular immune responses were assessed using isolated cells from 
the spleen stimulated with gD antigen (B) or the draining lymph nodes stimulated with 
gD antigen (C). There are no error bars in C because this data was obtained using pooled 
samples (N=1).  Error bars represent standard error of the mean, * p<0.05, *** p<0.001 
vs naive.  
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Figure 3.2 Immune responses induced by immunization with pgD either by intradermal 
injection (i.d.) or by particle bombardment using the gene gun (g.g.).  
Groups of mice (n = 5) were immunized with 1.5 mg of pgD (i.d.) or with 0.05 mg of 
pgD administered by the gene gun (g.g.). At four weeks, two weeks following the final 
immunization gD-specific IgG1 was determined using ELISA (A) and? gD-specific 
IFN-g and IL-4 secreting cells in the spleen (B) and draining lymph nodes (C). There 
are no error bars in C because this data was obtained using pooled samples (N=1).  Error 
bars represent standard error of the mean of five animals per group, * p<0.05, ** 
p<0.01, *** p<0.001 vs naive. 
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observed were similar to those achieved by topical administration of the Biphasix™-
pgD/100µg patch at 6 weeks (i.e. about 200 ng/mL IgG by ELISA).  
Further characterization of intradermal and gene gun mediated plasmid delivery 
indicated the absence of gD-specific IgG2a antibodies (data not shown). The cellular 
immune responses elicited by the gene gun were characterized by a Th2 type response in 
the spleen (Figure 3.2B) and mixed Th1/Th2 in the lymph nodes (Figure 3.2C) In 
addition, gene gun immunization with 1 mg pgD still elicited a predominant Th2 
response (data not shown). In contrast, the cellular responses elicited by intradermal 
injection were predominantly Th1 in both spleen (Figure 3.2B) and lymph nodes (data 
not shown). 
Although there was no difference between the gD-specific antibody isotypes 
induced following immunization by a number of delivery methods, the cytokine profile 
generated varied depending on the type of delivery method used.  Therefore, the route of 
delivery influences the type of cellular immune response induced. Intradermal injection 
of pgD elicited a strong Th1 response, where as topical and gene gun administration 
elicited a predominant Th2. Antigen produced in the lymph node may result in increased 
antigen presentation by APCs compared to antigen produced in non- lymphoid tissue. 
These differences in antigen presentation may explain the differences in the immune 
responses elicited by the epidermal and intradermal routes. 
Although the doses of pgD used in these immunizations were quite different, 
depending on the method of delivery, the total amount of plasmid was identical between 
the gene gun and intradermal immunizations suggesting that the differences in the type 
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of immune responses generated was not due to the amount of immunostimulatory 
molecules present in the plasmid. 
The biphasic vehicles facilitate the penetration through the stratum corneum into 
the viable epidermis as well as hair follicles. Previous studies using liposomes suggest 
that hair follicles are important for transfection (Fan et al., 1999; Niemiec et al., 1997). 
However, it is not known which pathway(s) results in transfection from topical 
application of plasmid formulated in biphasic vehicles. From the three formulations 
tested in this study, formulation#3 containing PC/DOPE lipid combination, showed 
somewhat higher efficiency of transfection and immune response. This may indicate 
either a better skin interaction with vesicles containing unsaturated lipid or a better 
transfection ability with APCs, hence the expression in the lymph node.  
 
3.3.2 Evaluation of luciferase expression after topical delivery of pluc 
Plasmid delivery into the skin was evaluated by measuring the expression of 
luciferase activity 48 hours following topical, gene gun or intradermal administration. 
There was no increase in levels of luminescence in the skin after topical treatment with 
Biphasix™-pluc/100µg patch (formulation#3) (Figure 3.3A). Even when examined 
without the stratum corneum present (removed by tape stripping), expression of 
luciferase was not found in the skin following topical application of pluc (Figure 3.3A). 
However, there was an increase in luminescence in the lymph node homogenates after 
topical treatment on either intact or stripped skin. Topically applied naked pluc did not 
elicit any luciferase activity on normal or tape stripped skin (data not shown). 
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Figure 3.3 Gene expression following different delivery methods.  
Luciferase activity was determined in the skin (A) and in the draining lymph nodes (B) 
48 hours after topical administration of 100 mg of pluc formulated in lipid-based 
delivery system on normal and tape stripped (t.s.) skin, 0.05 mg of pluc administered by 
the gene gun (g.g.) or 1.5 mg pluc injected intradermally (i.d.). Luciferase activity was 
expressed in light units (LU) per 30 seconds. Numbers over bars represent the number 
of positive responses detected. Error bars represent standard deviation of the mean of 5-
15 mice per group, * p<0.05 vs non-treated skin. 
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Intradermal injection (1.5µg) resulted in luciferase expression only in the skin, 
whereas administration of pluc with the gene gun (0.05µg/dose) resulted in gene 
expression in both skin and lymph nodes (Figure 3.3A and B).  
 
3.4 Conclusions  
Immunization by topical application of vaccine antigens is a new concept that 
has a great potential. Non- invasive strategies for vaccine administration onto the skin 
have recently been reported for protein (Glenn et al., 1998) and for plasmid DNA 
vaccines (Fan et al., 1999, Shi et al., 1999). In this study the use of biphasic lipid 
vesicles (BiphasixTM) were assessed to enhance the delivery of plasmid DNA through 
the skin and subsequently the induction of immune responses to the encoded gene. Our 
results demonstrate that incorporating the plasmid in biphasic lipid vesicles enhances the 
immune responses induced following topical application. Furthermore, we extended 
previous studies by demonstrating that after topical administration, plasmid expression 
can be achieved in the draining lymph nodes. This observation may be important to our 
understanding of how such low doses of antigen, produced by DNA immunization, can 
elicit immune responses.  
Collectively, this study demonstrated the feasibility of using biphasic vesicles to 
enhance topical delivery of plasmid DNA into the skin. Furthermore, these results also 
suggest that the type of immune responses induced by various methods of immunization 
into the skin may be influenced by the location of gene expression. It is unknown why 
different modes of application result in different types of immune responses, however, 
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dendritic cells may influence the type of immune response elicited (Rissoan et al., 
1999). Our results indicated that gene expression in the draining lymph nodes likely 
results from directly transfected dendritic cells, which corresponded with induction of a 
Th2 response with the gene gun and topical administration. The ability to induce 
different types of immune responses is significant because different diseases require 
different types of immunity to provide protection (Sjolander et al., 1998). This 
information is relevant to the development of non- invasive vaccine delivery strategies.  
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4.0 NEEDLE-FREE TOPICAL ELECTROPORATION IMPROVES GENE 
EXPRESSION FROM PLASMIDS ADMINISTERED IN PORCINE SKIN 
(Manuscript submitted) 
 
4.1 Introduction 
Vaccination is the most cost-effective way to prevent disease.  However, there 
are still many diseases for which no vaccine exists or for which the currently available 
vaccines are inadequate.  DNA immunization, which entails the administration of DNA 
encoding an antigen, may offer solutions in at least some of these cases.  DNA vaccines 
use host cells as bioreactors for the production of proteins in vivo (Tang et al., 1992).  
By doing so, DNA vaccination mimics viral infection, with improved antigen 
presentation to the immune system relative to standard protein vaccines, and work more 
effectively at inducing cellular immunity as a result (Ulmer et al., 1993).  Moreover, it 
offers these potential benefits without the safety and stability concerns associated with 
the administration of infectious agents. 
DNA immunization has been effective in several mouse models (Donnelly et al., 
1997).  To achieve significant levels of immunity in humans and large animals with 
DNA delivery methods often requires very high doses of plasmids and multiple boosts 
(van Drunen Littel-van den Hurk et al., 2000).  Clearly, there is a need to increase the 
potency of DNA vaccines in large mammals including humans (Gerdts et al., 1999).  
Even at high doses, DNA vaccines in humans still have failed to be efficacious (Le et 
al., 2000; MacGregor et al., 1998; Ugen et al., 1998; Wang et al., 1998).  Therefore, 
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more potent forms of the DNA vaccines themselves and/or more effective means of 
delivery must be developed in order for the technology to realize its potential. 
One reason for the inefficacy of DNA vaccines in humans could be inefficient 
cellular uptake of plasmid DNA and consequent poor gene expression.  In vivo 
electroporation may allow increased gene expression by enhancing cellular uptake of 
plasmids by the application of short electrical pulses that transiently permeabilize cell 
membranes.  Electroporation may enhance nuclear uptake as well.  It has been clearly 
shown that DNA delivery to muscle tissue of mice, followed by electroporation, 
strongly increases gene expression and immunogenicity of DNA vaccines (Widera et 
al., 2000; Zucchelli et al., 2000).  Furthermore, when used for DNA delivery in the skin, 
electroporation amplifies gene expression with both intradermal injection (Heller et al., 
2001) and topical administration (Dujardin et al., 2001) of plasmids. Thus, it would 
follow that electroporation of skin should enhance DNA immunizations, and 
experimental results have confirmed that prediction in mice (Drabick et al., 2001).   
One objective of this study was to explore whether the use of needle-free surface 
electroporation would significantly enhance gene expression and immune responses to a 
DNA vaccine in pigs.  Another objective was to minimize the invasiveness of the 
immunization procedure.  For this reason, needle-free injection of the DNA, using a 
BioJectTM device was compared with conventional injection by needle and syringe.  An 
additional incentive for using fluid jet injection over needle and syringe was the 
previous findings that jet injection was more effective for DNA immunization in 
monkeys and sheep (Haensler et al., 1999; Jenkins et al., 1995) compared to 
intramuscular needle administration of plasmid.  Both the fluid jet and needle methods 
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of DNA injection were assessed with respect to their ability to induce an immune 
response with and without needle-free surface electroporation. 
Numerous studies have shown that the most powerful property of DNA vaccines 
may be their ability to prime the immune system for responses to other vaccines 
(Richmond et al., 1998; Robinson et al., 1999).  The effects of electroporation were 
examined in the context of a DNA-prime/DNA-boost/protein-boost strategy to enhance 
immune responses in large animals, and compared the responses with the responses 
following standard protein vaccination.  This strategy resembled DNA-prime/protein-
boost strategies previously used in non-human primates, which yielded outstanding 
results for both malaria (Jones et al., 2001) and HIV vaccinations (Amara et al., 2001). 
 
4.2 Materials and methods  
4.2.1 Plasmids  
The luciferase encoding plasmid (pluc), under the control of the CMV promoter 
in the pMAS backbone (Krieg et al., 1998b), was a gift from Dr. Heather Davis 
(University of Ottawa, ON) (Weeratna et al., 1998). The plasmid encoding green 
fluorescent protein (GFP) under the control of the CMV promoter was obtained through 
Quantum Biotechnologies (Montreal, QC).  The hepatitis B surface Ag expression 
plasmid (pHBsAg), under the control of the human elongation factor 1a promoter with 
the first intron and the polyadenylation signal from human G-CSF cDNA in a pUC9 
prokaryotic backbone, was previously described (Widera et al., 2000), and was custom-
manufactured by Elim (San Francisco, CA).  The other plasmids were purified using 
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Qiagen Endo Free plasmid kits (Qiagen, Mississauga, ON) according to the 
manufacturer's instructions. 
 
4.2.2 Animals and Immunization 
Four to six week old male and female outbred pigs weighing 20 to 40 pounds 
were purchased from the Prairie Swine Center (University of Saskatchewan, Saskatoon, 
SK).  Animals were housed and treated the in compliance with the Canadian Council for 
Animal Care.  Pigs were randomly assigned to six groups of five animals each.  They 
were anesthetized with halothane prior to DNA injection and electroporation.  Group 1 
received 250 mg pHBsAg in 100 ml 0.1 M phosphate buffered saline (PBS) by a dermal 
BioJect B 2000 needle-free injection device (Bioject, Inc. Portland, OR) at each of two 
sites/animal on the abdomen, for a total of 500 mg pHBsAg. Group 2 was identical to 
group 1 except both sites were also treated with 70 V electroporation using a flat patch 
needle-free surface electrode, immediately following plasmid injection. Group 3 
received 250 mg pHBsAg in 100 ml PBS by an intradermal injection at each of two 
sites/animal on the abdomen for a total of 500 mg pHBsAg. Group 4 was identical to 
group 3 except sites were treated with a 60 V electroporation, immediately following 
plasmid administration. Group 5 received 500 ml of the commercial hepatitis B protein 
subunit vaccine (Engerix-B, SmithKline Beecham Pharma, Oakville, ON) injected 
intradermally with the Bioject device in two 250 ml doses an the abdomen and Group 6 
was immunized with Engerix-B by an intramuscular injection using a needle. Pigs were 
boosted with the same injection conditions after four weeks.  All treatment groups were 
boosted at week eight with Engerix B vaccine by intramuscular needle injection for all 
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groups except group 5, which was injected intradermally with Engerix with the BioJect 
device as above (Table 4.1). 
 
4.2.3 Electroporation 
Electroporation was performed using the BTX ECM 830 Pulse Generator with 
the needle-free micropatch round electrode mounted on a handle (model MP 35) 
(Genetronics, San Diego, CA), and applying six square-wave pulses at 60, 70, or 80 V, 
respectively, with pulse duration of 60 msec, pulse interval of 200 msec, and reversal of 
polarity after three pulses.  
 
4.2.4 Luciferase expression and assay 
Plasmid DNA encoding luciferase was injected intradermally with the use of a 
26-gauge needle or a BioJect device (Dermal BioJectTM, BioJect, Inc., Portland, OR), 
followed by electroporation with various voltages.  Intradermal needle injection was 
tested with no electroporation and with electroporation at voltages of 60V and 80V.  
Bioject delivery was tested with no electroporation and with electroporation at voltages 
of 60V, 70V, and 80V.  
For each injection, a dose of 100 mg of pluc (Weeratna et al., 1998) in 100 ml 
PBS was administered into the shaved abdomen skin of the animals.  The luciferase-
encoding plasmid was injected at eight standard sites, and electroporation was applied to 
four of those sites.  Forty-eight hours after the administration of the plasmid, each 
injection site was sampled with an 8-mm diameter punch biopsy at a depth of 
approximately 8-mm.   
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Table 4.1 Experimental design for vaccine groups  
 
 1st and 2nd immunizations2 3rd immunization3 
(Engerix-B) 
Group1 Vaccine Route/Method Voltage (V) Route/Method 
1 pHBsAg i.d./BioJect - i.m./needle 
2 pHBsAg i.d./BioJect 70 V i.m./needle 
3 pHBsAg i.d./needle - i.m./needle 
4 pHBsAg i.d./needle 60 V i.m./needle 
5 Engerix-B i.d./BioJect - i.d./BioJect 
6 Engerix-B i.m./needle - i.m./needle 
 
1Each group consisted of five animals.   
2First and second immunizations were administered on day zero and four weeks later.  
3The third immunization was given eight weeks after the first immunization  
i.d., intradermal; i.m., intramuscular. 
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Skin was homogenized in 500 ml lysis buffer (Promega, Madison, WI) with a 
Polytron homogenizer (Brinkmann Instruments, Rexdale, ON) to produce protein 
extracts.  Luciferase activity in the protein extracts was determined using a luciferase 
assay system (Promega).  On a Packard Picolite Luminometer (Packard Instruments 
Canada LTD, Mississauga, ON), the bioluminescence of each 500 ml sample was 
counted for 30 seconds and recorded as relative light units (LUs).  Untreated or PBS-
injected tissues were used to determine the background luminescence levels.  
 
4.2.5 Histological examination of skin 
Forty-eight hours following intradermal injection by needle or BioJect of 100 ml 
PBS alone or 100 mg pluc in 100 ml PBS followed by electroporation with 60, 70, or 80 
V, skin tissues were taken and fixed in 10% formalin.  Tissues were processed routinely 
and embedded in paraffin wax, and 4-mm sections were stained with hematoxylin/eosin 
(HE). 
 
4.2.6 GFP gene expression 
To analyze the localization of gene expression, 100 mg of a plasmid encoding 
green fluorescent protein (GFP) in 100 ml PBS was administered by intradermal 
injection or Biojector, in combination with electroporation (60 V for intradermal 
injection and 70 V for Biojector administration). Twenty-four hours after administration 
the injection site was biopsied using an 8-mm punch. Skin samples were frozen in liquid 
nitrogen and stored at -70°C until they were sectioned. Skin samples were cut 
transversally with an IEC Minitome Microtome Cryostat (Damon, Needham, MS) into 
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7-mm sections. Sections were examined for GFP expressing cells and were 
photographed with an Olympus AH2-RFL microscope using blue fluorescent light. 
 
4.2.7 Measurement of humoral responses 
At various time points after immunization, serum was obtained by centrifugation 
of the blood collected from anesthetized animals.  To measure if animals would have 
immune responses that would be considered to protect against the disease.  Anti-HBsAg 
antibodies were quantitatively measured using the AUSABTM EIA Clinical Diagnostic 
Kit, and quantification in milli-International Units/ml was performed in parallel with the 
AUSABTM Quantification Panel, according to manufacturer instructions (Abbott 
Laboratories, North Chicago, IL).  In humans, an antibody level >10 mIU/ml is 
considered to be protective for Hepatis B (West and Calandra, 1996). 
Anti-hepatitis B IgG1 and IgG2 isotypes were also identified by ELISA as 
follows.  Immunlon 2 ELISA plates (DYNEX, Chantilly, VA) were coated with HBsAg 
(BioDesign International, Saco, ME) (1 mg/ml in 20 mM Na2CO3) overnight at 4°C.  
Plates were washed with phosphate-buffered saline-Tween (PBST) (PBS, 0.05% Tween 
20; Sigma Chemical Co., St. Louis, MO).  Serum was diluted in diluent (PBST, 0.5% 
gelatin) (Sigma) 20-fold, followed by serial 4-fold dilutions, and incubated overnight at 
4°C.  Plates were washed six times in PBST.  Porcine IgG1 and IgG2 isotypes were 
detected using specific mouse anti-porcine antibodies (Serotec, Hornby, ON).  
Following incubation at room temperature for one hour, plates were washed six times in 
PBST.  Anti-mouse IgG1 biotinylated antibodies (Caltag, Toronto, ON), diluted in 
diluent, were added and incubated for one hour at room temperature.  Plates were 
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washed six times in PBST, and streptavidin-alkaline phosphatase (Jackson Immuno-
Research Labs, West Grove, PA) was added to the plates and incubated for one hour.  
The alkaline phosphatase activity was measured by the conversion of p-nitrophenol 
phosphate (PNPP) (Sigma).  The absorbance was read after 15 to 20 minutes at 405-nm 
wavelength on a plate reader (Bio-Rad, Hercules, CA). 
 
4.2.8 Statistics 
 Differences between groups were analyzed using Prism graphpad statistical 
software (GraphPad Software, Inc.) using a one-way ANOVA, followed by Tukey's 
multiple comparison test. 
 
4.3 Results 
4.3.1 Gene expression and effect of electroporation on the skin. 
To characterize gene expression of plasmid DNA delivered by intradermal 
needle or needle-free BioJect delivery, luciferase and GFP reporter genes were used.  
First, it was determined where the injected materials were localized in the skin by using 
Evans blue dye.  Both the needle and the needle-free methods of injection delivered 
most of the dye to the dermis.  Needle-free injection also deposited dye in the epidermis 
and the hypodermis, and thus, resulted in a broader distribution than that obtained by 
standard intradermal needle injection (data not shown).   
To quantify the level of gene expression, the luciferase reporter gene was used.  
The luciferase assay results indicated that delivery by BioJect was significantly better 
than needle injections, with respect to the level of gene expression detected (Figure 4.1).  
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Figure 4.1 Electroporation improves gene expression levels, and intradermal jet 
injection is more effective than intradermal needle injection. 
Luciferase encoding plasmid DNA was administered to abdominal porcine skin, and 
enzymatic activity was measured 48 hours following administration.  Gene expression 
levels are shown for intradermal BioJect (b.j.) and needle (i.d.n.) injections, without or 
with electroporation, at the voltages indicated.  Error bars represent SEM. Statistical 
differences were i.d.n vs b.j. (p<0.05) and i.d.n. vs i.d.n plus electroporation (p<0.05) by 
one-way ANOVA followed by Tukey's multiple comparison test. 
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Electroporation at 60V or 80V significantly enhanced the level of expression following 
intradermal needle injection (Figure 4.1).  Similarly BioJect delivery of plasmids 
followed by electroporation enhanced gene expression following a 70V or 80V pulse, 
but did not following electroporation at 60V. 
Examination of the location of gene expression using a plasmid encoding GFP 
supported the results of luciferase expression. With BioJect showing greater expression 
than intradermal needle injection and electroporation enhancing gene expression 
following both BioJect and intradermal needle injection (data not shown). 
Following electroporation, there was superficial damage on the stratum corneum 
that increased with higher voltages.  This superficial damage to the stratum corneum 
was transient and no longer detectable one week following electroporation. This 
observation supports the contention that topical electroporation is relatively safe and did 
not cause long-term scaring. 
Histological examination of tissue sections was performed to determine how 
voltage could influence gene expression.  The results of histological examination 
(Figure 2) showed that increasing the voltage increased the size of the lesion on the 
surface of the skin, as well as the increasing the level of cellular infiltration consisting of 
macrophages in the dermis and epidermis of the skin.  The voltages chosen for the DNA 
immunizations were voltages that enhanced gene expression with the minimal amount 
of tissue damage.  Those voltages were 60V with the intradermal needle injections and 
70V with the BioJect deliveries.   
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Figure 4.2 Electroporation causes tissue damage and inflammation in pig skin. 
Skin tissues were collected 48 hours following electroporation at 60V (A), 70V (B) and 
80V (C), (HE stain).  Infiltration of neutrophils into the stratum corneum, forming small 
intracorneal pustules, was found (A). Moderate infiltration of neutrophils into the 
epidermis was found, forming superficial epidermal pustules (B). Severe epidermal 
pustule formation and as well subjacent dermal infiltration predominantly of neutrophils 
were observed (C). Bar is 100 µm. 
A 
B 
C 
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4.3.2 Immune Responses in Immunized Pigs 
Four weeks after the primary immunization, no animals in any of the groups, had 
any detectable immune responses to HBsAg. At 8 weeks following a second protein 
immunization, the two groups of animals that were immunized with a subunit vaccine 
injected either intramuscularly using a needle and syringe (the recommended route) or 
intradermally with the BioJect responded with antibody levels considered protective by 
the AUSAB (Table 4.2).  Results indicated that the intramuscular injection of the 
conventional vaccine resulted in all animals 5/5 responding, whereas only 4/5 animals 
responded to intradermal injection of the conventional vaccine using the BioJect (Table 
4.2).  At 8 weeks, following a secondary plasmid vaccination, no animals immunized by 
intradermal injection with or without electroporation had any responding animals as 
detected by the AUSAB assay.  Animals immunized with plasmid administered using 
the BioJect or BioJect with electroporation had 1/5 and 2/5 animals responding 
respectively with antibody levels considered protective by the AUSAB.  
To assess the efficacy of DNA vaccination in priming the immune system, 
animals in all experimental groups were boosted with the HBsAg protein vaccine at 
week 8.  Results in Table 4.2 demonstrate that even though immune responses were 
undetectable in most of the animals after two rounds of DNA immunization with respect 
to the AUSAB clinical assay, most animals responded rapidly to the protein boost with 
all immunized groups significantly different than the prebleed.  The fact that nearly all 
DNA immunized animals responded within two weeks of the protein boost demonstrates 
an anamnestic response, since the protein vaccine alone did not induce detectable 
immune responses 4 weeks post immunization (Figure 4.3).  There were no statistical 
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Table 4.2 Responses in Pigs to Various Hepatitis B Vaccination Protocols 
        Number of Animals Responding2 
Vaccine Group1 Week 4 Week 8 Week 10 
 AUSAB ELISA AUSAB ELISA AUSAB ELISA 
(1) DNA, b.j. 0/5 0/5 1/5 1/5 4/5 3/5 
(2) DNA, b.j. + EP 0/5 0/5 2/5 5/5 5/5 5/5 
(3) DNA, i.d.n. 0/5 0/5 0/5 0/5 5/5 3/5 
(4) DNA, i.d.n. + EP 0/5 0/5 0/5 1/5 5/5 5/5 
(5) Engerix B, b.j. 0/5 0/5 4/5 4/5 5/5 5/5 
(6) Engerix B, i.m.n. 0/5 0/5 5/5 5/5 4/4 4/4 
 
1Hepatitis B vaccines were administered intradermally or intramuscularly, as indicated.  
Sera collected at four, eight, and ten weeks after the first immunization were analyzed 
by conventional ELISA or by using an AUSABTM diagnostic kit.  
2The number of animals that showed an immune response out of the total number of 
animals in a group is indicated.  To be considered positive animals needed to have an 
antibody titer of at least 10 I.U. and an optical density of 2 SD over background for the 
AUSAB and ELISA respectively. 
Groups 1-4 received plasmid at day 0 and week 4 and received the HBsAg protein 
vaccine after the week 8 bleed. 
Groups 5 and 6 received the HBsAg protein vaccine at day 0, week 4 and week 8 
administered by BioJect or intramuscular needle respectively. 
b.j., BioJect; EP, electroporation; i.d.n. intradermal needle; i.m.n. intramuscular needle. 
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Figure 4.3  Immune responses to Hepatitis B after the different DNA prime/protein 
boost immunizations.  
HBsAg antibody titers at 10 weeks (two weeks after the protein boost) were determined 
using the AUSABTM EIA, and are the geometric mean of 5 animals for all the groups 
except for the i.m. subunit group which had 4 animals. Error bars are SEM. Statistical 
differences were determined using a one-way ANOVA followed by Tukey's multiple 
comparison test **p<0.01, ***p<0.001 vs prebleed. 
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differences between the immunized groups at 10 weeks when immune responses were 
determined by the AUSAB clinical assay. However, only DNA vaccines administered 
with electroporation and the HBsAg protein vaccines were significantly different 
compared to prebleed serum. 
To determine whether the experimental manipulations had an impact on the 
antibody isotypes generated, the sera were analyzed for the presence of anti-HBsAg 
IgG1 and IgG2 using an ELISA.  Needle-free plasmid injection in combination with 
electroporation lead to a more rapid induction of immune responses compared to other 
methods of plasmid delivery (Figure 4.4). Figure 4.4 demonstrates that in those animals 
mounting an early response, most produced primarily IgG1 at 8 weeks.  However, after 
boosting with protein, a much more balanced response with approximately equivalent 
levels of IgG1 and IgG2 were evident.  There were no significant differences between the 
groups at week 10.  Although, the groups injected with DNA and treated with 
electroporation (2 and 4) produced antibodies similar in titer to those in the cohorts 
receiving multiple protein injections (5 and 6). In contrast, those groups that received 
DNA without electroporation (1 and 3) produced antibodies of lower titer, even after the 
protein boost. 
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Figure 4.4 Antibody isotypes responses elicited by Hepatitis B immunizations. 
Hepatitis B specific IgG1 and IgG2 titers at 8 and 10 weeks, data represent individual 
animals at 8 and 10 weeks and the bar is the geometric mean. Group 1 is BioJect DNA, 
Group 2 is BioJect DNA + EP, Group 3 intradermal injection DNA, Group 4 
intradermal injection DNA + EP, Group 5 is BioJect administration of the subunit 
vaccine, and Group 6 is intramuscular injection of the subunit vaccine. At week 8 prior 
to boosting with protein the level of antibody (IgG1) in the BioJect DNA plus 
electroporation group vs i.d.n DNA plus electroporation (p<0.001) was statistically 
different by one-way ANOVA followed by Tukey's multiple comparison test.  There 
was no statistical difference between the level of antibody (IgG1) in the BioJect DNA + 
electroporation and the Engerix-B groups at eight weeks by one-way ANOVA followed 
by Tukey's multiple comparison test. There was high variablity of immune responses 
elicited following immunization with DNA vaccines. 
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4.4 Discussion 
There is a critical need to improve the potency of DNA vaccines if DNA 
vaccines are to be used routinely for vaccination.  Recently, electroporation was shown 
to enhance the potency of DNA vaccines in mice and rabbits (Widera et al., 2000) as 
well as pigs (Babiuk et al., 2002).  However, these intramuscular electroporations using 
2- and 6-needle arrays were relatively invasive.  Using a unique needle-free surface 
patch electrode, a significant enhancement of gene expression following intradermal 
plasmid administration was demonstrated.  Furthermore, to eliminate the use of needles 
in the vaccine administration, a needle-free intradermal injection device combined with 
non- invasive electroporation was tested and it was found to be more effective than 
intradermal needle injection.  It was shown that a totally needle-free delivery-
electroporation system was the most effective way to administer DNA vaccines in the 
skin. 
Luciferase gene expression experiments revealed that needle-free BioJect 
administration resulted in higher levels of gene expression than needle injection.  This 
observation is in agreement with Sawamura, who showed that jet injections elicit higher 
gene expression levels than needle injections in rat and human skin (Sawamura et al., 
1999).  One possible reason for this result may be that administration with BioJect more 
efficiently distributes plasmid in the tissue, as determined by gross visualizations of 
injection patterns with Evans blue dye and GFP expression.  This corroborates recent 
research finding that larger fluid injection volumes elicit enhanced gene expression in 
muscle tissues (Dupuis et al., 2000).  Another possible reason for greater gene 
expression following delivery by the BioJect device could be the transient disruption of 
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membranes by the jet streams.  Such disruption would increase the ability of the plasmid 
DNA to enter the cells and resemble the role of electroporation, which permeabilizes the 
cell membranes through the formation of pores as a result of applying high- intensity 
electrical fields.  This would explain why electroporation enhanced needle injection to a 
greater extent than jet injection.  However, any cellular DNA uptake resulting from 
membrane disruption by the jets appear to be much less significant than the permeability 
increase offered by electroporation, because substantial gains were still seen from 
coupling electroporation with jet injection, relative to the use of BioJect alone. 
Topical electroporation sets up an electrical field that is greatest at the surface of 
the skin and diminishes in strength with increased distance from the electrodes.  
Although electroporation enhances gene expression with both needle injection and 
BioJect administration, the electroporation voltage needed was higher in the case of the 
jet injection.  The difference in depth of plasmid distribution in the skin by the two 
delivery methods may explain this observation.  The BioJect device delivered liquid 
more deeply into the skin than the purposely shallow intradermal needle injection.  This 
deeper delivery may require a greater electroporation voltage because a sufficient 
electrical field is required to permeabilize cells in deeper layers of skin.  However, 
electroporation at higher voltages causes greater tissue damage, which can reduce gene 
expression, especially in the epidermis, seen in the GFP studies (data not shown).  
Increased gene expression in the dermis offsets this effect.  These conclusions concur 
with those of Glasspool-Malone et al, who used invasive electrodes and showed that 
electroporation of skin changes the distribution of gene expression and concentrates it in 
the dermis (Glasspool-Malone et al., 2000). 
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Although the mechanisms by which electroporation enhances immunogenicity of 
DNA vaccines are not yet completely understood, the increase in antigen production 
associated with electroporation is likely important.  Studies in mice showed that 
reduction of antigen expression decreased immune responses (Weeratna et al., 1998), 
and increases in antigen expression enhanced immune responses (zur Megede et al., 
2000).  The results here support these suggestions since electroporation enhanced both 
gene expression and immune responses.  Increasing the effectiveness of a DNA vaccine 
requires raising the levels of antigen production and/or increasing antigen uptake by 
APCs to heighten the immune response.  Electroporation may serve to enhance the 
immune response not only by increasing antigen expression, but also by other effects on 
the electroporated tissue.  The tissue damage caused by electroporation may trigger the 
release of cytokines that attract APCs to the exact site where increased levels of antigen 
are being produced.  This explanation would resemble the mechanism of agents such as 
bupivacaine that damage muscle and thereby enhances the immune response when it is 
delivered prior to DNA immunization (Davis et al., 1995).  Thus, the minor damage 
caused by electroporation could be advantageous for eliciting immune responses.  
The determination of antibody titers by both AUSABTM and conventional ELISA 
generally yielded similar results for the various animal groups.  However, there were 
discrepancies for individual animals.  These individual differences are explainable by 
the different parameters measured by each assay.  AUSABTM, in effect, measures levels 
of antibodies by sandwiching them between antigen and other antibodies.  In contrast, 
the conventional ELISA less selectively measures levels of antibodies that bind at a 
certain affinity/avidity.  Therefore, the observed discrepancy is expected. 
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The needle-free means of injection in combination with electroporation was 
more effective than needle injection at improving the kinetics of the immune response to 
DNA priming and boosting.  These results are consistent with our luciferase assay 
results, which indicate that electroporation enhances gene expression, and needle-free 
delivery is more effective than needle delivery of plasmid DNA.  Both delivery 
methods, each with electroporation, were about equally effective at producing an 
immune response after the protein boost.  The conventional intramuscular route of 
administration of the HBsAg subunit vaccine was previously found to be superior to the 
intradermal route of administration (Henderson et al., 2000).  Antibody titers at ten 
weeks support that result, but also offer the perspective that needle-free intradermal 
delivery may be comparable to conventional intramuscular delivery, in terms of its 
elicitation of an immune response.  That result is quite promising given the much less 
invasive nature of intradermal BioJect delivery. 
In a previous experiment, when 1 mg of the identical HBsAg encoding plasmid 
was administered in muscle using a needle. Only 2/6 pigs responded by the AUSAB 
assay after two immunizations (data not shown), therefore there are no significant 
differences between DNA immunization with HBsAg plasmid in the skin and the 
muscle.  However, electroporation with the 6-needle array in muscle resulted in all 6 
pigs responding to the HBsAg DNA vaccine by the AUSAB assay.  The likely reason 
why electroporation in muscle was more effective than needle-free electroporation in the 
skin was that electroporation in muscle resulted in a 10 fold greater level of gene 
expression compared BioJect in combination with needle-free electroporation as 
measured by luciferase. 
 83 
In summary, these experiments demonstrate that the needle-free method of 
intradermal DNA-vaccine delivery offers advantages, including increased efficacy of 
gene expression and safety, over injection with needle and syringe.  In addition, 
electroporation is quick and simple to apply, and is tolerated well by animals.  These 
results are very encouraging for the development of needle-free vaccination methods, 
and the development of DNA vaccines.
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5.0 ELECTROPORATION IMPROVES THE EFFICACY OF DNA 
VACCINES IN LARGE ANIMALS 
(Manuscript in press) 
 
5.1 Introduction 
The vaccination of individuals with plasmid-based vaccines continues to attract 
attention as a novel approach to inducing immunity to a wide variety of infectious 
agents including viruses, bacteria and parasites [reviewed in (van Drunen Littel-van den 
Hurk et al., 2000), (Davis et al., 1996; Hoffman et al., 1994; Ulmer et al., 1998)]. The 
main attraction of this approach is that the immune response generated by DNA 
immunization closely resembles those induced by natural infection (Ulmer et al., 1993), 
due to the endogenous production of viral proteins and glycoproteins.  This intracellular 
synthesis is especially important for inducing cell-mediated immunity (CMI) as well as 
antibody responses.  Cell-mediated immunity by cytotoxic lymphocytes is often critical 
for helping clearance of the pathogen (Lehmann-Grube et al., 1993), which generally 
does not occur following immunization with killed, or sub-unit protein vaccines, which 
induce primarily a humoral immune response.  Secondly, DNA vaccination is 
considered to be safer than using live attenuated vaccines, however, there are still 
perceived risks associated with DNA vaccines.  More importantly does not require a 
cold chain to maintain the efficacy of the vaccine.  This latter consideration is critical in 
developing countries where a cold chain is both expensive and often difficult to 
maintain. 
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However, for DNA vaccination to become routine, specific improvements are 
required to induce immune responses in humans and large animals.  Thus, even with 
plasmid constructs that are very effective in inducing immune responses in mice, 
transferring these same plasmids to humans or large animals has generally resulted in 
disappointing results (MacGregor et al., 1998; Turnes et al., 1999; Ugen et al., 1998).  
In these human and large animal experiments, the responses are often extremely variable 
and require large and multiple doses of plasmid to develop detectable responses.  DNA 
vaccination of humans and large animals is, however, often good at priming the immune 
response (Robinson et al., 1999).  Thus, there is an increasing interest in using DNA 
vaccination for priming immune responses followed by boosting with proteins (Jones et 
al., 2001; Richmond et al., 1998).  Although this is proving to be effective, having two 
different vaccine production and delivery systems is expensive and cumbersome to 
administer and monitor.  Thus, if it were possible to enhance the efficacy of DNA 
vaccination it would benefit both the patients and the vaccine companies.  Even if a 
prime boost regime were still required, having effective priming would be tremendously 
beneficial in vaccine development and delivery. 
Although the reasons for reduced efficacy of DNA vaccination in humans and 
large animals are unknown, one factor is probably the amount of protein produced in 
vivo.  One way of increasing protein expression is by using plasmids with strong 
promoters (van Drunen Littel-van den et al., 1998), or by reconstructing genes to 
improve codon biases (Kotsopoulou et al., 2000).  However, even these modifications to 
the plasmid are not sufficient to induce effective levels of immunity in humans or large 
animals, possibly due to the fact that only a small percentage of the DNA enters and is 
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functional in cells.  Thus, if it were possible to increase the level of transfection it might 
be possible to improve the efficacy of DNA vaccines.  To address this issue 
electroporation was tested in parallel with intramuscular DNA delivery. 
Electroporation has not only been shown to improve transfection efficiency in 
vitro, but recent studies have also shown enhanced gene expression in muscle (Widera et 
al., 2000; Zucchelli et al., 2000) and in skin (Glasspool-Malone et al., 2000; Heller et 
al., 2001).  To further investigate the efficacy of in vivo electroporation, some cohorts 
used plasmids encoding two completely different antigens – the bovine herpesvirus 
glycoprotein gene gD – a membrane protein, and a plasmid expressing hepatitis B 
surface antigen (HBsAg) which assembles into a 22 nanometer particle. This allowed us 
to examine immune responses to membrane bound and particulate antigens in a single 
animal. Since these plasmids were delivered simultaneously into the same muscle, it 
also allowed the investigating of the compatibility of incorporating multiple plasmids 
into a single vaccine. This is a major consideration for protecting individuals against 
multiple diseases by a single vaccination. This approach would not only reduce costs of 
vaccination, but also improve compliance. 
The pig was chosen as a model for both humans and large animals since it is 
significantly more difficult to induce immune responses in pigs (a large animal) than in 
mice (Turnes et al., 1999) and there appear to be many similarities in immune responses 
of pigs and humans.  Thus, the outbred pig is an excellent model for testing efficacy of 
vaccines that may then be transferred to the outbred human population. 
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5.2 Materials and methods  
5.2.1 Plasmids  
The luciferase encoding plasmid (pluc) with the luciferase coding sequence 
under the control of the CMV promoter in the pMAS backbone was a gift from Dr. 
Heather Davis (University of Ottawa, ON) (Krieg et al., 1998b). The hepatitis B surface 
Ag expression plasmid (pHBsAg), with the HBsAg coding sequence under the control 
of the human elongation factor 1a promoter with the first intron and the polyadenylation 
signal from human G-CSF cDNA in a pUC9 backbone was previously described 
(Widera et al., 2000). Plasmid pgD expresses glycoprotein D (gD) of bovine herpes 
virus 1 (BHV-1).  To generate this plasmid, the vector pCAN1 (Uwiera et al., 2001) was 
digested with BglII and the 1254 bp BglII fragment of pSLRV.Agd (Lewis et al., 1999) 
was inserted. Plasmids were purified using Qiagen Endo Free plasmid kits (Qiagen, 
Mississauga, Ont.) according to the manufacturers instructions. 
 
5.2.2 Animals and immunization 
Four to six week old male and female outbred pigs weighing 9-18 kg were 
purchased from the Prairie Swine Center (University of Saskatchewan, Saskatoon, SK). 
Animals were housed and treated in compliance with regulations of the Canadian 
Council for Animal Care. Animals were assembled randomly into six groups.  
Pigs were anesthetized with halothane and shaved on the quadriceps of both hind 
legs, the site of vaccination. The experimental design is displayed in Table 5.1.  
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Table 5.1 Study Design: Immunization of Pigs With DNA and Protein Vaccines 
 1st a and 2nd b  immunizations 3rd c immunization 
(Engerix-B) + (tgD/VSA) 
 Route/Method Voltage Vaccine Route/method 
Group 1 i.m./needle 
 
- pHBsAg i.m./needle 
Group 2 i.m./needle 
 
- pHBsAg 
+ pgD 
i.m./needle 
Group 3 i.m./single-needle 
electrode 
150 V pHBsAg i.m./needle 
Group 4 i.m./single-needle 
electrode 
150 V pHBsAg 
+ pgD 
i.m./needle 
Group 5 i.m./6-needle 
electrode 
200 V pHBsAg i.m./needle 
Group 6 i.m./6-needle 
electrode 
200 V pHBsAg 
+ pgD 
i.m./needle 
a 1st immunization consisting of plasmid (pHBsAg only in groups 1, 3 and 5) or 
(pHBsAg + pgD in groups 2, 4, and 6) was administered at day 0. 
b 2nd immunization consisting of plasmid (pHBsAg only in groups 1, 3 and 5) or 
(pHBsAg + pgD in groups 2, 4, and 6) was administered at four weeks. 
c 3rd immunization consisting of (Engerix-B) + (tgD/VSA) was administered at six 
weeks to all the groups. 
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Groups were as follows: Group 1 received 1000 mg pHBsAg in 1000 ml 0.1 M 
phosphate buffered saline (PBS), delivered by two 500 ml intramuscular injections, one 
in each quadriceps muscle. Group 2 was co- immunized with 1000 mg of pHBsAg in 
1000 ml PBS and 1000 mg pgD in 1000 ml PBS delivered by two adjacent 500 ml 
intramuscular injections into each quadriceps muscle. Group 3 received 1000 mg 
pHBsAg in 1000 ml PBS by intramuscular injections with the single-needle 
electroporation device into each quadriceps muscle as described above. Group 4 was co-
immunized with 1000 mg of pHBsAg in 1000 ml PBS and 1000 mg pgD in 1000 ml PBS 
with the single-needle electroporation device into each quadriceps muscle as described 
above. Group 5 received 1000 mg pHBsAg in 1000 ml PBS by intramuscular injections 
into each quadriceps muscle, followed by electroporation with the six-needle electrode 
as described above. Group 6 was treated the same as group 5, except pigs were co-
immunized with pHBsAg and pgD. Pigs were boosted in an identical fashion at four 
weeks. The third immunization at week six was delivered to all groups by intramuscular 
injection into the quadriceps muscles of both hind limbs, using the Engerix-B sub-unit 
vaccine (SmithKline Beecham Pharma, Oakville, Ont.), as well as 20mg tgD in 500 ml 
VIDO stimulatory adjuvant (VSA) (van Drunen Littel-van den Hurk et al., 1994) in two 
separate injections.  
 
5.2.3 Electroporation and electrodes 
Electroporation was performed using the BTX ECM 830 Pulse Generator with a 23 
gauge hypodermic needle (insertion depth: 1 cm) placed in a novel single-needle 
electrode holder, or with the six-needle electrode (insertion depth: 1 cm) with auto-
 90 
switcher device (Genetronics, San Diego, CA.).  The single-needle electrode uses the 
single needle as one arm of the electrode, which is in the center of the circular needle 
holder containing the second arm of the electrode, consisting of a 1 cm diameter ring 
that is placed on the surface of the skin.  This single-needle electroporation set up results 
in a cone shaped electrical field. The six-needle electrode consists of six sharp needles 
(1 cm long) arranged equidistantly around a circle of 1 cm diameter, forming a regular 
hexagon resulting in a cylindrical shaped electrical field. Electroporation with the single 
needle electrode was performed with four pulses of 150 V and 20 msec duration each, at 
5 Hz, and polarity was not switched.  
The six-needle electroporation was performed with six pulses of 200 V and 20 
msec duration each, at 5 Hz. The six pulses were delivered by firing two parallel needle 
pairs each, resulting in electrical fields rotating in a clockwise direction generated with 
the aid of an auto-switcher box allowing rotation of the electric field between opposing 
pairs of needles (Hofmann et al., 1999a). The polarity was reversed after each pulse 
using the auto-switcher box (Nanda et al., 1998). 
The voltages selected were based on previous studies, which demonstrated a low 
level of tissue damage 24 hours after electroporation, but did indicate delivery of 
electricity by slight twitching of the muscle during electrical pulsing. 
 
5.2.4 Luciferase assay  
To determine the level of gene expression, a plasmid encoding the luciferase 
gene (pluc) (Weeratna et al., 1998) was used. A dose of 100 mg of luciferase encoding 
plasmid in 500 ml was administered by intramuscular injection into the quadriceps at 
five similar sites per pig in three additional pigs. Groups were as follows, no 
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electroporation, single-needle electroporation and six-needle electroporation, using the 
same electroporation conditions used for the immunizations.  Twenty-four hours after 
administration of plasmid, the muscle tissue surrounding the injection site was sampled 
using an 8 mm biopsy punch. Muscle samples were homogenized and the luciferase 
activity was determined using Promega’s (Madison, WI) luciferase assay system. 
Samples were counted for 30 seconds. Untreated muscle from each pig was used to 
measure the background level of light units (LU). 
 
5.2.5 Measurement of antibody responses 
At various time points blood was collected and serum was obtained following 
centrifugation. Anti-hepatitis B surface Abs were measured using the AUSABTM EIA 
Diagnostic Kit, and quantification in milli- international Units/ml was done in parallel 
with the AUSABTM Quantification Panel following instructions provided by the 
manufacturer (Abbott Laboratories, Abbott Park, IL). 
Anti-hepatitis B IgG1 and IgG2 isotypes were determined by ELISA as follows. 
Immunlon 2 (DYNEX, Chantilly, VA) ELISA plates were coated with HBsAg 
(BioDesign International, Saco, Maine) (1 mg/ml) in 20 mM Na2CO3 overnight at 4°C. 
Plates were washed with phosphate buffered saline-Tween (PBST)(PBS, 0.05% Tween 
20, Sigma, St. Louis, MO). Serum was diluted 1/20 in diluent (PBST, 0.5% gelatin, 
Sigma) followed by serial 4 fold dilutions and incubated overnight at 4°C. Plates were 
washed 6X in PBST and porcine IgG1 or IgG2 isotypes were determined using mouse 
anti-porcine IgG1 or mouse anti porcine IgG2 antibodies (Serotec, Hornby, ON), diluted 
in diluent and incubated at room temperature for 1 hour. Plates were washed 6X in 
PBST and anti-mouse IgG1 biotinylated antibodies (Caltag, Toronto, ON) diluted in 
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diluent were added, followed by a 1 hour incubation. Plates were washed 6X in PBST, 
streptavidin-alkaline phosphatase (Jackson Immuno-research Labs, West Grove, PA) 
was added, and plates were incubated for 1 hour. The alkaline phosphatase activity was 
determined using p-nitrophenyl phosphate (PNPP) (Sigma). The absorbance was read at 
405 nm with a spectrophotometer (Bio-Rad, Hercules, CA) after 15-20 minutes. 
The anti-gD IgG1 and IgG2 isotypes were determined by ELISA as above, 
except plates were coated with 1 mg/ml tgD. 
Titers of anti-BHV-1 neutralizing antibody in sera were determined as 
previously described (van Drunen Littel-van den Hurk et al., 1990). The titers were 
expressed as the highest dilution of serum that caused a 50% reduction in viral plaques 
compared to the virus control. 
 
5.2.6 Measurement of cellular responses 
 Porcine blood was collected in Vacutainer tubes containing citrate (Becton 
Dickinson, Franklin Lakes, NJ). Peripheral blood mononuclear cells (PBMCs) were 
isolated from the blood as follows. Blood was centrifuged at 2000 rpm for 30 minutes. 
The buffy coat was removed and resuspended in PBS-0.1 M EDTA and cells were 
overlayed on ficoll-paque (Pharmacia Biotech, Uppsala, Sweden) and centrifuged at 
2500 rpm for 45 minutes. The PBMCs were removed and washed three times in PBS-
EDTA and resuspended in RPMI medium (Gibco Life Technologies, Burlington, ON).  
 Proliferation of gradient-purified cells were measured as previously described 
(Tikoo et al., 1995). Briefly, 2.5 X 105 PBMCs in RPMI media (Gibco) were plated per 
well in 96 well plates either with no antigen, full length gD protein (1 mg/ml), or with 
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5mg/ml phytohemagglutinin (PHA) (Sigma) as a positive control. All assays were 
performed in quadruplicate. Cells were incubated at 37°C in 5% CO2 /air for 4 days and 
then pulse- labeled with 0.4 mCi/well methyl [H3] thymidine (Amersham Biosciences, 
Baie d'Urfe, QC) for 8 hours. Cells were harvested from wells using a semiautomatic 
cell harvester (Skatetron Inc, Sunnyvale, CA.) and ß emissions were measured as counts 
per minute (cpm) using a LS 1701 scintillation counter (Beckman Coulter, Mississauga, 
ON). Stimulation indexes (SI) represent mean cpm (stimulated cells)/ mean cpm  (non-
stimulated cells). The PHA stimulated control cells all had SIs greater than 100, 
indicating a high viability of cells. 
To determine the number of gD-specific INF-? secreting cells, a porcine INF-? 
ELISPOT assay was performed as described (Baca-Estrada et al., 1996) with the 
following changes:  1x106 cells/well were placed in 96 well culture plates with and 
without antigen (gD 1 mg/ml) in RPMI medium (Gibco) and incubated at 37°C and 5% 
CO2 for 24 hours. Cells were resuspended in fresh medium and 5x105 cells were seeded 
on nitrocellulose plates (Millipore, Napean, ON) coated with mouse monoclonal anti-
porcine IFN-g capture antibody, 5 mg/ml (BioSource International, Camarillo, CA.).  
Plates were washed in cold water followed by PBST. Rabbit polyclonal anti-porcine 
IFN-g specific antibodies (BioSource International) at 5 mg/ml in diluent (PBST, 0.5% 
albumin) (Sigma) were added to the plates and incubated for 2 hours at room 
temperature. Plates were washed, biotinylated rat anti-rabbit IgG (Zymed, San 
Francisco, CA.) at 5 mg/ml in diluent was added, and the plates were incubated at room 
temperature for 2 hours. Plates were washed and streptavidin-alkaline phosphatase 
(Jackson Immuno-Research Labs) was added. Plates were developed using 5-bromo-4-
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chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) substrate tablets 
(Sigma). Spots representing gD specific cytokine secreting cells were counted and 
expressed as number of cytokine secreting cells per 5x105 cells. PHA stimulated cells 
were used as a positive control, with greater than 20 cytokine secreting cells per well. 
 
5.2.7 Histological examination of muscle tissue  
Twenty-four hours after injection of 100 mg pMAS-luc in 500 ml PBS followed 
by no electroporation, single-needle electroporation or six-needle electroporation, 
muscle biopsies were taken and fixed in 10% formalin. Tissues were embedded in 
paraffin and 4 mm sections were stained with hematoxylin/eosin (HE). 
 
5.2.8 Statistics 
Differences between groups were analyzed using Prism graphpad statistical 
software (GraphPad Soffware, Inc.) using a one-way ANOVA followed by Tukey's 
multiple comparison test. 
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5.3 Results 
5.3.1 Gene expression 
A luciferase reporter gene was used to compare the amount of gene expression 
induced from plasmid administered without electroporation, and with single-needle and 
six-needle electroporation treatment. Figure 1 clearly shows that electroporation with 
the single-needle electrode enhances gene expression 100 times over no electroporation 
and electroporation with the six-needle array enhances gene expression an order of 
magnitude above the single-needle electrode.  
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Figure 5.1  Increase in gene expression in the muscle by electroporation. 
Porcine muscle was injected with 100 mg of pluc in 500 ml PBS at 5 different sites in the 
quadriceps muscle, followed by no electroporation, electroporation with a single-needle 
electrode (1 EP), or a six-needle array electrode (6 EP). Luciferase activity in the 
excised tissue was measured 24 hrs following administration of plasmid. No EP Vs 6 EP 
p<0.05 by one-way ANOVA followed by Tukey's multiple comparison test.  There was 
no statistical difference between 1 EP Vs 6 EP.  Error bars represent SEM. 
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5.3.2 Immune responses 
No animals had detectable antibody responses to HBsAg at four weeks after the 
primary immunization. This was expected since vaccination with the commercial 
vaccine Engerix-B does not elicit antibody responses in pigs four weeks after primary 
immunization (data from previous chapter). However, by six weeks, immune responses 
to HBsAg elicited by a plasmid encoding the particular antigen (HBsAg) were evident if 
animals were treated with electroporation. Thus the re was very little evidence of an 
immune response at six weeks post-vaccination in the absence of electroporation but 
excellent immune responses were detected in animals immunized with the six-needle 
electrode (Figure 5.2A).  Indeed, animals immunized with a six-needle electrode had 
immune responses two orders of magnitude higher than those animals not experiencing 
electroporation and one order of magnitude higher than those immunized with a single-
needle electrode.  What was even more encouraging was that the number of animals 
responding increased following electroporation.  Six weeks after immunization, all 
animals responded in the six-needle electroporated group vs. 66% in the group that 
received single-needle electroporation, and only 33% in the non-electroporated group.  
The immune response differences were maintained even after boosting with the HBsAg 
protein vaccine (Figure 5.2B).  The six-needle electrode treated group had a ten-fold 
higher immune response when compared to the single-needle electrode group even after 
protein boost.  The anti-HBsAg IgG1 and IgG2 response was also compared at 6 and 8 
weeks. At 6 weeks, animals immunized with DNA without electroporation and the 
single-needle electroporated group were predominantly IgG1 whereas animals 
immunized with the six-needle electrode gave a more balanced response with both IgG1  
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Figure 5.2 Effect of electroporation on anti-HBsAg titers in pigs at six and eight weeks 
after immunization.  
Anti-HBsAg titers were determined using the Abbott kit. A: Anti-HBsAg titers are 
shown at six weeks after immunization with pHBsAg at 0 and 4 weeks with no 
electroporation (no EP), electroporation with a single-needle electrode (1 EP) or a six-
needle electrode (6 EP), no EP Vs 6 EP p<0.01 and 1 EP Vs 6 EP p<0.01 by one-way 
ANOVA followed by Tukey's multiple comparison test. B: Anti-HBsAg titers at week 8 
after HBsAg subunit boost at week 6, no EP Vs 6 EP p<0.01 by one-way ANOVA 
followed by Tukey's multiple comparison test.  C and D: Data from Graphs A and B 
broken down into animals receiving pHBsAg only or pHBsAg and pgD. Groups 1 and 2 
were immunized with no electroporation, Groups 3 and 4 were immunized with 
electroporation using the single-needle electrode and Groups 5 and 6 were immunized 
with electroporation using the six-needle electrode (see Table 1). For C and D: White 
bars represent pigs immunized only with pHBsAg and black bars are pigs co- immunized 
with pHBsAg and pgD. Numbers above the bars indicate the number of animals 
seroconverting per group; error bars represent SD. 
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and IgG2 isotypes (data not shown). At 8 weeks all groups had a more balanced 
response with both IgG1 and IgG2 isotypes present (data not shown). 
To determine whether similar responses as to HBsAg could be generated to a 
membrane protein antigen, a plasmid encoding a bovine herpes virus glycoprotein (gD) 
was used. Figure 5.3 demonstrates that at 6 weeks after primary immunization with a gD 
encoding plasmid, followed by a boost at 4 weeks all animals exposed to electroporation 
developed more robust immune responses in both IgG1 and IgG2 isotypes compared to 
DNA immunized animals without electroporation and that the six-needle electrode was 
more effective than the single needle electrode.  This response was further increased 
following a boost with purified recombinant protein (Figure 5.4).  Furthermore the 
response in animals primed with a DNA vaccine was significantly higher than that in 
animals immunized with a protein alone, indicating that the DNA vaccine could 
effectively prime the immune response of pigs to a truncated (t)gD protein vaccine.  The 
fact that DNA immunization induced neutralizing antibodies against bovine herpesvirus-
1 (Figure 5.3C) confirms that the glycoprotein produced in vivo possessed the correct 
conformational epitopes, since gD conformation is critical for induction of neutralizing 
antibodies (van Drunen Littel-van den Hurk et al., 1990). 
Although there have been no detailed studies comparing murine and porcine 
isotypes reported, isotype analysis was performed in animals immunized in the presence 
or absence of electroporation to determine if electroporation could influence the balance 
of antibody responses (Figure 5.4).  Immunization with gD protein alone produced a  
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Figure 5.3 Increase in gD-specific IgG1 and IgG2 by electroporation.  
Pigs were immunized with pgD and pHBsAg at 0 and 4 weeks with no electroporation 
(no EP), electroporation with a single-needle electrode (1 EP) or electroporation with a 
six-needle electrode (6 EP). Anti-gD titers were determined at 6 weeks using ELISA for 
IgG1 (A) and IgG2 (B).  BHV-1 neutralizing antibodies from animals primed and 
boosted once at week 4 with pgD DNA (C). There are no significant differences beteen 
the groups in A and B.  Error bars are not visible in C since all animals in each group 
had the same neutralization titer.  Error bars represent SD and n = 3.  
no EP 1 EP 6 EP
0
1
2
3
4
5
A
gD
-s
pe
ci
fic
 Ig
G
1 
tit
er
(L
o
g 1
0
) 
(w
ee
k 
6)
No EP 1 EP 6 EP
0
1
2
3
4
5
B
gD
-s
pe
ci
fic
 Ig
G
2 
tit
er
(L
o
g 1
0)
 (
w
ee
k 
6)
no EP 1 EP 6 EP
0
10
20
30
40
C
B
H
V
-1
 n
eu
tr
al
iz
at
io
n
an
tib
od
y 
tit
er
 (
w
ee
k 
6)
 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Effect of DNA prime and protein boost on gD-specific IgG1 and IgG2 titers. 
Anti-gD IgG1 and IgG2 titers were determined by ELISA at week 8. Groups 1 and 2 
were immunized with no electroporation, Groups 3 and 4 were immunized with 
electroporation using the single-needle electrode and Groups 5 and 6 were immunized 
with electroporation using the six-needle electrode (see Table 1). White bars represent 
groups not primed with pgD, while black bars are groups immunized twice with pgD 
(week 0 and 4) and then given a gD protein vaccine at 6 weeks *p<0.01 and **p<0.001 
by one-way ANOVA followed by Tukey's multiple comparison test compared to group 
1. Error bars represent SD and n = 3. 
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higher level of IgG1 (Figure 5.4), as expected for a soluble protein (Benne et al., 1997).  
However, immunization with a gD DNA vaccine produced a much more balanced 
response with higher levels of gD-specific IgG2 as compared to animals immunized first 
with a plasmid encoding HBsAg followed by gD protein immunization.  This balanced 
response was maintained even after a boost with purified protein.  It is of interest to note 
that if animals were first immunized with DNA and electroporated with a six-needle 
array and subsequently (two weeks later) immunized with glycoprotein at the same site, 
they developed high levels of gD specific IgG1 as well as IgG2 (Group 5).  
To determine if Th1- like responses were obtained, it was investigated if 
lymphocytes from immunized pigs could produce interferon gamma – the true measure 
of Th1- like responses.  Figure 5A demonstrates that DNA immunization stimulated 
significant numbers of interferon gamma secreting cells, whereas immunization with the 
glycoprotein generally did not.  Thus, our studies support previous reports that DNA 
vaccination polarizes the response towards a Th1-like or balanced response (Martinez et 
al., 1997; Sjolander et al., 1998).  It is of interest to note that electroporation with a six-
needle array and subsequent (two weeks later) immunization with a purified 
glycoprotein in the same site resulted in, induction of high levels of interferon gamma 
secretion (Group 5).  Indeed, these animals developed the same level of interferon-
gamma secreting cells as animals first immunized with a gD-encoding DNA plasmid 
and then boosted with a glycoprotein (Figure 5.5A).  Similarly, the lymphocytes from 
these animals had high levels of T-helper cell responses, as demonstrated by their ability 
to respond in a lympho-proliferative assay against purified gD glycoprotein in vitro 
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Figure 5.5 Cellular immune responses in gD immunized pigs.  
The number of gD-specific IFN-? secreting lymphocytes was determined by ELISPOT 
(A) ** p<0.001 compared to groups 1 and 3 by one-way ANOVA followed by Tukey's 
multiple comparison test. Glycoprotein D-specific proliferative responses (B) were 
determined * p<0.01 compared to group 1. Groups 1 and 2 were immunized with no 
electroporation, Groups 3 and 4 were immunized with electroporation using the single-
needle electrode and Groups 5 and 6 were immunized with electroporation using the six-
needle electrode (Table 1). White bars represent groups not primed with pgD and black 
bars represent groups immunized twice with pgD.  Naive pigs were age-matched 
controls housed with the experimental pigs. Error bars represent SD and n = 3. 
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(Figure 5.5B).  The proliferation responses of animals exposed to the DNA vaccine 
without electroporation or to DNA immunization and electroporation with a single 
electrode followed by booster immunization with a glycoprotein further supported the 
suggestion that DNA vaccination primed the animal’s immune response.   
 
5.3.3 Plasmid compatibility 
One of the major potential advantages of plasmid immunization is the 
compatibility of plasmids, allowing co-administration of vaccines directed against 
different pathogens.  Incorporation of multiple antigens into a single vaccine should 
dramatically improve compliance and, thereby, vaccine coverage.  Unfortunately, few 
studies have been done to date demonstrating plasmid compatibility in humans or large 
animals (Braun et al., 1998).  To test this possibility, co-administration of plasmids 
encoding gD and HBsAg either with or without electroporation was evaluated.  Figures 
2C and 2D demonstrate that there was no significant interference in the level of antibody 
responses to HBsAg in either the number of responder animals or the magnitude of the 
immune responses following DNA administration alone (Figure 5.2C), or after a boost 
with protein (Figure 5.2D).  Responses to tgD were also not altered when pgD was co-
administered with pHBsAg since gD-specific antibody titers were detectable as early as 
two weeks following immunization in all animals (data not shown).   
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5.3.4 Histology of injection sites 
To examine if electroporation would cause any tissue damage, histological 
examination of the electroporation site 24 hours after electroporation with the single-
needle and six-needle electroporation was compared to no electroporation.  There was 
an infiltration of neutrophils into the muscle as well as some minor muscle cell damage 
after electroporation with the six-needle array (Figure 5.6).    
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Figure 5.6 Effect of electroporation on muscle tissue.  
Histological examination (HE stain) of muscle biopsies 24 hours after injection of 
plasmid (pMAS-luc) with no electroporation (A), single-needle electroporation (B) and 
six-needle electroporation (C). Mild infiltration of macrophages and neutrophils was 
observed in (A). Moderate infiltration was seen in (B) and severe infiltration was 
observed in (C). Bar is 100 µm. 
A 
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5.4 Discussion 
It was demonstrated that electroporation was effective in enhancing immune 
responses to two different antigens, the weakly immunogenic HBsAg, as well as the 
strongly immunogenic gD antigen. It is interesting that the kinetics of responses to these 
two antigens remains the same regardless whether administered by an electroporation 
enhanced DNA delivery approach or a protein subunit vaccine in an adjuvant:  gD 
induces immune responses as early as two weeks after primary immunization and 
HBsAg induces immune responses only after a boost. In addition, it was shown that 
there was no interference with two different DNA vaccines.  These results support the 
contention that injection of at least some combinations of multiple plasmids is possible 
without causing interference. However, different plasmid and antigen combinations 
must still be tested for compatibility on a case by case basis, because different antigen 
combinations may behave differently. 
DNA immunization elicits IFN-? secreting cells a measure of Th1 immune 
responses whereas protein immunization generally do not induce IFN-? secreting cells.  
However, protein immunization with CpG in pigs was recently shown to promote Th1 
IFN-? responses in pigs (Van der Stede et al., 2002). These results are in agreement with 
this finding, however, it was also demonstrated that once the immune system is primed 
for a Th1 response, the Th1 response predominates Th2 promoting immunizations. In 
addition, electroporation prior to a gD protein immunization elicited a Th1 response 
indicating the possibility that electroporation may promote Th1 responses.  
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Inflammatory cytokines induced by electroporation as well as cellular infiltration may 
be possible mechanisms for the observed Th1 response. 
Currently, it is assumed that the reason for the increased efficacy of DNA 
vaccines if delivered by electroporation is due to the increase in the transfection 
efficiency and concomitant increase in antigen expression in vivo (Widera et al., 2000).  
It was shown that electroporation significantly enhances gene expression in vivo in large 
animals and that antigen expression correlated with the magnitude of elicited immune 
responses.  Although the exact reason of observing increased gene expression as well as 
increased neutrophil infiltration and muscle damage with the 6-needle electrode 
compared to the single needle electrode is not currently understood, but is probable due 
mainly to differences in electrode configuration and firing patterns and less likely due to 
the different voltages used.  It is not known whether electroporation favors expression of 
antigen in any specific cell population or whether all cells are equally affected.  
Furthermore, it is unclear whether the muscle cells in this case are damaged, thereby 
take up more plasmid and, therefore, release more antigen, or whether the damage 
results in enhanced inflammation in the vicinity of the plasmid, which creates a cytokine 
microenvironment more conducive to effective immune priming and expansion of 
immune cells.  The suggestion that inflammation and cellular infiltration may play a role 
in enhancing the immune response was provided in animal group 5 as shown in Figures 
4 and 5.  DNA immunization with pHBsAg and electroporation of muscle tissue with 
the 6-needle array followed by administration of the tgD protein antigen two weeks later 
in the same location resulted in a very rapid response to tgD.  Interestingly, this response 
was of similar magnitude as the one in pgD DNA primed animals, with or without 
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electroporation (animal groups 2 and 4).  In contrast, the immune response after tgD 
administration in non-electroporated sites (animal group 1) and animals pretreated with 
the single-needle electrode (animal group 3) was weak.  Histological examination of the 
electroporation site 24 hours after electroporation clearly demonstrated an infiltration of 
neutrophils into the muscle after electroporation with the six-needle array. This 
inflammatory response following electroporation with the 6-needle array lasts for at 
least two weeks (data not shown).  The inflammatory responses as a result of 
electroporation are unlikely to cause long-term histological changes or pain, since 
systematic studies on electroporation effects on pig skin and muscle, albeit under 
different pulse conditions, did not show lasting side effects (Rabussay DP, 2002).  
Although pain elicitation on electroporation has been reported by a segment of patient 
population (Rodriguez-Cuevas S, 2001), experimental studies in animals examining the 
pain response to electroporation have not been investigated so far.  Although previous 
studies have shown electroporation after protein delivery did not result in priming 
(Widera et al., 2000) this is not surprising since it is expected that the protein will have 
been cleared from the injection site by the time the peak of inflammatory response 
occurs following electroporation.  It is possible these inflammatory responses also are 
important in enhancing immune responses to DNA vaccines, since antigen produced by 
plasmids would not be cleared from the site of inflammation as fast as conventional 
protein immunization. These issues are being addressed to determine the impact of gene 
expression and tissue damage on immune responses elicited by DNA immunization.  
These and additional studies will have to be performed before proceeding to clinical 
applications.
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6.0 INCREASED GENE EXPRESSION AND INFLAMMATORY 
RESPONSES CAUSED BY ELECTROPORATION ARE BOTH IMPORTANT 
FOR IMPROVING THE EFFICACY OF DNA VACCINES 
(Manuscript in preparation) 
 
6.1 Introduction 
 DNA vaccines continue to generate considerable interest among researchers in 
the vaccine field as well as commercial companies for several reasons. DNA vaccines 
are 1) economical, 2) simple and 3) considered safe as compared to other vectors 
(Donnelly et al., 1997).  While DNA vaccines are effective in mice, they are, however, 
less so in large animals and humans.  
Although the reasons for reduced efficacy of DNA vaccination in humans and 
large animals are unknown, one potential factor is the low amount of protein produced 
in vivo.  One way of increasing protein expression is by using plasmids with strong 
promoters (van Drunen Littel-van den Hurk et al., 1998); another is by reconstructing 
genes to improve codon biases (Kotsopoulou et al., 2000).  Even these modifications to 
the plasmid, however, are not sufficient to induce effective levels of immunity in either 
humans or large animals, possibly due to the fact that only a low level of gene 
expression occurs from the small amount of intact plasmid entering cells.  
Electroporation, a delivery method which temporarily increases cell permeability, has 
been shown to increase the level of gene expression and significantly improve immune 
responses elicited to DNA vaccines in both small (Glasspool-Malone et al., 2000; 
Widera et al., 2000) and large animals (Babiuk et al., 2002). 
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Until recently, it was thought that the increase in gene expression caused by 
electroporation was the only mechanism responsible for increasing immune responses to 
DNA vaccines (Widera et al., 2000).  Intramuscular administration of a protein vaccine 
in the same site previously treated with electroporation two weeks before, resulted in an 
enhancement of antigen-specific immune responses to the vaccine antigen, suggesting 
that muscle damage and ensuing inflammatory cell infiltration caused by electroporation 
may also be important mechanisms for enhancing immune responses to DNA vaccines 
(Babiuk et al., 2002).   
In this study plasmids encoding two different antigens were used, namely the 
bovine herpesvirus type 1 glycoprotein gene gD, a membrane protein and highly 
immunogenic antigen, and a plasmid expressing hepatitis B surface antigen (HBsAg) 
which assembles into a 22 nanometer particle. This allowed a comparison of immune 
responses to membrane bound and particulate antigens in a single animal. Co-
administration of vaccines is a major goal in the drive to protect individuals against 
multiple diseases by a single vaccination.  This approach would not only reduce costs of 
vaccination, but also improve compliance if appropriate vaccines could be administered 
simultaneously in a single injection. 
The pig was chosen as a model for both humans and large animals since there 
are many similarities between pigs and humans, such as they are both out bred 
populations and share common immune responses. 
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6.2 Materials and methods  
6.2.1 Animals.  
Four to six week old male and female out bred pigs weighing 9-18 kg were 
purchased from the Prairie Swine Centre Inc. (University of Saskatchewan, Saskatoon, 
SK). Animals were housed and treated in compliance with regulations of the Canadian 
Council for Animal Care.  
 
6.2.2 Plasmids  
The luciferase encoding plasmid (pluc) with the luciferase coding sequence 
under the control of the CMV promoter in the pMAS backbone was a gift from Dr. 
Heather Davis (University of Ottawa, ON) (Krieg et al., 1998). The hepatitis B surface 
Ag expression plasmid (pHBsAg), with the HBsAg coding sequence under the control 
of the human elongation factor 1a promoter, with the first intron and the 
polyadenylation signal from human G-CSF cDNA in a pUC9 backbone, was previously 
described (Widera et al., 2000). pgD expresses glycoprotein D (gD) of bovine herpes 
virus 1 (BHV-1).  To generate this plasmid, the vector pCAN1 (Uwiera et al., 2001) was 
digested with BglII, and the 1254 bp BglII fragment of pSLRV.Agd (Lewis et al., 1999) 
was inserted. Plasmids were purified using Qiagen Endo Free plasmid kits (Qiagen, 
Mississauga, ON) according to the manufacturer's instructions. 
 
6.2.3 Immunization 
Animals were randomly assembled into six groups of six. Pigs were anesthetized 
with halothane and a square (3 cm) shaved over the quadriceps muscle (vastus lateralis) 
of the right hind leg to prepare the site for vaccination. The experimental design is 
 113 
displayed in Table 6.1. All vaccine groups received a single intramuscular injection, 
consisting of 100 mg of pgD and 500 mg of pHBsAg in 500 ml of PBS, at that site.  The 
dose of pgD used was lower than that of pHBsAg since in previous studies pgD elicited 
immune responses earlier than pHBsAg (Babiuk et al., 2002).  Pigs were immunized on 
day 0 and received a second identical injection 4 weeks later contra-laterally (left leg) in 
the same muscle at the equivalent site.  Vaccine treatments for groups were as follows: 
Group 1 received plasmid and no electroporation; Group 2 was treated with 
electroporation one hour prior to DNA immunization using the following parameters - 
electroporation with 6 rotating pulses of 20 msec at 200 V, with reversal of polarity 
between pulses; Group 3 was treated immediately following DNA immunization with 2 
pulses of 60 msec at 100 V, without reversing the polarity; Group 4, immediately 
following DNA immunization, received 6 rotating pulses of 20 msec at 200 V, reversing 
the polarity between pulses; Group 5 was treated immediately following DNA 
immunization with 2 pulses of 60 msec at 200 V, without reversing the polarity.  Naive 
pigs received no treatment.
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Table 6.1 Experimental design: Vaccination parameters  
 
Group Electroporation (EP) 
conditions 
Vaccinea Number of  
Animals 
1 No EP 100 mg pgD plus 
500 mg pHBsAg  
6 animals 
2 200 V/20 msec/6 pulses 
1 hour prior to DNA 
administration  
100 mg pgD plus 
500 mg pHBsAg  
6 animals 
 
3 100 V/60 msec/2 pulses 100 mg pgD plus 
500 mg pHBsAg  
6 animals 
4 200 V/20 msec/6 pulses 100 mg pgD plus 
500 mg pHBsAg 
6 animals 
5 200 V/60 msec/2 pulses 100 mg pgD plus 
500 mg pHBsAg 
6 animals 
6 No treatment No treatment  2 animals 
 
1 Plasmids were mixed together in 500 ml PBS and was administered in one 
intramuscular injection on days 0 and 28 on opposite sides. 
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6.2.4 Electroporation and electrodes 
Electroporation was performed using the BTX ECM 830 Pulse Generator with a six-
needle electrode (insertion depth: 1 cm) with an auto-switcher device (Genetronics, San 
Diego, CA.).  The electrode consists of six sharp needles (1 cm long) arranged 
equidistantly around a circle of 1 cm diameter to form a regular hexagon, resulting in a 
cylindrical shaped electrical field.  
For electroporation performed with six pulses, the pulses were delivered by 
firing two opposing parallel needle pairs around the injection site in a clockwise 
direction generated with the aid of an auto-switcher box allowing rotation of the electric 
field among opposing pair s of needles (Hofmann et al., 1999), and for reversal of the 
polarity after each pulse (Nanda et al., 1998).  For electroporation parameters with 2 
pulses, electrical charges were delivered by firing two opposing parallel needle pairs of 
the six-needle electrode without rotation of the field and without reversal of polarity, in 
effect using a four-needle array for pulse delivery. 
The voltages were selected based on previous studies (Genetronics, unpublished 
data), which demonstrated differences in the level of tissue damage according to the 
voltage used for electroporation. 
 
6.2.5 Luciferase assay 
To determine the level of gene expression, a plasmid encoding the luciferase 
gene (pluc) (Weeratna et al., 1998) was used. Five additional pigs were used to 
determine luciferase gene expression following plasmid administration under the 
different electroporation parameters used for the vaccine trial (Table 6.1.) by 
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administering a dose of 100 mg of pluc in 500 ml by intramuscular injection into the 
quadriceps muscle on both hind legs at eight similar sites per pig for each parameter.  
Forty-eight hours after administration of plasmid, the muscle tissue of the eight 
injection sites was sampled using an 8 mm biopsy punch. Muscle samples were 
homogenized in 1 ml of lysis buffer (Promega, Madison, WI) with a Polytron 
homogenizer (Brinkmann Instruments, Rexdale, ON) to yield protein extracts. 
Luciferase activity of the protein extracts was determined using a luciferase assay 
system (Promega). Samples were counted for 30 seconds on a Packard Picolite 
Luminometer (Packard Instruments Canada LTD, Mississauga, ON). Untreated muscle 
samples were used to calculate the background levels of light units (LU). 
 
6.2.6 Measurement of antibody responses 
At various time points, blood was collected and serum was obtained following 
centrifugation. Anti-hepatitis B surface antibodies were measured using the AUSABTM 
EIA Diagnostic Kit, and quantification in milli- international Units/ml was done in 
parallel with the AUSABTM Quantification Panel, following the instructions provided by 
the manufacturer (Abbott Laboratories, Abbott Park, IL). In humans, the protective level 
is considered >10 mIU/ml (West and Calandra, 1996). 
Titers of anti-BHV-1 neutralizing antibody in sera were determined as 
previously described (van Drunen Littel-van den Hurk et al., 1990). The titers were 
expressed as the highest dilution of serum that caused a 50% reduction in the number of 
viral plaques compared to the untreated virus control. 
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6.2.7 Measurement of cellular responses 
 Porcine blood was collected in Vacutainer tubes containing citrate (Becton 
Dickinson, Franklin Lakes, NJ). Peripheral blood mononuclear cells (PBMCs) were 
isolated from the blood as follows. Blood was centrifuged at 900 g for 30 minutes. The 
buffy coat was removed and resuspended in PBS-0.1 M EDTA. The cells were 
overlayed on ficoll-paque (Pharmacia Biotech, Uppsala, Sweden) and centrifuged at 
1400 g for 45 minutes. The PBMCs were removed, washed three times in PBS-EDTA 
and resuspended in RPMI medium (Gibco Life Technologies, Burlington, ON).  
 Proliferation of gradient-purified cells was measured as previously described 
(Tikoo et al., 1995). Briefly, 2.5 X 105 PBMCs in RPMI media (Gibco) per well were 
plated in 96 well plates either with no antigen, full length gD protein (1 mg/ml), or with 
5 mg/ml phytohemagglutinin (PHA) (Sigma Chemical Co., St. Louis, MO) as a positive 
control. All assays were performed in quadruplicate. Cells were incubated at 37°C in 5% 
CO2 /air for 4 days and then pulse- labeled with 0.4 mCi/well of methyl [H3] thymidine 
(Amersham Biosciences, Baie d'Urfe, QC) for 8 hours. Cells were harvested from wells 
using a semiautomatic cell harvester (Skatron Inc, Sunnyvale, CA.) and ß emissions 
were measured as counts per minute (cpm) using a LS 1701 scintillation counter 
(Beckman Coulter, Mississauga, ON). Stimulation index (SI) represent mean cpm 
(stimulated cells)/ mean cpm (non-stimulated cells). The PHA stimulated control cells 
all had SI greater than 100, indicating a high viability of cells. 
To determine the number of gD-specific INF-? secreting cells, a porcine 
ELISPOT assay was performed as described (Baca-Estrada et al., 1996) with the 
following changes:  1x106 cells/well were placed in 96 well culture plates with and 
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without antigen (gD 1 mg/ml) in RPMI medium (Gibco) and incubated at 37°C and 5% 
CO2 for 24 hours. Cells were resuspended in fresh medium and 5x105 cells were seeded 
on nitrocellulose plates (Millipore, Napean, Ont.) coated with mouse monoclonal anti-
porcine IFN-g capture antibody, 5 mg/ml (BioSource International, Camarillo, CA.).  
Plates were washed in cold water followed by PBST. Rabbit polyclonal anti-porcine 
IFN-g specific antibodies (BioSource International) at 5 mg/ml in diluent (PBST, 0.5% 
albumin) (Sigma) were added to the plates, which were incubated for 2 hours at room 
temperature. Plates were washed, biotinylated rat anti-rabbit IgG (Zymed, San 
Francisco, CA.) at 5 mg/ml in diluent was added, and the plates were incubated at room 
temperature for 2 hours. Plates were again washed, streptavidin-alkaline phosphatase 
(Jackson Immuno-Research Labs) was added, and 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate added (Sigma). Spots 
representing gD-specific cytokine secreting cells were counted and expressed as the 
number of cytokine secreting cells per 5x105 cells. PHA stimulated cells were used as a 
positive control, with greater than 20 cytokine secreting cells per well. 
 
6.2.8 Histological examination of muscle tissue  
Muscle samples were obtained from all injection sites, using an 8 mm punch, 
immediately following euthanasia with an overdose of euthanol.  Each of the muscle 
sites injected with pluc was sampled forty-eight hours post- injection for each of the 
plasmid administration conditions.  From pigs immunized with gD and HBsAg DNA, 
the injection sites of both the primary immunization and the contra-lateral secondary 
immunization were sampled (at 6 and 2 weeks, respectively).  Tissues were fixed in 
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10% neutral buffered formalin, processed routinely and embedded in paraffin wax.  Four 
mm sections were cut, and stained with hematoxylin and eosin (HE). With this routine 
stain, hematoxylin stains nuclei blue while cytoplasm/sarcoplasm is stained pink with 
eosin. Prior to analysis the identity of the slides were masked, so the treatment group of 
origin was unknown to the researcher.  Determination of the total area of blue (nuclear) 
staining) is a crude method to measure inflammatory cell infiltration since the nuclear to 
cytoplasmic ratio is extremely low area in the cytoplasm (sarcoplasm)- rich muscle 
fibers, and is considerably higher for macrophages and neutrophils - thus an influx of 
inflammatory cells into muscle results in an increase in the area of blue staining roughly 
proportional to the severity of the response. Measurements of normal muscle from the 
control group of naïve pigs were used to determine the background level of nuclear 
staining. A standard area of 2.5 mm2 from within the most severely affected area 
(selected subjectively by microscopic examination) on each tissue section, was captured 
and analyzed using Northern Eclipse computer software Version 6.0 (Empix Imaging 
Inc. Mississauga, ON) and the total area of blue staining was calculated. 
 
6.2.9 Statistics 
 Differences between groups were analyzed using Prism GraphPad statistical 
software (GraphPad Software, Inc.) using a non-parametric Kruskal-Wallis one-way 
ANOVA for showing differences in gene expression and chi-squared test for showing 
differences between immune responses. 
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6.3 Results 
6.3.1 Differences in the level of gene expression and cellular infiltration following 
different conditions of DNA administration  
 Before the DNA immunization experiments were conducted, gene expression 
and cellular infiltration were assessed in quadriceps muscle under the electroporation 
conditions described in Table. 6.1. Using the luciferase reporter gene, gene expression 
was determined for each treatment (Fig. 6.1 and Table 6.2). Pretreatment with 
electroporation (Group 2) did not significantly change gene expression compared to 
plasmid administered without electroporation (Group 1). In contrast, different 
electroporation parameters administered immediately following plasmid administration 
all increased gene expression similarly in all groups (Groups 3, 4 and 5) given 
electroporation. 
 Histological examination was carried out for each treatment on tissue from the 
injection sites sampled forty-eight hours following administration of plasmid.  Plasmid 
administered without any electroporation (Group 1) caused a mild inflammatory 
response, assessed by the amount of blue (nuclear) staining, and consisted primarily of 
macrophages and neutrophils (Fig. 6.2 and Table 6.2).  Electroporation conditions of 
200 V/20 msec/6 pulses (Groups 2 and 4) and 200 V/60 msec/2 pulses (Group 5) caused 
muscle necrosis in addition to severe inflammation (marked influx of macrophages and 
neutrophils), whereas electroporation conditions of 100 V/20 msec/2 pulses (Group 3) 
resulted in muscle necrosis with moderate to severe infiltration of macrophages and 
neutrophils. In all groups treated with electroporation (Groups 2, 3, 4 and 5) there were 
scattered muscle fibers showing degeneration characterized by mildly increased 
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Table 6.2 Gene expression of luciferase encoding plasmid, and tissue damage 48 hours 
following administration determined by digital analysis of nuclear area. 
 
Group Electroporation conditions 
 
Luciferase 
Gene expression 
Severity of histological 
inflammatory reaction 1,2 
 
1 No EP 
 
Low expression Mild 3 
(7% area 1) 
 
2 (200 V)/20 msec./6 pulses 
1 hour prior to DNA 
administration  
Low expression 
 
Severe 
(33% area 1) 
3 (100 V)/60 msec./2 pulses High expression 
 
Moderate-Severe 
(24% area 1) 
 
4 (200 V)/20 msec./6 pulses High expression 
 
Severe 
(33% area 1) 
 
5 (200 V)/60 msec./2 pulses High expression 
 
Severe 
(29% area 1) 
 
6 
 
Naive None Normal 
(3% area area 1) 
 
 
1 The area of nuclear staining in a 2.5 mm2 area was assessed on the most severely 
affected area determined subjectively prior to analysis.  
 
2 Nuclear area was used as a measurement of inflammatory cell infiltration. 
 
3 Mild < 5%, Moderate 5%-25% and Severe > 25% 
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Figure 6.1 Luciferase gene expression in muscle 48 hours following administration of 
plasmid under different conditions.  
Differences between groups, **p<0.01 100V/60ms/2X vs naive (no plasmid) and 
200V/20ms/6X vs naive by one-way ANOVA Kruskal-Wallis test. 
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Figure 6.2 Histological examination of muscle (HE stain) 48 hours following plasmid 
administration.  
(A) Muscle injected with plasmid, (B) muscle injected with plasmid followed by 
electroporation (2 Pulses 100V), (C) muscle injected with plasmid followed by 
electroporation (6 Pulses 200V) representative of (2 Pulses 100V). Mild infiltration of 
macrophages and neutrophils was observed in (A) and severe infiltration of 
macrophages and neutrophils was observed in (B) and (C) with scattered necrotic 
myofibers (arrow) were also noted. Bar is 100 µm. 
A 
B 
C 
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eosinophilia.  
 
6.3.2 Immune responses 
 Glycoprotein D-specific antibody responses were determined by BHV-1 
neutralization assay (Fig. 6.3). A neutralization titer ³ 32 can reduce viral shedding and 
clinical symptoms from BHV-1 challenge in cattle (van Drunen Littel-van den Hurk et 
al., 1998). Immunization with plasmid without electroporation (Group 1), conditions 
that give low gene expression and low cellular infiltration, elicited the lowest number, of 
animals, only 2/6, achieving a neutralization titer of ³ 32. Animals treated with 
electroporation one hour prior to plasmid administration (Group 2), showed low gene 
expression with high cellular infiltration, with similar BHV-1 neutralization antibody 
responses to Group 2 (Fig. 6.3). Animals treated with electroporation immediately 
following immunization (Group 3, 4, and 5), conditions which gave high gene 
expression and high cellular infiltration (Table. 6.2), resulted in more animals achieving 
a neutralization titer of ³ 32 compared to those treated with conventional plasmid 
immunization (Group 1) (Fig. 6.3). 
Glycoprotein D-specific proliferation assays showed responses (Fig. 4) similar to 
the antibody responses (Fig. 6.3), with a trend of greater stimulation indexes in animals 
that received electroporation (Groups 2, 3, 4 and 5). 
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Figure 6.3 Glycoprotein D-specific antibody responses following electroporation.  
Numbers above the groups indicate the number of animals that clinical signs would be 
expected reduced (>32 BHV-1 neutralization titer).  Group 3, 4, and 5 vs prebleed 
p<0.01 by chi-squared test. 
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To determine if Th1- like responses were obtained, lymphocytes from immunized 
pigs were assessed for production of IFN-g – the true measure of Th1- like responses. 
DNA immunization with a gD-encoding plasmid stimulated gD-specific interferon 
gamma secreting cells (Fig. 6.4), supporting previous reports that DNA vaccines 
polarize the response towards a Th1-like or balanced response (Martinez et al., 1997; 
Sjolander et al., 1998).  However, all immunization conditions elicited similar numbers 
of gD-specific IFN-g secreting cells.  
Immune responses to HBsAg were determined using the Abbott clinical ELISA 
(Fig. 6.5). Animals immunized without electroporation (Group 1) had the weakest 
immune responses, with only two animals responding to the immunization and only 1/6 
animals responding with a titer considered to be protective (>10 mIU/ml) (Fig. 6.5). In 
groups that received electroporation at the time of DNA immunization (Groups 3, 4 and 
5), more animals responded and group 4, which received the strongest electroporation 
treatment, had the most animals considered protected (4/6).  Animals which received 
electroporation one hour prior to DNA immunization (Group 2) had immune responses 
similar to animals which received an identical electroporation treatment at the time of 
immunization; with 4/6 animals considered protected despite the low level of antigen 
expression. 
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Figure 6.4 Cellular immune responses in gD immunized pigs assessed by proliferation 
and IFN-g cytokine secreting cells.   
Glycoprotein D-specific proliferative responses were determined at week 6.  The 
number of gD-specific IFN-g secreting lymphocytes was determined using ELISPOT at 
week six.  There was no significant difference between the groups. Error bars represent 
SD and n = 6. 
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Figure 6.5 Effect of electroporation on anti-HBsAg titers in pigs six weeks after 
immunization.  
Anti-HBsAg titers were determined using the Abbott clinical ELISA. Numbers above 
the groups are the number of animals considered protected (>10 mIU/ml). Groups 1 and 
4 vs prebleed p<0.01 by chi-squared test. 
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6.3.3 Histological examination of muscle biopsies at two and six weeks following 
electroporation 
Examination of muscle samples from animals two weeks following the second 
immunization carried out at day 28 in conjunction with electroporation (Groups 2, 3, 4 
and 5) showed a greater degree of cellular infiltration than of those from animals that 
received no electroporation (Group 1) (Fig. 6.6). In animals treated with electroporation 
at the time of plasmid administration (Groups 3, 4, and 5), the cellular infiltration at two 
weeks following the second immunization consisted primarily of aggregates of 
lymphoblasts surrounding small vessels within the muscle, whereas in animals treated 
with electroporation prior to plasmid administration, the mild cellular infiltration 
consisted predominantly macrophages and neutrophils. 
 Muscle tissue examined six weeks after the primary immunization following 
electroporation conditions of 200V/20msec./6pulses (Groups 2 and 4) showed a mild 
cellular infiltration consisting predominantly of macrophages and neutrophils.  Muscle 
tissue from all the other treatments (Groups 1, 3 and 4) was normal. 
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Figure 6.6 Histological examination of muscle (HE stain) 14 days following plasmid 
administration.  
 
(A) Muscle treated with electroporation one hour prior to plasmid injection had a very 
minimal cellular infiltration of macrophages and neutrophils. (B) Muscle injected with 
plasmid and not treated with electroporation had no detectable cellular infiltration. (C) 
Muscle injected with plasmid followed by electroporation (200V/6P), (representative of 
groups 3, 4 and 5) showed moderate to severe multifocal lymphocytic infiltration. Bar is 
100 µm. 
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B 
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6.4 Discussion 
These data provide evidence of a role for inflammation/cellular infiltration, 
caused here by the use of electroporation, in enhancing immune responses on immune 
responses following DNA immunization.  Although the effect of the inflammatory 
response was not as dramatic for gD compared to HBsAg (groups 2 and 4, respectively).  
The two antigens differ in their immunogenicity with gD being more immunogenic than 
HBsAg. The difference in immunogenicity between the two antigens may explain why 
the effect of cellular infiltration was less dramatic for gD than for HBsAg. 
The inflammatory cell infiltration was demonstrated to be an important 
component for enhancing immune responses to DNA vaccines since prior treatment 
with electroporation enhanced immune responses to the HBsAg DNA vaccine but did 
not increase gene expression.  However, the increase in gene expression caused by 
electroporation is absolutely critical for inducing protective immune responses as 
demonstrated using the gD DNA vaccine.  The level of antigen produced is critical for 
inducing immune responses to DNA vaccines illustrated by the previous experiment 
where induction of antibody titers that would be considered protective in humans from 
hepatitis B could be achieved in 100% of animals, under electroporation conditions of 
200V/20msec./6pulses and using two administration sites of 500 mg pHBsAg for the 
primary and secondary immunization (Babiuk et al., 2002).  In the current study, with 
only one administration site of 500 mg pHBsAg for the primary and secondary 
immunization, the number of animals with titers considered protective was reduced to 
66%.  Thus, the mechanisms by which electroporation enhances immune responses to 
 132 
DNA vaccines is a combination of increased gene expression and increased 
inflammation and cell infiltration.  Previous studies using bupivacaine to enhance 
immune responses to DNA vaccines (Davis et al., 1995) suggested that muscle 
damage/inflammation was important for enhancing immune responses. 
 Improved antigen presentation is one possible mechanism by which increased 
inflammatory cell infiltrates may enhance immune responses to DNA vaccines delivered 
with electroporation.  Infiltration of APCs such as macrophages or dendritic cells may 
result in increased antigen uptake, resulting in more efficient cross priming.  It is not 
known whether electroporation affects other aspects of antigen presentation through 
leakage of antigen from injured muscle cells, or more efficient presentation of antigen to 
APCs when damaged muscle cells die. Electroporation may also activate APCs through 
danger signals allowing more efficient antigen presentation (Murtaugh and Foss, 2002). 
Interestingly, lymphocytic infiltrations occurred only in muscle exposed to 
electroporation conditions that elicited high gene expression (Groups 3, 4 and 5).  This 
can be explained as follows: antigen is the critical factor for the retention of 
lymphocytes, and if only a few cells are transfected, there will be very little antigen 
produced, so that the probability of finding lymphocytic infiltrates is very unlikely 
(Groups 1 and 2). Antigen specific lymphocytes may surround transfected cells 2 weeks 
after the secondary immunization since antigen is likely to still be present (Muramatsu 
et al., 2001).  More supporting evidence for antigen specific lymphocytes in the muscle 
are gene therapy experiments where the rejection of transfected muscle fibers occurs 
within 3 weeks in the absence of immunosuppression (Vilquin et al., 2001).  
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The development of combination vaccines is a major goal in vaccine research. 
DNA vaccines encoding different antigens have been shown to be compatible (Braun et 
al., 1998). In previous studies, gD and HBsAg encoding plasmids did not cause 
interference when administered in the same muscle (Babiuk et al., 2002), although the 
plasmids were not mixed together.  Here, different plasmids were mixed and 
administered in a single site and immune responses were induced to both antigens (gD 
and HBsAg); however, for development of combined DNA vaccines, different antigens 
will have to be tested for compatibility.  Co- immunization with two different encoded 
antigens either in one plasmid or in different plasmids may actually improve immune 
responses to both antigens by providing additional T cell help through additional helper 
epitopes (Maecker et al., 1998).  Further investigation of co- immunization of different 
antigen combinations will be necessary to determine the extent of this effect. 
These experiments also demonstrate that electroporation is an effective delivery 
method for enhancing immune responses elicited by DNA vaccines.  A similar effect on 
gene expression and infiltration could be achieved using the 6-needle array with 6 
electrical pulses as with 2 electrical pulses.  Muscle tissue examined histologically at six 
weeks following the two pulse electroporation parameters was indistinguishable from 
normal muscle, indicating that electroporation under these conditions does not cause any 
long-term effects.  Reduction in the number of pulses may allow this electroporation 
procedure to be more useful clinically.  Only partial sero-conversion to HBsAg plasmid 
immunization was achieved using electroporation under the experimental conditions of 
one administration site with a secondary immunization. It may be possible to increase 
the response and the number of responding animals by optimizing the plasmid promoter, 
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vector and gene and increasing the dose of plasmid used.  The commercial HBsAg 
vaccine Engerix B requires three immunizations in humans to offer protection although 
recent data in humans suggest two immunizations may suffice (Iwarson, 2002).  
Immunization with Engerix B results in 100% of pigs responding after two 
immunizations (data not shown).  Therefore, these results indicate the efficacy of DNA 
immunization administered with electroporation is approaching that of a conventional 
vaccine. Although efficacy in terms of immune response may be similar, long-term 
safety issues will need to be studied further.  Modifications in the electroporation 
parameters such as voltage/time/number of pulses resulting in effective gene expression 
with less severe tissue damage are a step in that direction. 
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7.0 CPG ODNs DO NOT ENHANCE IMMUNE RESPONSES TO DNA 
VACCINES EVEN WHEN DELIVERED WITHOUT INTERFERING WITH 
ANTIGEN EXPRESSION  
(unpublished) 
7.1 Introduction 
CpG ODNs are potent adjuvants for subunit vaccines (Davis et al., 1998). In 
addition, CpG motifs in plasmid vectors may be essential for DNA vaccines to be 
effective (Krieg et al., 1998c).  However, when CpG ODNs are mixed with plasmids 
and administered by injection, immune responses are suppressed (Weeratna et al., 
1998).  This suppression may be the result of decreased plasmid uptake by cells and 
consequently reduction of antigen expression (Weeratna et al., 1998).  The 
incompatibility of CpG ODNs and plasmid may be overcome by delivering plasmid 
directly into cells using the gene gun. The effect of co-administering CpG ODNs with 
plasmids was evaluated by comparing gene expression and immune responses following 
administration after intradermal injection and gene gun delivery. 
 
7.2 Materials and methods  
7.2.1 Plasmids and oligonucleotides 
The following plasmids were used, a CMV promoter-driven luciferase 
expression vector pMAS-luc (pluc) (gift from Dr. Heather Davis, University of Ottawa, 
ON), and a full length gD gene from BHV-1 under a CMV promoter pCAN-gD (pgD) 
and pCAN-null (gifts from Dr. Reno Pontarollo, VIDO, Saskatoon, SK) were used in 
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this study. Plasmids were purified using Qiagen (Mississauga, ON) endotoxin free 
plasmid kits. Phosphorothioate backbone ODNs 1826 TCCATGACGTTCCTGACGTT 
containing two CpG motifs and 1982 TCCAGGACTTCTCTCAGGTT containing no 
CpG motifs (Qiagen) were used. 
 
7.2.2 Immunization 
Mice were injected intradermally in the back using a 27-gauge syringe with 1.5 
mg pgD in 10 ml PBS alone or together with 10 mg of ODNs. For gene gun 
immunization gold beads were prepared according to the manufacturer's instructions for 
the Helios Gene Gun System (Bio-Rad, Hurcules, CA) using doses of 0.05 mg of pgD 
supplemented with 1.45 mg of pCAN-null (plasmid backbone) per shot. ODNs were 
coated on separate gold beads using doses of 1.5 mg ODNs per shot (Oehen et al., 2000) 
and administered by the gene gun immediately after plasmid was delivered with the 
gene gun. An additional group of mice were immunized using the gene gun under the 
identical conditions, with subsequent delivery of 10 mg of ODNs administered 
intradermally by injection under the subjacent area of skin. 
 
7.2.3 Luciferase assay 
Identical doses of plasmids used for immunization by the three delivery methods, 
were used to determine the level of gene expression. Forty-eight hours after plasmid 
administration, skin at the delivery site (1 cm2) as well as the draining lymph nodes were 
removed from mice and homogenized. Luciferase activity was determined using a 
luciferase assay system (Promega, Madison, WI). Samples were counted for 30 seconds.  
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7.2.4 Characterization of humoral and cellular immune responses 
Immunlon 2 (DYNEX, Chantilly, VA) ELISA plates were coated with tgD (1 
mg/ml) or IgG standards (Serotec, Hornby, ON) in 20 mM Na2CO3 overnight at 4°C. 
gD-specific IgG and IgG1 was determined using IgG or IgG1 specific biotinylated 
antibodies diluted 1:10,000 (Caltag, Toronto, ON), followed by streptavidin-alkaline 
phosphatase diluted 1:10,000 (Jackson Immuno Research Labs, West Grove, PA), 
developed by p-nitrophenol phosphate (PNPP) (Sigma Chemical Co., St. Louis, MO). 
The absorbance was read after 15-20 minutes at 405 nm (Bio-Rad). ELISPOT assays for 
IFN-? and IL-4 were performed using cells from individual spleens or pooled lymph 
nodes as previously described (Baca-Estrada et al., 1997). Briefly, 1x106 cells/well were 
placed in 96 well culture plates with and without antigen (gD 0.4 mg/ml) in AIM-V 
(Gibco, Life Technologies, Burlington, ON) and incubated at 37°C and 5% CO2 for 24 
hours. Cells were resuspended in fresh media and seeded on Nitrocellulose plates 
(Millipore, Napean, ON) coated with either IFN-? or IL-4 specific mouse cytokine 
capture antibody 2 mg/ml (PharMingen, San Diego, CA). Biotinylated anti mouse IFN-? 
or IL-4 specific antibodies a 2 mg/ml (PharMingen) followed by streptavidin-alkaline 
phosphatase diluted at 1:1,000 (Jackson Labs) and developed using 5-bromo-4-chloro-3-
indolyl phasphate/nitro blue tetrazolium (BCIP/NBT) substrate tablets (Sigma). Spots 
representing gD specific cytokine secreting cells were counted and expressed as number 
of cytokine secreting cells per 1x106 cells. 
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7.3 Results 
Luciferase gene expression in the skin and the lymph nodes was determined 48 
hours following intradermal or gene gun administration of plasmid with or without 
ODNs (Figure 7.1A and D).  Following intradermal administration of pluc, luciferase 
expression was detected in the skin but not in the draining lymph nodes (Figure 7.1A).  
When either CpG or null ODNs were mixed with pluc and administered intradermally 
there was a decrease in luciferase expression in skin.  Following administration of pluc 
using the gene gun, luciferase expression was found in the skin and draining lymph 
nodes (Figure 7.1D). Luciferase gene expression in the skin and the lymph nodes was 
not influenced by co-administration of ODNs with pluc using the gene gun (Figure 
7.1D).  
Intradermal immunization with pgD alone elicited significant gD-specific IgG1 
antibody responses but no gD-specific IgG2a responses, as well as gD-specific IFN-? 
secreting cells (Figure 7.1B and C).  However, when ODNs were co-administered with 
pgD by intradermal injection, no significant gD-specific antibody or gD-specific IFN-? 
secreting cells were detected (Figure 7.1B and C).  
Gene gun immunization with pgD alone elicited significant gD-specific IgG1 
antibody responses but no gD-specific IgG2a responses, as well as gD-specific IL-4 
secreting cells (Figure 7.1E and F).  In contrast to intradermal administration, co-
administration of ODNs with pgD using the gene gun did not influence the induction of 
humoral or cellular immune responses (Figure 7.1E and F). In addition, mice given CpG 
ODNs intradermally and immunized with the gene gun also did not generate enhanced 
immune responses (data not shown).  
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Figure 7.1 Effect of CpG ODNs on luciferase gene expression and immune responses 
induced by pgD.  
Gene expression elicited in skin and lymph nodes by intradermal injection of pluc alone 
or together with CpG or null ODNs (A). Mice were immunized by intradermal injection 
with pgD alone or together with CpG or null ODNs. (B and C). Gene expression elicited 
in skin and lymph nodes by gene gun administration of pluc alone or together with CpG 
or null ODNs (D). Mice were immunized using the gene gun with pgD alone or together 
with CpG or null ODNs elicited antigen specific IL-4 and IFN-? secreting cells (E and 
F). Error bars represent standard error of the mean of five animals per group, * p<0.05, 
** p<0.01, *** p<0.001 to naïve by ANOVA Tukey’s multiple comparison test. 
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By comparing the two delivery methods, it was clear that intradermal injection 
elicited a Th1 response characterized by IFN-? secreting cells and that gene gun 
administration elicited a Th2 response characterized by IL-4 secreting cells. CpG ODNs 
were not able to modulate the Th2 responses elicited following gene gun immunization. 
 
7.4 Discussion 
Co-administration of ODNs with plasmid by intradermal injection causes a 
reduction in the magnitude of immune responses elicited compared to intradermal 
injection of the DNA vaccine without CpG ODNs.  This effect is likely due to ODNs 
interfering with plasmid uptake into the cell (Weeratna et al., 1998).  Since ODNs and 
plasmids both have similar properties such as a net negative charge, they will bind to 
similar receptors on the surface of a cell.  There is a competition for receptors and there 
will be a lower level of receptor-mediated endocytosis with plasmids.  As a 
consequence, fewer plasmids enter cells and gene expression by plasmid vectors is 
reduced.  CpG ODNs did not interfere with the gene expression of plasmids when they 
were delivered using the gene gun, because in this case plasmid can be directly 
administered into the cell.  CpG ODNs were not able to enhance or modulate the 
immune responses elicited by administration of plasmid using the gene gun, even 
though the doses of CpG used were suitable for adjuvanting protein vaccines in mice.  In 
addition, CpG ODNs have been shown to be adjuvants for protein antigens following 
topical powder administration (Chen et al., 2001a), indicating that CpG ODNs have 
adjuvant activity in the epidermis.  A higher dose of CpG ODNs likely would not be 
able to immunomodulate the Th2 responses elicited by plasmid administered by the 
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gene gun. One hypothesis for why gene gun administration elicits Th2 responses may be 
that transfection of Langerhans cells primes Th2 responses. 
CpG motifs may not be critical for DNA vaccines to be effective.  When CpG 
ODNs and plasmid are mixed together and administered with electroporation gene 
expression is not altered compared to plasmid administered by electroporation. 
However, even when CpG ODNs and plasmid are administered using electroporation, 
there was no adjuvant effect of CpG ODNs determined by comparing immune responses 
elicited by plasmid and CpG ODNs to plasmid alone (Dr. Jeffrey Ulmer, Chiron 
Corporation, personal communication).  Even more convincing evidence that CpG 
motifs may not be critical for DNA vaccines to be effective are the observations that 
TLR9 knockout mice, which do not respond to CpG ODNs (Hemmi et al., 2000) 
develop immune responses to DNA vaccines (unpublished data, Shawn Babiuk).
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8.0 BIPHASIC LIPID VESICLES (BiphasixTM) ENHANCE THE 
ADJUVANTICITY OF CpG OLIGONUCLEOTIDES FOLLOWING SYSTEMIC 
AND MUCOSAL ADMINISTRATION 
(Manuscript in preparation) 
 
8.1. Introduction 
Bacterial DNA has immunostimulatory activity in mammals.  This effect is 
mediated by the ability of certain CpG motif patterns to activate a variety of cells of the 
immune system, such as B cells (Krieg et al., 1995), macrophages (Stacey et al., 1996) 
and dendritic cells (Jakob et al., 1998).  Since CpG oligonucleotides (ODNs) activate 
antigen-presenting cells (APCs), they are potent systemic and mucosal adjuvants 
(McCluskie and Davis, 1998; Moldoveanu et al., 1998).  In addition, CpG ODNs 
stimulate IL-12 cytokine secretion in vivo (Krieg et al., 1998a) and therefore are also 
potent stimulators of Th1 type immune responses. 
In contrast to mice, protocols for immunizing humans and livestock require high 
doses of CpG ODNs to exert adjuvant activity.  Enhanced immunostimulatory activity 
of CpG ODNs has been achieved by physically attaching the antigen to the CpG ODN 
(Cho et al., 2000) or by incorporating the vaccine antigen and the CpG ODNs into lipid 
or oil formulations (Gursel et al., 2001; Li et al., 2001; Mui et al., 2001).   
Biphasic lipid vesicles (BiphasixTM) are novel formulations suitable for the 
delivery of proteins, peptides and oligo/polynucleotides. The formulations employed in 
this study were designed specifically for vaccine application [Vaccine-Targeting 
Adjuvants (VTA)].  The objective of this study was to assess whether VTA formulations 
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were capable of enhancing the adjuvanticity of CpG ODNs when administered by 
systemic and mucosal routes. As well, potential adverse effects of VTA formulations 
were assessed using histology to determine their safety. 
 
8.2 Materials and methods  
8.2.1 Animals 
Six-week-old female BALB/c mice, purchased from the Animal Resource Centre 
at the University of Saskatchewan, were used for all experiments. Animals were treated 
in compliance with the regulations of the Canadian Council for Animal Care.  
 
8.2.2 Oligonucleotides 
 The CpG oligonucleotide 5’-TCCATGACGTTCCTGACGTT-3’(1826) and the 
non-CpG oligonucleotides 5’TCCAGGACTTCTCTCAGGTT-3’(1982) (Qiagen,) were 
used at 10 mg per subcutaneous immunization and 1 mg per mucosal immunization. Both 
these oligonucleotides contain a nuclease-resistant phosphorothioate backbone and have 
previously been used as systemic and mucosal adjuvants (McCluskie and Davis, 1998; 
Moldoveanu et al., 1998). The CpG oligonucleotide GGGGGACGATCGTCGGGGG 
(2116) contains a chimeric phosphodiester and phosphorothioate backbone. 
 
8.2.3 Vaccine delivery system 
Antigen in endotoxin-free saline (Baxter Corporation, Toronto, ON) was mixed 
with VTA formulations using a ratio of 1 part antigen to 9 parts VTA. 
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8.2.4 Immunizations  
 Subcutaneously immunized mice received 0.5 mg of recombinant glycoprotein D 
(truncated form)(tgD) from herpes simplex virus type 1 (HSV-1) (BioDesign 
International, Saco, ME) alone or in the presence of 10 mg of CpG ODNs or non-CpG 
ODNs. Vaccine groups were as follows: tgD in PBS (Group 1), tgD and non-CpG ODN 
in PBS (Group 2), tgD and CpG ODN in PBS (Group 3), tgD in VTA (Group 4), tgD 
and non-CpG ODN in VTA (Group 5), tgD and CpG ODN in VTA (Group 6), and tgD 
and CpG in 30% Emulsigen Plus (MVP Laboratories, Ralston, NE) (Group 7). Mice 
were immunized on day 1 and received a second immunization on day 15. 
 Intranasally immunized mice received 0.5 mg of tgD (BHV-1) with or without 10 
mg of CpG ODNs in 20 ml (10 ml per nostril).  Vaccine groups were as follows: tgD in 
PBS (Group 1), tgD and CpG ODNs in PBS (Group 2) and tgD and CpG in VTAM1 
(Group 3). Mice were immunized on day 1 and received a second immunization on day 
15. 
 
8.2.5 HSV-1 challenge and clinical examination 
 Mice were challenged with HSV-1 using a skin scratch model two weeks 
following secondary immunization. The skin on the back was scratched with a lancet 
and HSV-1 was applied topically three times using a culturette swab with an 
approximate total volume of 35 ml of HSV-1. After infection, groups of mice were 
monitored without knowledge of the treatments they received.  The viral challenge was 
assessed using a clinical score on a five-point scale: 0, no apparent infection; 1, minor 
redness; 2, small herpetic vesicles on the skin; 3, medium sized herpetic skin lesions; 4, 
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medium sized herpetic skin lesions and rough hair coat; 5, severe skin lesions with 
systemic dissemination of lesions and rough hair coat. Mice were euthanized if a clinical 
score of 5 was reached. 
 
8.2.6 Characterization of antibody responses 
Lung washes and nasal secretions were collected post mortem using 1.5 cm long 
tubes of Teflon TFE 24 (Cole-Parmer Instrument Company, Niles, IL) connected to a 
23-gauge needle. For the lung washes the tube was inserted into the trachea and 500 ml 
of PBS was flushed in and out of the lungs twice. For the nasal washes, 300 ml of PBS 
was flushed cranial through the trachea and collected at the nares. Antibody responses 
specific for gD were determined using ELISA, as previously described (Baca-Estrada et 
al., 1997). Immunlon 2 (Dynex, Chantilly, VA) ELISA plates were coated either with 
tgD (HSV-1) (BioDesign International, Saco, ME) (0.1 mg/ml) or tgD (BHV-1) (1 
mg/ml) in 20 mM Na2CO3 overnight at 4 °C. Biotinylated antibodies specific to IgA, IgG 
and IgG subclasses (Caltag, Toronto, ON) were used, followed by streptavidin-alkaline 
phosphatase (Jackson Immuno-Research Labs, West Grove, PA). Alkaline phosphatase 
activity was determined by p-nitrophenol phosphate (PNPP) (Sigma). The absorbance 
was read after 15-20 minutes at 405 nm (Bio-Rad). 
 
8.2.7 Determination of IL-12 in plasma following CpG administration 
Eight hours after mice were injected with 50 mg CpG ODNs (2116) in saline or 
formulated in VTA, plasma was collected in syringes containing heparin (HEPALIN 10 
U.S.P. units)(Organon Teknika, Toronto, ON).  Blood was centrifuged to separate the 
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plasma from the red blood cells and the plasma was collected and frozen at -20°C.  Plasma 
concentrations for IL-12 was determined by ELISA as follows: Immunlon 2 (Dynex) 
ELISA plates were coated with anti-mouse IL-12 (p70) (2 mg/ml) (PharMingen, San 
Diego, CA) in 20 mM Na2CO3 overnight at 4°C. Plates were washed 4X with phosphate 
buffered saline 0.05% Tween 20 (Sigma) (PBST).  Plasma samples, diluted with PBST-
0.5% gelatin (Sigma) in serial dilutions, were placed on the plate with known amounts of 
recombinant mouse IL-12 (ranging from 5 ng/ml to 0.3 ng/ml) and incubated overnight at 
4°C.  The following day plates were washed 4X in PBST and biotin anti-mouse IL-12 
(p40/70) (2 mg/ml in PBST-gelatin) (PharMingen) was added to the wells and incubated 
for 1 hour at room temperature. Plates were washed 4X in PBST and streptavidin-alkaline 
phosphatase (Jackson Immuno-Research Labs) was added to the wells. Plates were washed 
8X in PBST and alkaline phosphatase activity was determined by p-nitrophenol phosphate 
(PNPP) (Sigma). The absorbance was read after 15-20 minutes at 405 nm (Bio-Rad). 
 
8.2.8 Histological examination of skin following injection of CpG in various 
formulations  
 Skin tissue samples of the injection sites were taken at 1, 7, 14 and 29 days 
following subcutaneous administration of CpG ODNs in PBS, VTA or emulsigen as 
well as VTA alone. Tissues were fixed in 10% neutral buffered formalin, processed 
routinely and embedded in paraffin wax.  Four mm sections were cut and stained with 
hematoxylin and eosin (HE). Prior to analysis, the identity of the slides was masked, so 
that the researcher was unaware of the treatment group of the individual tissues.  The 
area of nuclear staining (blue with hematoxylin in HE stain) is an indirect measure of 
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cellular infiltration since cutis consists mostly of adipocytes that have a low nuclear to 
cytoplasmic ratio, infiltrating macrophages and neutrophils increase the area staining 
blue. Measurements of normal skin from the naive control group were used to determine 
background staining.  The most severely affected area from each tissue section was 
determined subjectively prior to analysis. Within a standard area of 0.25 mm2, the total 
area staining blue was calculated using Northern Eclipse computer software version 6.0 
(Empix Imaging Inc. Mississauga, ON). 
 
8.2.9 Statistics  
Differences in immune responses among vaccine groups were analyzed with 
Prism statistical software (GraphPad Software, Inc.) using a one-way ANOVA followed 
by Tukey's multiple comparisons test. 
 
8.3 Results 
8.3.1 Immunization with CpG formulated in VTA increased serum antibody 
titers  
 Subcutaneous immunization with gD and CpG ODNs formulated in VTA 
induced significantly higher gD-specific IgG titers than immunization with gD in PBS. 
In contrast, the responses induced by immunization with gD and CpG ODNs (1826) 
were not statistically different from those induced by gD in PBS (Figure 8.1) In 
addition, the gD-specific IgG titers induced by immunization with gD and CpG (1826) 
in VTA were similar to those induced by gD and CpG (1826) in Emulsigen (Figure 8.1). 
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Since CpG ODNs are known to induce Th1 type immune responses, gD-specific 
IgG1 and IgG2a titers in serum were determined two weeks after the second 
immunization.  Immunization with formulations that did not contain CpG ODNs 
induced a Th2 type response characterized by predominant gD-specific IgG1:IgG2a titer 
ratios (Figure 8.2). However, incorporation of CpG ODNs into the vaccine resulted in an 
increase in the titer of gD-specific IgG2a titers (Figure 8.2).  VTA formulations 
significantly enhanced the gD-specific IgG1 titers when compared to the responses 
induced by gD in PBS. 
 
8.3.2 Protection from HSV-1 infection 
 To evaluate the level of protection conferred by immunization with different 
formulations, mice were challenged with HSV-1 using a scratch model. All naïve and 
control (CpG alone) mice failed to control the HSV-1 infection and were euthanized 
(Table 8.1). Mice immunized with gD and non-CpG ODN (1982) developed severe 
infection and only 2 out of 5 mice survived the challenge (Table 8.1). Mice immunized 
with gD and CpG (1826) survived the challenge but developed moderate clinical scores; 
however, animals that received gD and CpG ODNs (1826) in VTA developed minimal 
signs of disease and therefore, were better protected against HSV-1 infection when 
compared to the other groups. 
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Figure 8.1 Effect of VTA formulation on gD-specific IgG responses following 
subcutaneous immunization.  
All animals were immunized twice subcutaneously at two week intervals with 0.5 mg 
gD. Total gD-specific IgG was determined in serum two weeks after the boost by 
ELISA. Error bars represent SEM with 7 animals/group. gD+VTA+CpG is better than 
gD in PBS and gD+CpG in PBS, gD+Emul+CpG is better than gD in PBS, *p<0.01 by 
one-way ANOVA and Tukey’s multiple comparison test. 
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Figure 8.2 Effect of CpG ODNs on IgG1 and IgG2a antibody isotypes following 
subcutaneous immunization.  
All animals were immunized twice subcutaneously at two week intervals with 0.5 mg 
gD. Total gD-specific IgG1, IgG2a titers and IgG1/IgG2a isotype ratios were 
determined from serum two weeks after the boost by ELISA. Error bars represent SEM 
with 7 animals/group, * p<0.01 compared to gD in PBS by one-way ANOVA and 
Tukey’s multiple comparison test. 
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Table 8.1 Protection from HSV-1 scratch challenge 
Group Highest clinical 
score* 
Survival 
gD and non-CpG ODNs 
(PBS) 
4 2/5 
gD and CpG ODNs (PBS) 3 5/5 
VTA gD and CpG ODNs 1 5/5 
CpG alone 5 0/5 
Naive 5 0/5 
* Clinical scores increase with an increase in severity with higher numbers 
In a separate experiment mice were immunized subcutaneously twice with gD in the 
formulations indicated above at two week intervals.  Mice were challenged with HSV-1 
two weeks after the boost.  
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8.3.3 Formulation of CpG ODNs in VTA enhances cytokine secretion  
 One possible mechanism by which VTA enhance the immuno-adjuvant activity 
of CpG ODNs is by increasing bioavailability and consequently biological effect. 
Therefore, it was assessed whether formulation of CpG ODNs in VTA resulted in an 
increase in IL-12 when administered in vivo. Mice were administered with CpG ODNs 
(2116) in saline or formulated in VTA by intraperitoneal injection and eight hours later 
the levels of IL-12 were determined in the plasma of treated animals, using an ELISA. 
The levels of IL-12 in plasma were significantly higher in animals that received CpG 
ODNs (2116) formulated in VTA when compared to those administered CpG ODNs 
(2116) in saline (Figure 8.3). 
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Figure 8.3 Effect of VTA formulation on IL-12 induction by CpG.  
Mice were administered VTA alone, 50 mg CpG (2116) in PBS or 50 mg CpG (2116) 
formulated in VTA by intraperitoneal injection. Eight hours after administration of CpG, 
plasma was collected and the IL-12 concentration was determined. Error bars represent 
SD with 6 animals/group, * p<0.01 compared to CpG in PBS by one-way ANOVA and 
Tukey’s multiple comparison test. 
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8.3.4 VTA formulations are safer than Emulsigen  
To evaluate the safety of CpG ODNs and VTA formulations, skin tissue samples 
were obtained from the inoculation site 1, 7, 14 and 29 days following subcutaneous 
administration, and examined to characterize the type and the inflammatory cell 
response (Figure 8.4).  
At one day after administration, CpG ODNs (1826) in saline caused a mild 
infiltration of macrophages into the hypodermis.  Severe cellular infiltration of 
macrophages was observed in the hypodermis following subcutaneous inoculation with 
CpG (1826) in VTA or in Emulsigen, and VTA administered alone.  The inflammatory 
response consisted of macrophages and neutrophils in the hypodermis.  Administration 
of VTA with or without CpG and Emulsigen with CpG resulted in macrophages swollen 
with multiple vacuoles consistent with phagocytosis of lipid or oil. 
At 7 and 14 days following administration, all treatments resulted in a severe 
subcutaneous cellular infiltration, predominantly of macrophages. Swollen vacuolated 
macrophages were observed in the groups that received VTA and Emulsigen.  When 
CpG was delivered in Emulsigen, macrophages and neutrophils surrounded large clear 
vacuoles, interpreted to be oil droplets. 
Twenty-nine days after the administration of CpG in saline, the skin appeared 
normal, whereas at the inoculation site of CpG in VTA there was a moderate cellular 
infiltration of lesser severity than at the previous time points, suggesting a resolution of 
the inflammatory response (Figure 8.5).  However, in tissue samples obtained from mice 
treated with Emulsigen and CpG lesions were severe, characterized by the presence of 
 155 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 Cellular infiltration in skin following administration of CpG in different 
formulations.  
Following administration of CpG in different formulations, skin was examined at 1, 7, 
14 and 29 days after injection using HE sections. Cellular infiltration was determined by 
calculating the area of blue stain in the cutis as an indirect method to determine cellular 
infiltration. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA followed by Tukey's 
multiple comparison test compared to naive. 
 
N
ai
ve
C
pG
V
TA
2
C
pG
+V
TA
2
C
pG
+E
m
ul
0
10
20
30
40
*
**
A
re
a 
(%
) 
of
 c
el
lu
la
r
in
fil
tr
at
io
n 
(D
ay
 1
)
N
ai
ve
C
pG
V
TA
2
C
pG
+V
TA
2
C
pG
+E
m
ul
0
10
20
30
40
A
re
a 
(%
) 
of
 c
el
lu
la
r
in
fil
tr
at
io
n 
(D
ay
 7
)
** **
N
ai
ve
C
pG
V
T
A
2
C
pG
+V
T
A
2
C
pG
+E
m
ul
0
10
20
30
40
A
re
a 
(%
) 
of
 c
el
lu
la
r
in
fil
tr
at
io
n 
(D
ay
 1
4)
**
***
N
ai
ve
C
pG
V
T
A
2
C
pG
+V
T
A
2
C
pG
+E
m
ul
0
10
20
30
40
A
re
a 
(%
) 
of
 c
el
lu
la
r
in
fil
tr
at
io
n 
(D
ay
 2
9)
*
***
 156 
 
 
A        B         C 
 
 
Figure 8.5 Effect of different vaccine formulations on mouse skin. 
Mouse skin (HE stain) 29 days after administration of PBS (A), CpG in VTA (B), and 
CpG in Emulsigen (C). No change in cellularity was observed following PBS 
administration (A - i and ii). Infiltration of macrophages was observed in both 
treatments, mainly in the hypodermis (B and C -i and ii). Macrophages and neutrophils 
surrounded large clear vacuoles (presumed oil) indicated by arrow in (C -i and ii). Bar is 
100 µm. 
 
 
 
i i i 
ii
D 
ii
ii
ii
F 
 157 
large numbers of macrophages and neutrophils surrounding large clear vacuoles (Figure 
8.5). 
 
8.3.5 VTA formulations enhance mucosal immune responses induced by CpG 
ODNs. 
 To evaluate the effect of VTA formulation in enhancing the immunoadjuvant 
effect of CpG ODNs (1826) following intranasal administration, gD-specific IgA in the 
lung and nasal secretions was determined.  The gD-specific IgA responses in the lungs 
and nasal cavity induced by immunization with gD and CpG ODNs (1826) in VTA were 
significantly higher than those induced by gD and CpG (1826) (Figure 8.6). 
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Figure 8.6 Effect of CpG and formulation on mucosal immune responses. 
Mice were immunized and boosted intranasally at two-week intervals.  Two weeks after 
the boost lung and nasal washes was characterized for gD-specific IgA.  Error bars 
represent SD with 8 animals/group, gD vs gD + CpG (***p<0.001) and gD + CpG vs 
gD + CpG + VTAM (**p<0.01) for both lung and nasal IgA by one-way ANOVA and 
Tukey's multiple test. 
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8.4 Discussion 
 Numerous reports have demonstrated the immunostimulatory properties of CpG 
(Davis et al., 1998); however, the majority of these use CpG administered systemically 
in PBS. It has been previously reported that oils can improve the immuno-adjuvant 
activity of CpG ODNs (Jones et al., 1999; Sun et al., 1998). The results of this study 
demonstrated that formulation of CpG ODNs in Emulsigen enhance antibody responses. 
Also, VTA formulations enhanced the immuno-adjuvant activity of CpG and are safer 
than non-metabolizable oil adjuvants. Both VTA and Emulsigen cause severe cellular 
infiltration at early time points.  However, 29 days following administration skin 
administered VTA formulations was healing, whereas skin injected with Emulsigen was 
not resolving.  Formulation of CpG and gD in VTA increased IgG responses and 
protection from HSV-1 challenge. 
The mechanism of enhancement of CpG immuno-adjuvant activity likely differs 
between Emulsigen and VTA.  Emulsigen creates a depot effect of antigen and CpG 
ODNs.  Although the exact mechanism of enhancement created by VTA formulations is 
currently unknown, it is likely that VTA formulations may: (1) increase antigen and 
CpG delivery to APCs or (2) protect CpG ODNs from degradation.  These effects could 
be related to the structural features of the biphasic vesicles, where both the antigen and 
the CpG ODN can associate with the positively charged vesicles and distribute upon 
mixing with either the hydrophilic or hydrophobic compartments of the vesicles. This is 
supported by the formulation of CpG in VTA increasing IL-12 cytokine production 
compared to CpG administered in saline, indicating that CpG ODNs in complexed lipid 
increase the number of CpG ODNs that stimulate APCs.  In contrast, VTA formulation 
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alone did not induce IL-12 production indicating that VTA formulations are not 
intrinsically stimulatory. One possible mechanism by which VTA formulations enhance 
the immunoadjuvant effect of CpG ODNs is by increasing the amount of CpG ODNs 
that interact with Toll- like receptor 9 (TLR9) (Hemmi et al., 2000).  Since TLR9 is 
located on the inside of the endosomal membrane, phagocytosed lipid CpG ODNs 
complexes may be able to stimulate the TLR9 receptor more efficiency than free CpG 
ODNs, since there would be an increased uptake by APCs of CpG ODNs in lipid 
complexes compared to unformulated CpG ODNs. 
CpG ODNs have been previously shown to be potent inducers of Th1 type 
immune responses to numerous antigens (Chu et al., 1997; Stacey and Blackwell, 1999).  
Results here are in agreement with these studies.  Using gD as an antigen, CpG ODNs 
significantly increased gD-specific IgG2a antibody titers following subcutaneous and 
mucosal immunization.  Non-CpG ODNs administered subcutaneously with gD did not 
show any immuno-adjuvant effect. 
There are a few reports have shown CpG ODNs as a mucosal adjuvant 
(Gallichan et al., 2001; McCluskie and Davis, 1999; McCluskie and Davis, 2000; 
McCluskie et al., 2001). However, there are no reports of CpG ODNs administered in 
lipids by the mucosal route. The results here, confirmed previous observations that CpG 
are effective mucosal adjuvants and further indicate that VTA formulations are suitable 
delivery systems to enhance the immunoadjuvant activity of CpG ODNs.  VTA 
formulations may increase the uptake of CpG ODNs at mucosal surfaces and APCs in 
the mucosa.  Thus VTA formulations may be useful for delivering CpG ODNs for 
immune modulation of allergies. 
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Histological examination of skin showed that VTA formulations do not cause 
long-term inflammation, whereas Emulsigen formulations cause severe tissue damage 
29 days following injection.  Since VTA formulations are made from metabolizable 
plant and synthetic lipids they are safer than Emulsigen (non-metabolizable oil). 
Formulation of CpG ODNs may be critical for CpG to be an effective adjuvant. 
VTA formulations are as effective as, and safer than conventional oil adjuvants. These 
promising results with VTA formulations are currently being evaluated in large animals.
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9.0 GENERAL DISCUSSION AND OVERALL CONCLUSIONS 
9.1 DNA vaccination: an ideal concept with tremendous technical obstacles 
 The concept of DNA vaccination is simply to transfect host cells with plasmid 
vectors encoding vaccine antigens to induce an immune response. Since it results in 
antigen being produced by host cells, it mimics intracellular pathogens allowing antigen 
presentation on both Class I and Class II MHCs. The Achilles' heel for DNA vaccines is 
delivery of plasmid vectors in an effective way to increase the amount of protein 
produced in vivo.  The efficacy of DNA vaccination is dependent on the quantity of 
antigen produced in vivo. Since the amount of antigen produced from plasmid vectors is 
significantly lower compared to subunit and viral approaches, it is not surpris ing that 
DNA vaccination is not as effective at inducing antibody responses. This was illustrated 
in Chapter 4 by a direct comparison of a DNA vaccine encoding HBsAg with the 
commercial HBsAg subunit vaccine, where the commercial protein vaccine was 
superior to the DNA vaccine. The reason for this result may be that the low amount of 
antigen is the critical limiting factor for DNA vaccines to elicit immune responses in 
large animals. For DNA vaccines a threshold level of antigen must be processed and 
presented by APCs. This can be achieved either (1) efficiently by direct transfection of 
APCs, or (2) inefficiently by production of antigen in non- lymphoid cells, followed by 
cross-presentation to APCs. These are the two different possibilities for enhancing 
antigen presentation with DNA vaccines. 
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9.2 Discussion of different delivery methods for DNA based vaccines and the 
critical role of gene expression for inducing immune responses 
A plasmid is not antigen itself; rather it contains the instructions to produce an 
encoded antigen. Therefore, for DNA immunization, it is not the dose of plasmid that is 
important, but how much antigen is produced from the plasmid in vivo.  Although DNA-
based vaccines have been shown to be effective in several mouse models, the results in 
large animals have been disappointing.  Immune responses to DNA vaccines were 
consistently achieved in mice using lower doses of plasmids (1 mg), whereas in pigs, 
immune responses were inconsistent, with only a fraction of the animals responding to 
orders of magnitude more plasmid (1 mg).  One possible reason for this result may be a 
difference between the two species in susceptibility to transfection.  It appears that 
mouse skin and muscle cells are much more permissive to transfection than the same 
tissues in larger animals.  This was illustrated by the luciferase gene expression 
experiments.  Luciferase levels of 106 RLU were obtained in mouse skin using 1 mg of 
plasmid by intradermal injection whereas luciferase gene expression levels of 105 RLU 
were measured in porcine skin using 100 mg of plasmid by intradermal injection. In 
addition, the volumes of diluent used to administer the plasmids in mice were lower than 
the volume used for pigs [increasing the volume of diluent, has been shown to increase 
the level of gene expression in mice (Dupuis et al., 2000)].  Even though there are 
differences in the size between biopsies from the different species compared, the size of 
the tissue biopsy is irrelevant as long as the entire injection site is sampled, since the 
level of reporter gene expression does not depend on the size of the tissue, only on the 
amount of reporter gene produced.  Clearly, transfection and gene expression in skin is 
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more efficient in mice than large animals.  The mechanism by which mouse skin is more 
easily transfected compared to porcine skin is unknown, just as the reason why different 
cell types are more easily transfected in vitro is also unknown.  However, in general, the 
transfection of cells in vivo in all species is a rare event.  In mice, high concentrations of 
plasmids are needed to transfect a small number of cells, and these events are even less 
frequent in large animals.  If exogenous DNA could transfect cells efficiently, it would 
have a tremendous impact on evolution, especially if germ line cells were transfected.  
Therefore it is advantageous that transfection is a rare occurrence. 
The low efficiency of transfection in all species has led to the development of 
different delivery devices for increasing gene expression and enhancing immune 
responses. These devices were directly compared to conventional needle injection with 
respect to gene expression and immune responses.  Delivery of plasmid using BioJect as 
well as surface electroporation following intradermal injection enhanced gene 
expression by one logarithmic order of magnitude (106 RLU by BioJect and 106 RLU by 
surface electroporation following intradermal injection vs 105 RLU by conventional 
injection) in porcine skin. The combination of BioJect delivery and surface 
electroporation further enhanced gene expression (107 RLU) and increased the number 
of animals responding after the second boost to a HBsAg DNA vaccine (2/5 vs 0/5 with 
conventional injection of the DNA vaccine).  Electroporation of muscle tissue using a 
six-needle array was more effective in increasing luciferase gene expression in muscle 
(108 RLU) compared to needle-free surface electroporation applied to the skin (107 
RLU).  In addition, electroporation using the six-needle array enhanced the immune 
responses to the HBsAg DNA vaccine in 6/6 animals assayed by the clinical Abbott 
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HBsAg ELISA.  These studies together demonstrate the critical role of the level of gene 
expression for induction of immune responses to DNA vaccines. 
Delivery devices such as BioJect and permeability enhancers such as 
electroporation possibly work by dispersing plasmid throughout the tissue more 
effectively than conventional injection. This may allow for increased gene expression 
due to plasmid uptake into more cells. In addition, it is also possible to disrupt 
membrane barriers by administering plasmids using the gene gun, jet injection or 
electroporation.  Although these methods use different physical techniques and enhance 
gene expression by different magnitudes compared to conventional injection, the 
principles for improved delivery such as spreading plasmid throughout the tissue and 
disrupting cell membranes remain the same with these devices.  In addition, the delivery 
devices may also influence the kinetics of gene expression.  For example, jet injection 
may administer the plasmid deeper into the skin compared to the gene gun delivery. 
Transfected cells in the epidermis are sloughed off, whereas cells found in the dermis of 
the skin are not.  However, even with electroporation, DNA based vaccines still produce 
less antigen than recombinant protein subunit vaccines.  Thus if it were possible for 
DNA based vaccines to produce enough antigen, these vaccines could be at least as 
effective as intramuscular injection of subunit vaccines for eliciting antibody responses, 
and superior for inducing CTL responses.  
Another approach to enhance the efficacy of DNA vaccines is to enhance antigen 
presentation by direct transfection of APCs.  This can be achieved by delivering 
plasmids to the region of the skin where dendritic cells are residing and was illustrated 
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from topical delivery of plasmids formulated in BiphasixTM lipid vesicles.  However, 
this approach did not elicit high gene expression in non- lymphoid cells in the skin.  
There are several different approaches to administer DNA based vaccines.  Each 
of these approaches has advantages and disadvantages with regards to efficacy, 
practicality and acceptability.  Table 9.1 shows a comparative ranking of a number of 
important parameters for all the delivery methods tested in this thesis.  Currently there is 
no delivery method that is effective, easily tolerated and painless. The simplest and most 
easily tolerated approach would be to apply the vaccine topically.  Biojector and gene 
gun delivery of plasmids showed improvements in immune responses but there are still 
limitations related to the devices, such as the loading of DNA and the accuracy of 
dosing. Electroporation was found to be the most effective delivery method for inducing 
immune responses. However, electroporation is invasive and causes tissue damage, 
therefore the pursuit of a suitable delivery system for plasmids will still be required.  
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Table 9.1 Comparison of delivery methods for DNA vaccines in large animals 
 
Method Efficiency1 Pain 
level 
Tissue 
damage 
Comments 
Electroporation ++++ severe severe Not very practical due to 
electroporation equipment 
and need for trained 
medical personnel 
Gene gun +++ moderate moderate Major formulation issues 
with coating DNA on 
beads 
BioJect +++ moderate moderate Simple; 
Jet injection device is 
already licensed 
Conventional 
injection 
 
++ moderate moderate Practical; 
Safety issues associated 
with accidental needle 
sticks  
Topical 
administration 
 
+ mild mild Simplest and safest 
method of administration 
 
1Efficiency ranking: 
+  inconsistent priming of immune responses 
++  consistent priming of immune responses 
+++  induction of protective immune responses in some animals 
++++  induction of protective immune responses in most animals approaching the 
efficiency of some conventional vaccines 
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9.3 Epidermal immunization results in the induction of Th2 type immune 
responses 
 Different delivery methods to the skin result in different types of immune 
responses.  Topical administration of proteins results in induction of Th2 responses 
(Baca-Estrada et al., 2000).  Similarly, plasmid administration following either topical 
or gene gun administration resulted in elicitation of Th2 type responses, whereas 
intradermal injection produced Th1 responses.  With topical or gene gun administration, 
plasmid is delivered to the epidermis, unlike intradermal plasmid administration into the 
dermis.  It is likely that Langerhans cells in the epidermis were transfected directly 
following both topical and gene gun administration of plasmid since luciferase activity 
was detected in the draining lymph nodes, whereas Langerhans cells were not 
transfected following intradermal administration of plasmid.  A likely hypothesis for 
why topical and gene gun administration results in Th2 responses following DNA 
immunization is that antigen presentation by Langerhans cells promoted Th2 responses.  
The induction of Th2 responses may enhance the disease for some pathogens such as 
Leishmania major.  Therefore, it will be necessary to modulate immune responses 
towards Th1 responses to develop topical vaccines for diseases where Th1 type immune 
responses are required for protection.   
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9.4 Role of inflammation/cellular infiltration in induction of immune responses 
 When APCs are stimulated by numerous factors such as LPS, CpG ODNs, and 
danger signals, they become activated, expressing a variety of co-stimulatory molecules 
that improve antigen presentation to the specific immune system.  The activation state of 
the APCs when they are presenting antigen is critical for the induction of immune 
responses.  Cellular infiltration caused by electroporation and CpG motifs in plasmids 
likely activate APCs, causing APCs to move to the draining lymph nodes and present 
the antigen.  Immune responses to a DNA vaccine were enhanced following 
electroporation treatment of muscle, and prior electroporation of muscle enhanced 
immune responses to a subunit vaccine.  These results indicate that damage/danger 
signals are potent adjuvants. 
Cellular infiltration and activation of macrophages by CpG ODNs are 
mechanisms by which immune responses are enhanced.  The increased cellular 
infiltration caused by formulating CpG ODNs in VTA or Emulsigen is a likely 
mechanism of how formulation enhances the immuno-adjuvant effect of CpG ODNs. 
 Some adjuvants such as CpG mimic the signals caused by tissue damage without 
actually causing tissue damage.  These adjuvants stimulate a cascade of signals 
including cytokines, chemokines, and co-stimulatory molecules, allowing cellular 
infiltration and activation of APCs.   
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9.5 Lipid-based formulation of CpG ODNs 
 Lipid-based formulations may enhance the biological activity of CpG ODNs by 
several possible mechanisms: (1) increasing the bioavailability of CpG ODNs by 
preventing dilution and degradation in vivo, (2) allowing improved delivery of CpG 
ODNs to APCs due to the particulate nature of lipid-based formulations, and (3) 
increasing the number of CpG ODNs that can stimulate TLR9 on a single cell level.  
Together these mechanisms result in a greater stimulation of TLR9 by CpG ODNs 
increasing the biological effects of CpG ODNs.  It was shown that formulation of CpG 
ODNs in VTA formulations enhanced the biological activity of CpG ODNs as assessed 
by increased IL-12 cytokine secretion and increased antigen-specific antibody immune 
responses following delivery in VTA formulations compared to PBS. 
 
9.6 Future of polynucleotide and oligonucleotides based vaccines 
9.6.1 DNA vaccines 
 It was hoped that DNA-based vaccines would allow many new vaccines to be 
developed.  However, DNA-based vaccines are not the panacea they were proposed to 
be.  The hurdle of increasing the potency of DNA-based vaccines in a practical way is 
still a major problem with significant technical obstacles.  Topical administration of 
plasmids further increases technical obstacles for gene expression. Currently, 
electroporation is the most effective way to administer DNA-based vaccines, as 
demonstrated by the results in Chapters 5 and 6. However, electroporation in its current 
form is quite invasive and would not be used for regular immunization in the general 
public, although it may have applications for use in cancer immunizations as well as 
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biodefence immunizations for military personnel since the benefit of immunization in 
these circumstances would outweigh the temporary pain from electroporation. 
 In the future, if electroporation could be developed to be minimally invasive, it 
could gain widespread acceptance. This could be achieved possibly by targeting the 
epidermis of the skin using microneedles or perhaps in combination with multiple 
microjet injection. However, currently there are not even prototypes of these devices, 
therefore they are likely years away from being developed and fully tested. 
 
9.6.2 CpG ODNs as an adjuvant 
 Alum currently is the only approved adjuvant on the market for use in humans in 
North America, whereas MF59 is approved in Europe for a human influenza vaccine 
(Gasparini et al., 2001). CpG ODNs are now in clinical trials and preliminary results 
look promising; however, time will reveal if CpG ODNs will become a licensed 
product. In this project, it was found (see Chapter 8) that simply mixing CpG ODNs 
with the antigen is not as effective at inducing antibody immune responses as 
formulating CpG ODNs in VTA formulations. For CpG ODNs to become a successful 
adjuvant for multiple vaccine antigens a suitable delivery vehicle will be required. 
 
9.7 Future research directions  
There are several potential directions where future research can build on the 
work from this thesis.  These include continuing the investigation of delivery of 
plasmids and further test new delivery methods such as magnetofection (Scherer et al., 
2002), based on principles of distribution and membrane disruption.  Currently, 
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increasing the distribution of plasmids as well as techniques that temporarily disrupt 
membranes are the most promising approaches to enhance the gene expression of 
plasmids in vivo. Physical methods of plasmid administration are likely to be more 
effective compared to molecular targeting approaches such as peptides, polymers or 
liposomes, that could theoretically enhance entry into the cell by receptor mediated 
endocytosis. 
Another direction in research could be the molecular characterization of danger 
signals caused by electroporation. By comparing gene expression profiles between 
normal and electroporated muscle tissue using DNA microarray analysis, the genes 
involved in tissue damage/danger signals could be identified, which may lead to the 
understanding of how adjuvants work and how new adjuvants can be developed. 
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